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Introduction Malignant Rhabdoid Tumours (MRT) are aggressive early childhood 
tumours characterised by biallelic inactivation of SMARCB1. Having the potential to 
arise in an array of distinct tissues (CNS-located atypical teratoid rhabdoid tumours, 
ATRT; extra-cranial rhabdoid tumours, ECRT) they are often treated as distinct 
entities therapeutically and in clinical/biological studies although emerging sub-
groups of MRT have provided new understanding of the disease heterogeneity. Lack 
of consensus on sub-group number and biology can be seen as a hurdle to future 
studies. 
Methods Gene expression and methylation array profiling of primary MRT was 
performed on clinico-pathologically annotated tumour profiles from UK cancer 
centres and combined with published MRT data in a meta-analysis. To characterise 
the common biological features of MRT, regardless of location, differential 
expression, methylation, gene and pathway analyses were compared to other 
paediatric embryonal tumour expression and methylation profiles (i.e. 
Medulloblastoma, Ewings Sarcoma, Rhabdomyosarcoma, Wilms tumour and 
Neuroblastoma). Survival analysis was carried out on UK MRT samples to identify 
novel DNA methylation markers associated with disease outcome. Based on 
evidence suggesting immune system involvement in at least one MRT subgroup, 
“methylCibersort” a novel in-silico method was used to estimate immune cell 
infiltration in a large cohort of pan-CNS tumours including MRT. 
Results Clustering all MRT together recapitulates the subgroups observed in ATRT 
alone; broadly overlapping with recently published ATRT and ECRT subgroup 
models. A putative expanded subgrouping model encompassing all MRT highlights 
additional heterogeneity and defines novel subgroup characteristics. Subgroup 
differences were shown to better explain differences in MRT biology than tumour 
location alone. Survival analysis identified a number of novel survival associations 
with DNA methylation state. Immune infiltration estimation using methylCibersort 
identified differences in immune interactions across a large dataset of different CNS 
tumours, and presented novel prognostic feature. 
Conclusion MRT is a complex disease owing both to the rarity of the tumour, 
resulting in lack of comprehensive genomic profiling, and heterogeneity observed in 
the tumour biology. This thesis presents evidence to support the definition of MRT as 
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a related tumour type with differences arising due to disease subgroups. In addition, 
a meta-analysis comparing published subgrouping schemes seeks to direct future 
research by providing a subgroup consensus encompassing all MRT. Novel survival 
associations and immune infiltration estimates provide new avenues for further 
research. 
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1.1 Significance of Study 
Malignant Rhabdoid Tumours (MRT) are a paediatric malignancy with a dismal 
prognosis and pose a number of clinical and biological challenges. The tumours 
originate in very young children, and rapidly progress following diagnosis, while 
diagnosis can be challenging due to a heterogeneous and ambiguous pathology, 
expressing markers from multiple lineages and a variable amount of classical rhabdoid 
tumour cell features. The tumours are rare and the majority of current and past studies 
heavily rely on historical and archived material preventing modern genomic tools being 
utilised, and are typically hindered by poor clinical annotation. The main molecular 
feature of these tumours, bi-allelic inactivation or loss of SMARCB1 is not directly 
targetable by therapeutic intervention; while young age of the patients limits other 
therapy intensification strategies.  
Efforts to characterise MRT have generated a number of sub-grouping and 
stratification schemes, although it is currently not clear whether these schemes are 
compatible, both methodically and on the basis of their biological characterisation of 
MRT, or if there is a clear link between subgroup and patient prognosis. There is 
currently no consensus on the number or content of molecular subgroups in MRT.  
This study was developed to further characterise the heterogeneity seen in the 
disease, both in terms of extending current understanding in MRT biology and to further 
interrogate the disease to identify novel features. By expanding the current profiling 
cohorts through collecting previously unpublished cases and applying contemporary 
analysis tools to newly profiled and published data, this study seeks to continue to 
characterise the features of molecular subgroups and to develop a subgroup 
consensus, providing meaningful recommendations for future studies and the wider 
research community.  
1.2 Malignant Rhabdoid Tumours 
MRT are a group of related aggressive embryonal malignancies that can occur across 
a wide range of tissues. These malignancies occur rarely in the general population 
(age standardised >2 per 1000000) (Woehrer et al., 2010; Brennan et al., 2013), but 
represent a significant unmet clinical need due to a highly aggressive and rapidly 
progressing nature, with a dismal outcome for most patients and lack of effective 
therapeutic options or standardised therapy (Reinhard et al., 2008; Woehrer et al., 
2010; Lafay-Cousin et al., 2012; Brennan et al., 2013; Ostrom et al., 2014). 
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MRT comprise several sup-types, defined by the tumour localisation. Rhabdoid 
tumours of the kidney (RTK) are of renal origin (initially identified as an aggressive sub-
type of Wilm’s tumour and later classified as a distinct entity) (Beckwith and Palmer, 
1978; Haas et al., 1981) but more generally MRT can occur in a wide array of soft 
tissues and organs in the body, including the central nervous system (CNS) where they 
are named atypical teratoid / rhabdoid tumours (ATRT) (Rorke et al., 1996). 
Importantly, synchronous tumours have been described localised both within the CNS 
and extra-cranially, as well as metastases that encompass multiple distal sites. 
(Szymanski et al., 2013; Abu Arja et al., 2018; Pinto et al., 2018) 
In the literature, MRT of different sites have been designated by various names. For 
the purpose of consistency this thesis will employ the following nomenclature: MRT - 
general term referring to all malignant rhabdoid tumours; ATRT - CNS atypical teratoid 
/ rhabdoid tumours; ECRT - extra-cranial MRT, indicated as extra-renal where 
necessary; RTK - extra-cranial MRT occurring in the kidney. 
1.2.1 Atypical Teratoid / Rhabdoid Tumours 
MRT arising in the CNS were first identified in 1987, later defined as a distinct entity in 
1996 and recognised by the World Health Organisation (WHO) in 2000 (Kleihues and 
Sobin, 2000). The name ‘atypical teratoid / rhabdoid tumour’ refers to the “unusual 
combination of mixed cellular elements similar to but not typical of teratomas and the 
rhabdoid cells” (Rorke et al., 1996). ATRT present with a complex immune-staining 
phenotype, noting the presence of cells with immunophenotypes typical of glial, 
mesenchymal or neuronal alongside typical rhabdoid cells. Less than 20% of histology 
sample fields are predominated by rhabdoid cells, leading to ATRT being historically 
prone to misdiagnosis.  
ATRT can present within any part of the CNS. Infratentorial tumours (occurring below 
the boundary of the tentorium cerebelli), including the structures of the posterior fossa 
(cerebellum, tectum, 4th ventricle) and the brain stem (pons, medulla) have been 
reported to occur in 33-61% of cases. Supratentorial tumours including the cerebrum, 
pineal gland, choroid plexus, hypothalamus and ventricles have been reported in 26-
50% of cases. Isolated spinal tumours occur in <10% of cases, and up to around 15% 
of cases have a complex localisation spanning across the tentorial boundary or 





et al. (2012) 
Woehrer et al. 
(2010) 
Athale et al. 
(2009) 
Warmuth-Metz 




 n (%) n (%) n (%) n (%) n (%) 
Total cases 50 19 (100) 147 (100) 33 (100) 133 (100) 
Infratentorial 26 (52) 11 (57.9) 54 (36.7) 11 (33.3) 81 (60.9) 
Supratentorial 22 (44) 5 (26.3) 74 (50.3) 16 (48.5) 41 (30.8) 
Spine 2 (4) 2 (10.5) 9 (6.1) 1 (3) 1 (0.8) 










3 cases NOS 
Table 1. Summary of CNS localisation of ATRT at diagnosis based on available publications.  NOS - not otherwise 
stated, NA - not applicable; † tumours that are not localised to one CNS site 
1.2.2 Extra-cranial Rhabdoid Tumours 
RTK were the first type of MRT to be described and characterised (Beckwith and 
Palmer, 1978; Haas et al., 1981). They represent roughly 2% of all paediatric kidney 
tumours and possess the archetypal histological characteristics of rhabdoid tumours. 
RTK is more commonly associated with germline mutations in SMARCB1, tend to 
originate in younger patients and commonly progress within the CNS (Vujanic et al., 
1996; Tomlinson et al., 2005). 
Extra-renal ECRT are less common than RTK but can be found in almost any part of 
the body (Wick et al., 1995; Sultan et al., 2010b). Unlike the renal tumours, other ECRT 
often have a complex histological appearance due to involvement of numerous tissues 
and organ structures, with little to no presence of typical rhabdoid cell and has 
historically led to difficulties with diagnosing MRT. Extra-renal ECRT tend to originate 
in older patients (Sultan et al., 2010b). 
1.2.3 MRT Histology 
MRTs are defined by the presence of rhabdoid cells in the tumour. These cells 
resemble rhabdomyoblasts and have large, misshapen nuclei with prominent nucleoli, 
eosinophilic inclusions in the cytoplasm and well-defined cell membranes. Tumours 
frequently contain areas of mitotic activity or necrosis; calcification and haemorrhages 
can often also be found. Although rhabdoid cells are a defining characteristic of the 
tumours, they can constitute < 10% of the tumour, are not exclusive to MRTs and can 
occur in other malignancies (Tsuneyoshi et al., 1987; Ueyama et al., 1993; Perry et al., 
1998). This makes differential diagnoses routinely difficult. Immunohistochemical (IHC) 
identification of MRTs has often proven inconclusive with the tumours displaying only 
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some or none of the classic morphology and staining. Typical IHC staining protocols 
are listed in Table 2, however the type of staining employed is often centre-specific.  
Antigen ATRT MRT RTK 
Epithelial membrane antigen (EMA) ++ ++ + 
Vimentin ++ ++ + 
Smooth muscle antigen (SMA) +   
Glial fibrillary acidic protein (GFAP) +   
Neurofilament protein (NFP) +   
Neuron specific enolase (NSE)  + + 
Synaphophysin + +  
Myoglobin  -  
CD34  -  
CD99  + + 
Keratin ++ ++ ++ 
Desmin  - + 
S100  + + 
SMARCB1 -- -- -- 
Table 2. IHC staining protocols recommended for different localisations of MRT.  Adapted from The European 
Rhabdoid Registry (EU-RHAB) Protocol (2016) 
A key discovery in MRT was that the main recurring mutation (>85%) of MRT is the 
biallelic loss of SMARCB1, a component of the SWI/SNF chromatin remodelling 
complex. Initially identified due to commonly seen monosomy of chromosome 22 
(Biegel et al., 1989; Versteege et al., 1998; Biegel et al., 1999) without other recurrent 
genetic mutations (McKenna et al., 2008), SMARCB1 was shown to be the main target 
of inactivation or loss and a defining feature of MRT (Versteege et al., 1998; Biegel et 
al., 1999; Sevenet et al., 1999a; Hoot et al., 2004; Jackson et al., 2009; Eaton et al., 
2011). It should be noted that tumours with histological appearance incompatible with 
typical MRT features also display loss of SMARCB1 (Haberler et al., 2006; Bourdeaut 
et al., 2007); a small percentage of MRT patients also still retain SMARCB1 
expression. Here, analysis of cases with wild-type SMARCB1 identified another 
member of the SWI/SNF remodelling complex, SMARCA4, to be inactivated (Fruhwald 
et al., 2006; Schneppenheim et al., 2010; Hasselblatt et al., 2011). Loss of SMARCB1 
and SMARCA4 are now routinely screened for typically by histochemical approaches 
when MRT may be a potential diagnosis. 
1.2.4 Incidence 
Results published from the Austrian Brain Tumour Registry between 1996 and 2006 
identified 19 (6.1%) ATRT cases out of 311 study eligible tumours, age-standardised 
rate of 1.38 per 1,000,000 person-years with a median age of 1.44 years. In the 0-2 
year age group, ATRT were the most common tumour type analysed in the study and 
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11 (57.8%) cases were <2 years. 6 patients (31.6%) were older than 3 years and oldest 
patient in the cohort was 14.4 years. 10 (52.6%) cases were retrospectively diagnosed 
following central pathology review reaffirming the higher rate of misdiagnosis in cases 
before the inclusion of ATRT in the WHO brain tumour guidelines (Kleihues and Sobin, 
2000) and routine SMARCB1 screening. 
Central Brain Tumour Registry of the United States (CBTRUS) data between 2001 and 
2010 identified 586 ATRT cases of 0-19 years of age, representing 1.6% of all CNS 
tumours diagnosed in that age group (Ostrom et al., 2014). For patients under 1 year 
of age, ATRT constituted 10.1% of cases of primary CNS tumours, and 65.7% of ATRT 
cases occurred in patients <2 years old (median age 1 year). Gender distribution was 
reported to be roughly 1:1 males to females. 35.8% of tumours were supratentorial 
28.3% were infratentorial, 27.8% were recorded as ‘other brain’ or were shown to 
overlap across the boundary of the tentorium cerebelli, 4.6% were spinal tumours and 
3.4% were other CNS. With regards to age, supratentorial localisation was much more 
likely for older patients (69%, 6-18 years). 
Between 1993 and 2010, 106 children under the age of 15 who were diagnosed with 
ECRT in the UK were identified by the study (Brennan et al., 2013). 56 (61%) 
diagnosed were younger than 1 year, 15 (14%) between 1-2 years, 17 (16%) 2-4 years 
and only 9 (8%) were older than 5 years. Of the 106 cases, 51 (48%) were renal and 
the remainder distributed across extra-renal sites. The proportion of each type of ECRT 
appears to not be consistent across the age categories, but small numbers prevent 




Figure 1. Distribution of extra-renal ECRT cases from each localisation as reported by USA Surveillance 
Epidemiology and End Results (SEER) (Sultan et al., 2010b) 
The USA Surveillance Epidemiology and End Results (SEER) registry reported 3618 
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extra-renal ECRT. For patients younger than 1 year 43 (14.2%) were diagnosed as 
ECRT, and 41 (1.2%) were between 1-18 years (Sultan et al., 2010a). In a subsequent 
study focusing on MRT incidence in 1986-2005, Sultan et al. (2010b) identified 229 
MRT cases of which 45 were RTK and 103 were extra-renal ECRT. 69 (46.6%) were 
identified to be older than 18 years which suggests that the study may have included 
soft tissue sarcomas and renal tumours that were not definitive MRT cases. 79 (53%) 
were younger than 18 years. For extra-renal ECRT the most common localisation was 
soft-tissue for patients both <18 and >18 years of age (Figure 1). 
1.2.5 Survival 
Current estimates of MRT survival rely on single-centre reports usually utilising a single 
therapeutic strategy or retrospective cohort meta-analyses that comprise many 
different small studies, therapy modalities and cohort structure that may all confound 
the ability to measure survival. 
Early reports of survival suggested that median overall survival (OS) for ATRT was 
around 6-9 months (Rorke et al., 1996; Bambakidis et al., 2002). More recently, OS 
can be estimated to be around 12-14 months (Buscariollo et al., 2012; Lafay-Cousin 
et al., 2012). Patients typically relapse or progress within 6 months of diagnosis with a 
rate of about 60-80% (Chen et al., 2006; Athale et al., 2009; Biswas et al., 2015). 
Long term survival has been reported, typically associated with multimodal and 
intensified therapy (Woehrer et al., 2010; Buscariollo et al., 2012; Lafay-Cousin et al., 
2012; Slavc et al., 2014) although it is difficult to delineate which particular aspect of 
therapy has a significant contributing effect. 
In the UK between 1993 and 2010, ECRT survival after 1 year was reported to be 
around 31% (Brennan et al., 2013). In the NWTS, survival after 4 years was around 
20% with stage I-II tumours almost twice as likely to survive as stage III-IV. Other 
studies have also identified stage to be a significant factor in survival prediction (Sultan 
et al., 2010b). The same studies noted that patients under the age of 1 had <20% 
survival after 1 year. Survival has not improved over time, and in the UK has remained 
around 30% over the last two decades. When examined by primary site, the worse 
outcomes are seen for liver and for kidney tumours. 
1.2.6 Therapy 
Therapy for MRT approaches typically differ between ATRT and ECRT, and there is 
generally no consensus for standard therapy. A multimodal approach is employed with 
22 
 
surgery, radiotherapy and chemotherapy routinely used in various combinations and 
protocols and with differing success rates. In certain cases no therapy is noted, either 
due to extent of progression or other counter-indications (Lau et al., 2015).  
1.2.6.1 Surgical intervention 
Depending on the tumour site and disease progression, surgical resection is routine 
for MRT. Surgical intervention may sometimes be employed without curative intent, 
either to aid diagnosis or to manage symptoms such as raised intracranial pressure. 
Surgical outcomes are typically defined as gross total resection (GTR) and near-total 
resection (NTR) if the tumour is almost completely excised although studies describe 
varying criteria, and subtotal resection (STR) when only a part of the tumour is excised. 
In certain cases, partial resection or biopsy are the only interventions noted.  
In ATRT, multiple studies report that GTR/NTR has a significantly more favourable OS 
and, in some cases, EFS (Hilden et al., 2004; Ann Zimmerman et al., 2005; Tekautz 
et al., 2005; Gardner et al., 2008; Chi et al., 2009; Isikay et al., 2019). In certain studies, 
it is noted that the effects of surgery are difficult to disentangle from age, localisation 
and other factors, partially due to the small and retrospective nature of most of the 
available clinical annotation.  
In ECRT, the wide range of possible tumour localisations means resection is not 
always possible and complicates outcome comparison. The 2016 European Paediatric 
Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 
2005 Study (EpSSG NRSTS 2005) noted no significant benefit to surgical resection 
(Brennan et al., 2016), while The National Wilms' Tumor Study (NWTS) and SEER 
programme did not report resection as a factor in outcome, the latter citing incompatible 
surgical coding across sites (Tomlinson et al., 2005; Sultan et al., 2010b). Although, 
surgical resection is generally indicated where possible the lack of definitive 
information in ECRT means that the extent of impact on survival is still unclear. 
1.2.6.2 Radiotherapy 
Alongside surgery, radiotherapy is a recommended strategy and many differing 
protocols have been previously described. In ATRT, craniospinal radiation is especially 
deferred in infant patients under 3 years of age due to the effects on patient 
development; with patients suffering significant neuro-cognitive deficits due to effects 
on the developing brain. In ECRT, radiotherapy is more likely to be administered to 
infants though it is usually low dose (<25Gy) (Tomlinson et al., 2005). Data published 
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from the SEER programme series reports that radiotherapy was used in 35% of 
patients overall (lower in infant patients, 23%) and showed no particular site 
preponderance (Sultan et al., 2010b).  
In recent years, advancements in radiotherapeutic approaches have allowed for limited 
radiotherapy in infants. Proton therapy (PT) has become increasingly popular in the 
CNS as it is seen to be less damaging to developing brain structures due to the 
increased precision it offers (Clasie et al., 2012; Vogel et al., 2018). PT protocols have 
been employed in 3 studies on limited ATRT cohorts. The first included a total of 31 
ATRT patients, with a median age at diagnosis and therapy of 19 and 24 months, 
respectively (McGovern et al., 2014). A second study of 10 patients with a similar 
median age (28 months) receiving PT between 2004 and 2011 reported that 8 patients 
had complete response (CR) to therapy, and that following therapy 7 of initially 
positively-responding patients reporting NED (De Amorim Bernstein et al., 2013). The 
final reported single-centre study enrolled 16 patients median age 18.5 between 2007 
and 2013. The centre reported 11 patients with NED or stable disease following 
therapy and common toxicity criteria such as nausea, vomiting and skin erythema 
(Haskins et al., 2015). Although survival was not greatly enhanced, the studies all 
reported encouraging outcomes with regards to therapy-related effects. A study 
examining the incidence of therapy-related radiation necrosis in patients treated with 
PT identified the main risk factors to be the use combination chemotherapy and ATRT 
pathology (Kralik et al., 2015). 
1.2.6.3 Chemotherapy 
Adjuvant chemotherapy is often used to supplement radiotherapy and surgery, or in 
the case of infants with ATRT, is used to defer radiotherapy. No standard therapies 
exist and to date no large-scale trials examining combination drug protocols have been 
carried out.  
In ATRT, conventional dose chemotherapy has not been successful. Multi-agent 
therapies containing vincristine, cisplatin or carboplatin, cyclophosphamide or 
ifosamide and etoposide showed very poor EFS (< 10%) in the CCG-9921 trial which 
contained a small ATRT cohort (Geyer et al., 2005). A better response was noted, with 
a 2-year EFS of 53%, using a modified sarcoma regimen that incorporated doxorubicin, 
dactinomycin and either dacarbazine or temozolomide as well as intrathecal 
methotrexate, hydrocortisone and cytarabine (Chi et al., 2009). 
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High-dose chemotherapy (HDCT) is typically highly damaging for normal tissue and so 
typical high-dose regimens utilise autologous stem cell rescue (ASCR); a process that 
preserves the patient’s own stem cells following treatment. Initially used as a means to 
defer radiotherapy for infant patients in ATRT, HDCT has become widely utilised in 
therapy (Fangusaro et al., 2008; Gardner et al., 2008; Shih et al., 2008; Finkelstein-
Shechter et al., 2010; Nicolaides et al., 2010) as well as a means to de-escalate 
radiotherapy in older patients without affecting survival (Park et al., 2012; Lee et al., 
2017). Protocols vary in course length, number and drug combinations but many 
include high dose methotrexate, and thiotepa as well as typical induction and 
maintenance agents. A recently closed trial examined the effects of HDCT on EFS. 
Preliminary results from ACNS0333 showed significant improvements over historical 
studies especially in infant patients with EFS reaching 39%. The report noted that 
additional intensification was not feasible and recommended stratification and targeted 
therapy development as a means to further improve outcomes (Reddy et al., 2016).  
ECRT chemotherapy approaches are equally disparate and limited by the lack of 
comprehensive trial data. The basis for currently employed therapies may be attributed 
to two studies describing successful treatment of metastatic RTK. The use of 
ifosfamide, carboplatin, and etoposide and vincristine, doxorubicin, and 
cyclophosphamide in alternating courses (Waldron et al., 1999; Wagner et al., 2002). 
The use of doxorubicin was noted as being potentially important for success, although 
its inclusion in the National Wilm’s Tumour Study (NWTS) protocol showed no 
significant effect on outcome (Tomlinson et al., 2005) 
Brennan et al. (2013) raises the question of whether experience of HDCT with 
autologous stem cell rescue (ASCR) in ATRT could inform strategies in ECRT given 
the lack of any significant consensus of therapeutic approaches. In any eventuality, it 
is clear that escalation of conventional and currently available therapies is unlikely to 
significantly improve survival beyond current rates and that there is a clear necessity 
for novel therapy approaches, likely borne out of additional understanding of the 
molecular heterogeneity of MRT. 
1.2.7 MRT Subgrouping 
Initial evidence for the presence of putative sub-groups in MRT came from a 2013 
study describing a comparison of gene expression microarray profiles in ATRT and 
RTK with other tumours and normal controls. The analysis identified 2 ATRT clusters 
and an RTK cluster which separated MRT from other tumours (Birks et al., 2013) and 
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highlighted deregulated genes specific to each cluster when compared to other 
tumours and also normal tissue (906 and 424 genes in ATRT clusters and 453 genes 
in RTK).  
In her PhD thesis, Martina Finetti described the existence of putative sub-groups based 
on DNA methylation and RNA-sequencing profiling, analysing a combined cohort of 23 
RNA-sequencing and 39 DNA methylation array ATRT and ECRT profiles. DNA 
methylation clustering showed at least 2 sub-groups (Finetti, 2014). 
Torchia et al. (2015) showed survival differences between 70 ATRT tumours using a 
combination of gene expression microarray and immunohistochemistry for ASCL1, a 
regulator of the NOTCH signalling pathway. Expression of ASCL1 correlated with a 
15% improvement in survival over ASCL1-negative cases. The study showed that 
using molecular profiling could aid in risk stratification in ATRT, defining 3 risk 
categories based on a combination of localisation, evidence of metastases, surgical 
resection status and ASCL1 expression.  
Johann et al. (2016) and Chun et al. (2016) both carried out a combination of 
transcriptomic and epigenomic profiling in ATRT and ECRT respectively and 
suggested a sub-grouping scheme of either 3 groups for ATRT based on DNA 
methylation and gene expression microarray or 2 groups for ECRT based on RNA-
sequencing. The main defining features for the ATRT subgrouping appeared to be 
differences in age of diagnosis, localisation, gene expression, and an association with 
different ‘super-enhancer’ transcriptional regulators namely the tyrosinase (TYR), 
sonic hedgehog (SHH) and MYC proto-oncogene (MYC) pathways. In addition, 
Johann suggested that further heterogeneity could be observed in at least one of the 
putative sub-groups when analysed by DNA methylation clustering, but it was not 
possible to explore further due to limited cohort size.  
Chun et al. (2016) presented a sub-grouping based around differences in the 
expression Homeobox C (HOXC) cluster genes. Interestingly, clustering ECRT 
samples with miRNA from normal tissue and other tumours showed that ECRT readily 
clustered with normal cerebellum and brain malignancies, despite having originated in 
either the kidney, liver or soft tissue. 
In the same year Han et al. (2016) carried out parallel profiling of human primary 
tumour ATRT and ECRT cases and tumours obtained from mouse in order to develop 
and measure the effectiveness of an MRT mouse model. The resulting clustering 
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suggested 3 putative ATRT sub-groups with an additional sub-group that housed the 
ECRT cases. They identified expression differences between the proposed sub-groups 
that largely agreed with the previous publications. 
Torchia et al. (2016) published another sub-grouping publication describing 2 broad 
ATRT types (Neurogenic/Mesenchymal) further sub-divided into a total of 3 sub-
groups. Among the groups, they noted differences in the age and localisation, type of 
SMARCB1 mutation, differences in the conformation of chromatin and different 
transcriptional programmes. As before, this new sub-grouping model largely appeared 
to align with previously suggested models but was not completely homologous with 
previous sub-grouping strategies.  
It is clear from the existing evidence that there are disease sub-groups present in MRT. 
Notably, only one sub-grouping publication was able to carry out any survival analysis 
in association with the sub-grouping. While there is significant evidence for sub-groups 
in MRT, it is yet unclear whether these sub-groups represent clinically relevant disease 
sub-types that either allow more effective survival prediction and prognostication or 
whether they can shed light on the underlying biological drivers in these tumours with 
the potential to identify novel therapeutic targets. While a number of deregulated 
pathways have been identified in previous sub-grouping efforts, it has not been shown 
whether any are therapeutically targetable and effective in MRT.  
The need for an expanded and robust analysis of the number of sub-groups in these 
tumours as well as the incorporation of as much profiling data and clinical annotation 
is evident. A significant number of identified MRT primary material located in biobanks 
or held locally by cancer centres has yet not been profiled by any platform. 
1.3 Genetics of MRT 
1.3.1 SMARCB1 loss 
The main genetic abnormality of MRT was initially identified due to the commonly 
observed monosomy of chromosome 22, band 22q11.2 (Biegel et al., 1989; Douglass 
et al., 1990). The gene SMARCB1, a component of the SWI/SNF chromatin 
remodelling complex, was shown to act as a tumour suppressor and identified as being 
the main molecular feature of MRT and mutated in a majority of cases (Versteege et 
al., 1998; Biegel et al., 1999). While bi-allelic loss or inactivation of SMARCB1 is 
directly responsible for the development of MRT, it has also been identified in a number 
of other cancers including sarcomas, carcinomas and leukaemia (Sevenet et al., 
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1999b; Mueller et al., 2004; Bourdeaut et al., 2007; Hulsebos et al., 2007; Hadfield et 
al., 2008; Sullivan et al., 2013; Chatterjee et al., 2018). Despite this, SMARCB1 IHC 
staining is routinely used to diagnose MRT.  
Differences in mutation type have previously been noted. ATRT cases typically show 
deletions of the whole SMARCB1 gene, a loss of the 22q11.2 band or loss of 
heterozygosity (LOH). ECRT, on the other hand, typically presented with homozygous 
mutations in SMARCB1 (Biegel et al., 2002; Jackson et al., 2009). Point substitutions 
resulting nonsense mutations are commonly reported by the Catalogue of Somatic 
Mutations in Cancer (COSMIC, Figure 2). In addition, different exons of SMARCB1 are 
more likely to be affected in ATRT and ECRT. Notably almost no mutations are 
reported in Exon 1 or 8.  
 
 
Figure 2. Data obtained from the Catalogue of Somatic Mutations in Cancer  (COSMIC; http://cancer.sanger.ac.uk;) 




1.3.2 SMARCA4 mutation 
In a small sub-set of cases where bi-allelic SMARCB1 expression is retained, it has 
been shown that normal function of SMARCA4, another member of the SWI/SNF 
complex, is lost. Mutation in SMARCA4 is sufficient to cause MRT in the absence of 
any detectable SMARCB1 alterations (Schneppenheim et al., 2010). In a limited 
retrospective study, SMARCA4 alterations showed association with familial 
transmission, presenting as germline mutations and typically had worse prognosis 
(Hasselblatt et al., 2014).  
1.3.3 Genetic predisposition 
Germline mutations in SMARCB1 have been shown to predispose to a range of 
cancers including MRT (Sevenet et al., 1999b). A small proportion of germline 
mutations are identified as part of a familial transmission pattern as noted in a number 
of reports and these cases showed more aggressive disease, and multiple primary 
tumours with dismal outcomes (Proust et al., 1999; Eaton et al., 2011). However, MRT 
patients simply harbouring germline SMARCB1 mutations do not necessarily exhibit 
predisposition syndromes with poor outcome, and have been shown to achieve long-
term survival (mean EFS 7 years) with multimodal treatment. 
1.4 SWI/SNF chromatin remodelling complex 
1.4.1 Introduction 
SWI/SNF are a group of ATP-dependent chromatin remodelling complexes. These 
related complexes play an important role in controlling chromatin structure and 
regulating gene expression by modulating the accessibility of DNA to transcription 
machinery. They are one of four major families of complexes involved in chromatin 
remodelling. Three other chromatin remodelling complex families that rely on ATP 
hydrolysis are the ‘chromo-domain, helicase, DNA binding’ (CHD), inositol requiring 80 
(INO80) and imitation SWI (ISWI) complexes. These families all function to remodel 
chromatin for different cellular functions; CHD complexes are primarily associated with 
transcriptional repression, INO80 regulates expression of DNA-damage repair (DDR) 
pathways and ISWI associated with transcriptional regulation. 
Initially identified in yeast knock-out screening experiments to control mating type 
switching and sucrose fermentation pathways, SWI/SNF complexes are highly 
evolutionarily conserved and can be found in all eukaryotes including mammals. The 
complexes comprise many protein subunits with the combined function of translocating 
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across DNA to alter the condensed nucleosome structure, change histone dimers and 
octamer configuration and recruit other remodelling machinery in an ATP-dependent 
manner.  
In mammals, two main complex categories exist: BRG1- or BRM-associated factors 
(BAF) and polybromo associated factors (PBAF). SMARCB1, SMARCC1, and 
SMARCC2 are found in every type of SWI/SNF complex, while other subunits vary 
across complexes. Most of the subunits possess specific domains for interacting with 
a variety DNA and protein structures including BROMO domains, zinc finger and plant 
homeodomain (PHD) finger. The large number of potential constituent subunits can 
generate a vast array of unique complex combinations, largely cell-specific and 
carrying out distinct regulatory function. It is no surprise that alterations in members of 
the complex have been implicated in different cancers and deregulation of SWI/SNF 
function associated with tumorigenesis. 
1.4.2 Normal function of SWI/SNF 
SWI/SNF complex are involved in many important biological processes including 
differentiation and development, proliferation and DNA damage repair. The 
composition of SWI/SNF complexes have been shown to be highly cell-type specific 
and to also change with developmental stage of the tissue. The complex has been 
shown to regulate lymphocyte development, maintenance of pluripotency, myogenesis 
and neural development, and generally be critical for normal growth as shown by 
mutational studies where loss of SWI/SNF components SMARCB1 and SMARCA4 
during embryogenesis was lethal to the embryo. SWI/SNF has been shown to regulate 
senescence by interacting with p53, p21, p16 and RB1. Interestingly, the two main 
types of complex, BAF and PBAF have been suggested to act antagonistically to either 
repress transcriptional activation of genes, or to promote transcription.   
SWI/SNF has been shown to be important for normal function of multiple DDR 
pathways. Loss of the complex has been shown to significantly sensitise cells to DNA-
damaging agents. SMARCA2 and SMARCA4 rapidly localise to sites of DNA double 
stand breaks (DSB) by interacting with RB1 and E2F1. Loss of a number of SWI/SNF 
subunits can significantly impair the efficiency of DSB repair pathways including both 
non-homologous end-joining (NHEJ) and homologous repair (HR). In addition to DSBs, 
loss of SWI/SNF function sensitises cells to ultra-violet light damage and platinum 
agents which typically trigger nucleotide excision repair (NER). The full involvement of 
SWI/SNF in DDR is still unclear. The variability of the complex and their multiple 
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overlapping functionalities are still actively being studied in order to understand the 
extent of involvement of the complex in normal cell function and in cancer. 
Mutations in SWI/SNF components have been found in around 20% of human cancers. 
Of all the possible components of BAF and PBAF, over 60% have been implicated in 
different malignancies. SMARCA4 mutations have been implicated in ovarian cancers, 
medulloblastoma and melanoma. The involvement of SMARCB1 in various cancers 
has already been described in this thesis. SMARCA2 mutations are found in lung, 
gastric, breast and bladder cancers as well as sometimes being seen in MRT. 
SMARCC1 is mutated in prostate cancer, ARID1A in ovarian, breast, liver, lung and 
bladder cancers. PBRM1 is mutated in the majority of epithelioid sarcomas as well as 
various renal cancers. The gene SS18 is mutated in 100% of synovial cancers.  
1.5 Molecular profiling platforms 
1.5.1 Methylation and expression microarrays 
1.5.1.1 DNA methylation analysis by targeted microarray 
Enzymatic methylation of the 5’ position of cytosine in DNA is a highly complex form of 
epigenetic regulation in mammals. Methylation is non-randomly segregated across the 
genome at sites with cytosine and guanine separated by the DNA phosphate group 
(CpG). These CpG loci are typically found within high density clusters termed CpG 
islands (CGI) defined as regions larger than 200 bp, a GC proportion > 50% and a 60% 
observed-to-expected ratio of CpG sites (Gardiner-Garden and Frommer, 1987). CGI 
are associated with gene promoter regions where they typically repressed gene 
expression (Schubeler, 2015). Gene body methylation promotes expression and 
ensures that transcription is primed correctly (Yang et al., 2014; Neri et al., 2017). DNA 
methylation at distal regulatory sites has also been shown to control expression (Elliott 
et al., 2015).  
There is a specific interest in DNA methylation and its relation to cancer biology. The 
involvement of methylation in the development of cancer has been long established 
(Herman et al., 1994; Jones and Baylin, 2002; Xiao et al., 2016). The need to 
understand methylation changes in normal and cancer states has led to the 
development of high-throughput and whole genome approaches. 
Bisulphite conversion of DNA for the purpose of screening DNA methylation in the 
genome was developed by Frommer et al. (1992). The basis of the technique is the 
selective specific denaturation of cytosine and not 5-methylcytosine to uracil in single-
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stranded DNA without affecting the rest of the coding sequence. Subsequent 
polymerase chain-reaction (PCR) amplification converts the uracil to thymine, while 
any 5-methylcytosines are unaffected. This process is shown in Figure 3A.  
For a whole-genome analysis, historically, direct sequencing would be cost-prohibitive 
and require large amount of high-quality input material. Instead it was favourable to 
utilise a microarray platform which uses sequence-specific probes in order to detect 
the presence or absence of a specific target DNA sequence. In the specific case of 
using retrospective, archival material typically stored as Formalin-Fixed Paraffin-
Embedded (FFPE) blocks, DNA becomes fragmented due to the inherent cross-linking 
of protein molecules by formalin and is usually unsuitable for normal sequencing 
approaches.  
Most recently, the Illumina Infinium HumanMethylation450K (450K) and 
HumanMethylationEPIC (EPIC) BeadChip microarray provided a high-density 
microarray platform to measure DNA-methylation downstream from a bisulphite 
conversion reaction. 450K and EPIC arrays utilise BeadArray technology which relies 
on randomly self-assembling bead libraries on a purpose-designed silicone substrate 
to generate a high-density microarray. The beads are algorithmically decoded 
(Gunderson et al., 2004) to obtain a mapping of the hybridised array probes. Bisulphite-
converted DNA is fragmented and hybridised to the array. Primer extension and 
staining are then used to detect the specific DNA signal treating the specific C/T 
transversion as a “pseudo” single nucleotide polymorphism (SNP). Two types of 
probes are used by the 450K and EPIC arrays. Infinium I utilises two single-colour 
beads specific to either the methylated or unmethylated state of the DNA probe. 
Infinium II uses a single two-colour bead approach and is tailored to regions of the 




The assay process involves the hybridisation of DNA fragments to Infinium beads 
ligated to 50bp oligonucleotide probes and a single-base extension step occurs. 
Infinium I probes are complementary to either the methylated or the unmethylated 
sequence at each probe locus and so extension does not take place. Infinium II probes 
are end base-complementary to the guanine immediately upstream of the assayed 
cytosine base. During single-base extension the fluorochrome labelled base mixtures 
are added to the reaction. A/T are red-channel detectable and C/G green channel 
detectable. For Infinium I, depending on whether extension occurs with the methylated 
or unmethylated probe, a signal is detected in the correct channel. For Infinium II, a 
signal can be detected in either channel based on whether a red-labelled adenosine 
or green-labelled guanine is incorporated (Figure 3B).  
As the name would suggest, the 450K array targets roughly 450,000 genomic features 
(485,577 total) including genes, CpG islands (GCI) and distal features such as shores 
(< 2kb from GCI) and shelves (2-4kb from GCI) as well as known and predicted 
regulatory features, sites known to be differentially methylated in health and disease, 
and features used in assay quality control such as chromosome and non CpG loci. The 
EPIC array (sometimes referred to 850K array) introduced an additional 413,743 
features as well as retaining most of the content of the 450K.  
The analysis of data obtained from the 450K/EPIC arrays can be carried in several 
ways. Illumina provide the GenomeStudio software suite to carry out preprocessing 
Figure 3. Assay steps part of the Illumina Methylation Array assay  A)Diagram of steps in 
bisulphite conversion of methylated DNA, shown diagrammatically as a single strand; 5’ 
methylation is represented by CH3; B) The assay difference between Infinium I and II 
probe types. A – adenosine, C – cytosine, G – guanine, T – thymine, U – uracil.  
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and differential methylation analysis. However, it has become more common to utilise 
open-source analysis tools designed for analysis of DNA microarrays of many different 
types. Software provided as part of the Bioconductor software project using the R 
programming language has become one of the most common approaches to analysing 
450K/EPIC data due to availability, ongoing development and scalability with many 
tools allowing for high-throughput parallel analysis. 
1.5.1.2 Gene expression analysis by targeted microarray 
As with DNA-methylation microarrays, gene expression microarrays allow for high-
throughput genome-wide coverage by utilising probes bound to high density arrays. 
Gene expression microarrays equally arose due to the need to understand gene-level 
differences in health and disease with direct sequencing being technically impossible 
on a genome-wide level.  
One of the most common gene expression microarray platforms has been the 
Affymetrics GeneChip Human Genome U133 arrays. Of these, the most widely utilised 
array format, the U133 Plus 2.0 utilises around 54,000 probes to target approximately 
47,000 transcripts and designed to cover the whole human genome. 
The GeneChip utilises paired 25-mer oligonucleotide probes. One sequence in the pair 
is a perfect match to the target sequence while the other contains a mis-matching 
nucleotide complement. The signal difference between the two probes is then used to 
assay the efficiency of binding of the target sequence (Pease et al., 1994). 
Hybridization is measured in a single colour channel following the addition of a 
fluorescent compound to the sample labelled with biotin. 
1.5.1.3 Future of technologies 
While both DNA methylation and gene-expression have historically offered high-quality 
and reliable analysis methods for assaying different aspects of genomics and 
epigenomics the technologies are approaching the end of product life. Improvements 
in both sequencing technology and the rapid decrease in price for whole-genome 
sequencing as well as changes to how patient material is preserved following sampling 
resulting in more stability and less fragmentation of genomic material and in recent 
decades have meant that more powerful approaches are now more widely available.  
For DNA methylation, whole-genome bisulphite sequencing has already been shown 
as an effective replacement and applied to biological questions in health and disease 
ranging from studying normal immune B cell and T cell development to profiling the 
34 
 
epigenomic landscape of lung and liver malignancies(Kulis et al., 2015; Li et al., 2016; 
Delacher et al., 2017). For gene expression, RNA-sequencing has become a much 
more powerful and increasingly accessible technology allowing the identification of 
gene-fusions, novel transcripts and other features typically not well covered by 
microarray approaches (Cieślik and Chinnaiyan, 2017). In addition, RNA-sequencing 
has been used to analyse the expression of individual, single cells to a high degree of 
robustness and resolution (Hwang et al., 2018) and even allowed sequencing of FFPE 
material, previously believed to be far too fragmented and degraded to ever allow 
whole-genome gene expression sequencing (Li et al., 2018). 
1.5.2 RNA-Sequencing 
The sequencing of transcribed RNA products has multiple advantages over expression 
array measurements of gene expression. Rather than relying on probe-based 
interrogation of the input DNA, RNA-Sequencing (RNA-Seq) directly assays the 
sequence of complementary DNA (cDNA) transcribed from RNA. This greatly 
increases the sensitivity of the sequencing to detect low abundance transcripts as well 
as identify novel features such as mutations, gene fusions and novel transcripts. 
Extracted RNA is subject to several steps to select specific RNA populations. Positive 
selection for poly-adenylated (poly-(A)) RNA is carried out to enrich for protein-coding 
mRNA. At the same time ribosomal RNA is depleted from the pool since it is unlikely 
to be informative in typical RNA-Seq experiments. The next step is to obtain short 
fragments of cDNA complementary to the RNA sequences in the pool. Depending on 
the protocol, RNA can be fragmented prior to reverse transcription or cDNA can be 
fragmented following reverse transcription. A typical desired fragment length is around 
200-300 bp depending on the sequencing approach but longer fragments can also be 
used. Adapter sequences are ligated to the cDNA fragments in order to allow 
identification, incorporation into the sequencing reaction and for multiplexing of multiple 
samples. For single-end sequencing, the adapter typically contains a priming 
sequence in the 5’-3’ direction. For paired-end sequencing, adapter elements must 
contain a second 3’-5’ priming sequence on the complementary adapter. In addition to 
this, an index sequencing priming site can be included at the 5’-3’ strand of the second 
priming site if sequence indexing is needed. Following this step, amplification of the 
library is carried out by PCR to prepare the pool for sequencing. 
Fragment libraries are then sequenced. The sequencer returns short reads and an 
experiment will typically seek to obtain at least 30 million reads, although typically 
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higher read count (~100m) may be sought for more complex RNA-Seq analyses. Two 
common approaches for sequencing are employed- single end and paired end. Single-
end sequencing will only sequence from one end of a fragment (typically running in the 
5’-3’ direction of DNA) and so a single end dataset will contain unidirectional reads. 
Paired-end sequencing will generate reads from both sides of a fragment, firstly 
sequencing from 5’-3’ then priming at the opposite strand of the double-stranded 
fragment and running in the 3’-5’ direction. This the ability to resolve complex structure 
and, overlapping genes and allows greater sensitivity for mutations and gene-fusions. 
Paired-end sequencing also allows for the generation of de-novo transcriptome 
assemblies if a reference transcriptome is not available. 
Following sequencing, the analysis of the data follows a standard format. Raw data is 
subject to quality control (QC) measures which seek to identify problems in the 
sequencing results, variation due to technical error, enrichment of specific sequences 
or motifs which may confound downstream analysis. Necessary removal of samples 
can be carried out prior to alignment. The reads are aligned to a reference genome 
using an alignment program which is typically designed to specifically map short reads 
to a large genome. Many alignment tools exist and are typically chosen based on 
performance requirements or different downstream applications. Following alignment, 
quantification of gene expression is carried out in order to get gene-level counts that 
can be taken further into various downstream applications.  
1.6 Dimensionality reduction and clustering approaches 
1.6.1 Dimensionality reduction 
Genomic data is typically described as ‘high-dimensional’. This type of data is 
characterised by many variables, or ‘features’ with unknown correlation state. In a 
typical experiment, the features would represent the measured genes, or methylated 
loci and usually grossly outnumber the number of observations. If the goal is to make 
some inference on the relationship between the features and a biological state, high-
dimensional data presents an additional challenge. Commonly, analysing relationships 
between combinations of variables is carried out by expressing them as points in 
dimensional space and measuring the distance between points. Many clustering 
approaches rely on such distance metrics, however in a high-dimension space, 
combinations of distances between different sets of variables can have non-unique 
values. This is referred to as the ‘curse of dimensionality’ and significantly impacts the 
downstream analysis of such datasets. A way to effectively work with high-dimensional 
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data is therefore to employ dimensionality reduction methods. There are many 
methods, but they all seek to map the data to a lower dimension space while preserving 
as much of the variation observed in the original data as possible. Although many 
different types of dimensionality reduction approaches exist, here only the approaches 
utilised in this thesis will be covered in detail. 
One of the earliest approaches, principal component analysis (PCA), maps high-
dimensional data to a series of lower dimension uncorrelated variables (‘components’) 
which maximally represent the variance of the original data (Pearson, 1901; Hotelling, 
1933). These components are typically visualised in 2-D or 3-D space with the first 
principal component summarising the largest proportion of the variance, the second 
principal component the second-largest, and the others subsequently following the 
same decreasing pattern, preserving the hierarchy. While these components typically 
comprise important feature sets from the original dataset and can associate with 
different phenotypic effects in a biological context, the content of each principal 
component is mainly cryptic in nature, especially in the case of complex biological data, 
and may be hard to visualise. 
Non-negative matrix factorisation (NMF) is similar to PCA in that it aims to map high-
dimensional data to a lower dimensional space but the approach it utilises is to express 
the original dataset as a combination of two matrices (Paatero and Tapper, 1994; Lee 
and Seung, 1999; Devarajan, 2008). The NMF ‘basis’ matrix defines the number and 
content of variables in the reduced dataset and the ‘coefficients’ matrix estimates how 
each observation in the dataset relates to the reduced variables. Unlike PCA, NMF 
basis matrix outlines the necessary set of features of the original data it describes. Also 
referred to as a ‘metagene’ each variable in the basis matrix can be defined as a set 
of features, and in the case of a biological dataset this would usually be genes or 
methylation loci, although unlike PCA the metagenes are not ordered by any hierarchy 
by variance. Because of the way the NMF algorithm operates, the metagenes it derives 
can also be considered as clusters in the data and the method requires a set cluster 
number or range (‘rank’, k) of at least 2. Metagenes in NMF can also be ‘projected’ 
onto other data where a coefficients matrix is estimated in the new dataset using the 
metagenes derived from the original set (Brunet et al., 2004; Tamayo et al., 2007). This 
is particularly useful in biological data where it allows you to cross-validate results 




More recently, techniques for dimensionality reduction have employed non-linear 
approaches which utilise more abstract concepts such as embedded manifolds in 
dimensional space. The practical upshot of such methods is that they are much more 
compatible with non-linear data- which may be represented by a non-linear function; 
which is a more typical structure for biological data. Two common approaches used in 
biological analyses are t-distributed stochastic neighbour embedding (t-SNE) and 
uniform manifold approximation and projection (UMAP). Both methods function well 
with very large datasets and provide effective visualisation tools. T-SNE uses a 
probability model to identify neighbouring points and express them as a low dimension 
map (Maaten and Hinton, 2008). The downside of t-SNE is that the embeddings are 
probabilistic in nature and the final map is generated to produce the best visualisation, 
so it often discards most of the original dataset structure. UMAP utilises complex 
topology in order to map the relationship between points and preserves the structure 
of the original data to a greater degree than t-SNE (McInnes et al., 2018). Both 
methods are currently used to a limited extend in biological data, however the 
advantages they offer for visualising large datasets has been noted in several 
biological applications (Abdelmoula et al., 2016; Araújo et al., 2017). 
1.6.2 Clustering approaches 
One of the main applications for genomic sequencing or array data, aside from 
differential expression or methylation analysis, are class discovery approaches. Here, 
the aim is to use some subset of the features present in the data to categorise sub-
groups in the dataset. There are many downstream applications of sub-grouping such 
as prognostic significance, understanding biological mechanisms, therapy stratification 
as well as others. Due to the complexity of data, it is favourable to algorithmically 
search for and categorise samples into sub-groups by their features. Although a wide 
array of different clustering approaches exist, only those used in this thesis will be 
discussed in detail.  
Hierarchical clustering is one of the most common approaches to clustering. This 
approach seeks to generate a ‘hierarchy’ of clustering by comparing a (dis-)similarity 
metric between clusters in an unsupervised fashion. Two types of hierarchical 
clustering are used. Agglomerative clustering begins with each sample being a 
separate cluster and then these being combined based on similarity. A divisive 
clustering approach divide a single cluster into smaller groups based on a measure of 
dissimilarity. A typical metric to use for this purpose is distance between pairs of 
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observations with some common examples being Euclidean distance or Manhattan 
distance, or using 1-correlation measures for either Pearson or Spearman correlation 
coefficients. Hierarchical clustering can be susceptible to noise and can be complex to 
calculate in a large dataset (Jiang et al., 2004). Despite this hierarchical clustering can 
still be applied effectively to biological data, though usually with additional steps to 
measure robustness of clusters and allow resampling to test replicability. 
Another unsupervised clustering algorithm is the K-means group of algorithms. K-
means assigns objects to a random cluster and iterates the cluster location to minimise 
the distance metric between the object and the centre of the cluster. K-means requires 
an initial input of cluster number to generate the cluster result, so typically this algorithm 
is carried out across a set of cluster numbers and various metrics used to assess 
robustness and stability. As with hierarchical clustering, K-means can be subject to 
noise (Jiang et al., 2004) and also to the underlying cluster structure (Wu, 2008). 
Previously mentioned, NMF carries out clustering as the typical functionality of 
dimensionality reduction. It is another example of an unsupervised approach which 
requires an initial cluster number input and then seeks to minimise a measure of 
entropy of a probability distribution in the clustering, known as Kullback–Leibler 
divergence. The main positive feature of NMF is that while it generates clusters, it also 
generates metagenes for each cluster which seek to describe the features that define 
that cluster in a meaningful way. 
1.6.3 Measuring cluster robustness 
The unsupervised nature of many clustering approaches, the need to distinguish 
between multiple similar resulting cluster models and the fact that a clustering may 
utilise thousands of features in the result all raise an important issue for the need to 
effectively quantify and discriminate between clustering results and to also ensure the 
result is robust and not simply an artefact or error. 
Many different measures of robustness are employed, and the strategies can involve 
one or several specific statistical metrics or an application of the resulting clustering in 
order to test its performance. Each measures a unique aspect of the clustering, can be 
method specific and not clearly superior to other approaches. 
One of the most common visual measures of cluster consistency is the silhouette 
value. This value measures the similarity of a data point to its cluster compared to other 
clusters obtained using any meaningful distance metric (such as Euclidean distance or 
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1-correlation). For each object in the clustering, silhouette is calculated and compared 
across the whole dataset (Rousseeuw, 1987). A high silhouette score across the data 
suggests that the clustering is appropriate and an averaged silhouette for each 
clustering is readily expressed as a graphic and can be used to identify an optimal 
number of clusters.  
The cophenetic correlation coefficient is another single value method to assess cluster 
quality by comparing the dendrogram generated from a clustering to the original data 
pairwise distances. The higher the coefficient value, the more faithfully the original 
pairwise distances are preserved suggesting that the clustering model is an effective 
representation of the structure of the data (Sokal and Rohlf, 1962). 
The index or coefficient of dispersion can be used to assess whether objects in the 
cluster are clustered or dispersed compared to a model of a probability distribution or 
cluster. This measure of dispersion can therefore be used to assess how distributed or 
dispersed data are within a cluster (Hoel, 1943).  
As well as single measures of cluster stability and conformity, it us useful to measure 
how a particular clustering result may be used to classify novel data. This type of cross-
validation usually relies on the use of a ‘training’ and ‘validation’ dataset. By generating 
a clustering based on some known training data typically where some information 
about the underlying sub-grouping is already available, it is therefore possible apply 
the clustering to a novel dataset using several different machine learning approaches 
and ascertain how effectively the new data are assigned group calls. 
However, due to the limitations of certain biological analyses, it is not always possible 
to have a validation dataset available. In this instance the training data may be used 
to test the effectiveness of the clustering as a classifier by sampling only parts of the 
data at random for a set number of iterations and measuring the frequency with which 
a sample classifies to the same cluster (Dwass, 1957; Efron, 1992) as well as being 
able to calculate confidence intervals and a p-value estimate for hypothesis testing. 
This type of internal resampling is compatible with many clustering approaches where 
cluster order is hierarchical or is otherwise preserved. For methods like NMF, the use 
of metagene projection onto the new resampled clustering can be used in order to 
directly compare each iteration, since normal NMF typically does not preserve cluster 
order. Recently, it was shown that this type of approach could also be used to test non-
linear methods such as t-SNE (Sharma et al., 2019b). 
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1.7 Cancer immune interactions 
11 years after they initially defined the archetypal hallmarks of cancer (Hanahan and 
Weinberg, 2000), Hanahan and Weinberg (2011) refined their original definition to 
include a number of additional features which had become increasingly recognised as 
being critical for cancer development and the challenges regarding therapeutic 
approaches. Among them were the ideas of tumours avoiding destruction by the 
immune system and the environment surrounding the tumour potentially contributing 
to cancer development by supporting continued inflammation. Understanding how the 
immune system interacts with cancer has been shown to be a highly complex and 
nuanced process. 
As well as a growing understanding the underlying biology, studying the immune 
system in cancer can offer prognostic value potentially allowing clinicians to predict 
therapy response as well as offer new therapeutic targets by directly allowing the 
targeting of cancer-promoting immune interactions.  
1.7.1 Immune interactions with cancer 
It was shown 25 years ago that human tumours can trigger the generation of CD4+ 
and CD8+ cytolytic T cells specifically able to recognise cancer cells (Boon et al., 
1994). This function has been linked to the demonstrable propensity of cancer cells to 
produce neo-antigens and express combinations of markers not found on normal 
tissue (Tian et al., 2011). These T-cell interactions typically occur with low affinity due 
to the normal process of T-cell selection, maturation and removal of high-affinity 
autoimmune populations (Giraud et al., 2007) through promiscuous expression of 
tissue-specific antigens in the immune organs. However, high specificity lymphocytes 
can develop due to several specific causes, namely the presence of viral antigens, 
mutation in genes expressing antigen or expression germline genes not found in adult 




Figure 4. Usual process for tumour immune interaction and immune-mediated cancer cell killing 
The ability of cancer cells to actively avoid immune targeting by losing expression of 
reactive antigens (Dunn et al., 2002) and modulate T cell response by the activation of 
immune-checkpoint receptor PD-1 (Drake et al., 2006) as well as a number of other 
regulators add an additional layer of complexity to the tumour immune response 
(Figure 4). However, ongoing research to elucidate the nature of these types of 
immune interactions have already led to multiple successful therapeutic targeting 
strategies for tumour immunology.  
Programmed death 1 (PD-1) is an immune checkpoint receptor found on activated T-
cells and involved in immune modulation. Activation of PD-1 in peripheral tissues leads 
to immune suppression and inhibition of this interaction leads to enhanced immune 
response (Iwai et al., 2002). Ligands of the PD-1 receptor, namely PD-L1/2  are found 
on somatic tissue but are increasingly being encountered in tumours where interaction 
with PD-1 causes T-cell apoptosis (Dong et al., 2002). Monoclonal antibodies targeting 
either CTLA-4 (Hodi et al., 2003), PD-1 or its ligand (Larkin et al., 2015) have been 
developed and show a significant therapeutic potential although there is a great degree 
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of variability in patient response with only a small group of patients responding and a 
high prevalence of therapy-induced side effects (Shen and Zhao, 2018). 
Several factors have been shown to be predictive in response to immune therapy. The 
presence of CD8+ T-cells within the tumour or at the margin (Tumeh et al., 2014), PD-
L1 , CTLA-4 associated gene expression on infiltrating lymphocytes (Herbst et al., 
2016) and on tumour cells (Larkin et al., 2015). It is therefore clear that understanding 
the tumour microenvironment and the specific behaviour of tumour infiltrating 
lymphocytes is necessary for the success of targeted immune therapies. 
1.7.2 Known immune interactions in the CNS 
The CNS has historically been suggested to be a largely immune-privileged site – that 
is largely devoid of immune activity (Streilein, 1993). This was in part due to the 
presence of the blood-brain barrier (BBB), the lack of typical lymphatic structure and 
the significant lack of dendritic cell presence (D'Agostino et al., 2012). It has since been 
shown that immune functions are not absent in the CNS although they occur through 
alternative pathways. Microglia are the cell responsible for a large proportion of antigen 
presentation in the brain as well as several other functions including regulation of 
inflammation (Hayes et al., 1987; Gehrmann et al., 1995; Aloisi, 2001). There is also 
clear evidence for immune cell infiltration in CNS malignancies, with macrophage and 
lymphocyte infiltrates being described in glioblastoma (Rossi et al., 1987; Yang et al., 
2010). Immune therapies in glioblastoma have not been largely successful (Reardon 
et al., 2017a; Reardon et al., 2017b). Deeper understanding of immune infiltration of 
CNS tumours and the role of the TME is necessary to further develop therapeutic 
strategies, improve response and outcome and allow for stratification.  
1.8 Summary  
There is a clear need to further understand how differences genomic and epigenomic 
differences between ATRT and ECRT, the presence and clinical relevance of sub-
groups and novel aspects such as the immune landscape shape MRT biology and 
inform our ability to predict patient outcome and the development of new therapies. 
Ongoing sub-grouping strategies have identified multiple group-specific features but 
have yet not been able to define a single unifying sub-grouping scheme. In addition, it 
is not clear whether there is a clear link between molecular subgroups identified in 
MRT and any significant clinical benefit. Finally, little is known about the immune 
interactions of many CNS tumours including MRT. Understanding the TME in these 
cancers may shed a light on new therapeutic avenues. 
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1.9 Project aims  
This project aimed to expand on current understanding in MRT biology, differences 
between tumour types and the presence of any molecular sub-groups. The focus of 
the identification of subgroups was identifying the optimum number of subgroups and 
using available clinical and genomic data to define their clinical and biological 
relevance. This project aimed to provide guidance on consensus sub-group definitions 
both in terms of methodology and the nature of subgroups identified, as well as 
rationale for their adoption into clinical practice. Finally, this project sought to explore 
novel aspects of MRT biology such as the TME in MRT and any potential for 
therapeutic targeting.  
The major aims for this project were as follows: 
• Generate a UK-wide MRT cohort with molecular profiling and high-quality 
clinical annotation using new and retrospective cases obtained from UK 
cancer centres. Profiling of additional cases to be combined with published 
and collaborator datasets to generate a large multi-platform MRT study cohort 
(Chapter 2)  
• Evaluate current understanding of genomic and epigenomic features of ATRT 
and ECRT and how these differences impact the biology of the tumour to 
understand whether a combined approach of investigating all MRT regardless 
of location is a valid strategy for the development of novel therapeutic 
approaches and understanding of MRT biology (Chapter 3) 
• Develop a consensus in current MRT sub-grouping strategies and generate a 
molecular signature of MRT sub-groups alongside clinicopathological 
annotation addressing any additional heterogeneity in the disease not 
currently well characterised.(Chapter 4) 
• Define sub-group specific survival effects and investigate survival features 
independent of sub-group based on clinical annotation of tumour cohort 
(Chapter 5) 
• Examine the characteristics of immune infiltration of CNS tumours including 
MRT and investigate whether differences in immune infiltration are indicative 




2 Materials and Methods  
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2.1 Study Cohorts 
Datasets used in this study are detailed in the Thesis Appendix 
2.2 Processing of primary patient tumours 
2.2.1 DNA extraction from FFPE material 
Genomic DNA was extracted from scrolls of material obtained from FFPE blocks. 
Sections were obtained from multiple sources and were cut at varying thickness. 
Where possible, scrolls of thickness 20 μm were preferentially used. The number of 
scrolls used per sample was decided based on visual assessment of the block and the 
available scrolls. Extraction of DNA was carried out using the Qiagen QIAmp® DNA 
FPPE tissue extraction kit (Qiagen, Venlo, Netherlands) using the standard 
manufacturer-supplied protocol. The DNA was eluted in 50-100μl of DNase/RNase 
free water. 
2.2.2 DNA extraction from fresh-frozen material 
Genomic DNA was extracted from fresh-frozen material using the Qiagen DNeasy® 
bloody and tissue extraction kit (Qiagen, Venlo, Netherlands) using the standard 
manufacturer-supplied protocol. The DNA was eluted in 50-100μl of DNase/RNase 
free water. Prior to extraction, all handling of material was carried out under 
refrigeration utilising dry ice to avoid degradation of material due to repeated 
freeze/thaw cycles. For long-term storage, frozen material was stored at -80oC. 
2.2.3 RNA extraction from fresh-frozen material 
Patient RNA was extracted from frozen tissue homogenised with TissueLyser II 
(Qiagen) using Trizol Reagent (Ambion, Life Technologies) using the standard 
manufacturer-supplied protocol. 
2.2.4 Quantification of genomic DNA and RNA 
Initial quantity and quality of extracted genomic DNA was carried out using the 
NanoDrop 1000 Spectrophotometer to analyse the absorbance ratio 260nm/280nm. 
For the purposes of microarray analysis, the Qubit® PicoGreen dsDNA broad range 
assay kit (Invitrogen, Carlsbad, CA, USA) was used using the standard manufacturer-
supplied protocol to obtain the quantity of double-stranded DNA. 
RNA quality was assessed using a Bioanalyzer (Agilent Technologies) with an Agilent 
RNA 6000 Nano kit using the standard manufacturer-supplied protocol to assay 
46 
 
general quality of extracted RNA and to obtain the RNA integrity (RIN) number which 
is a measure of the level of degradation and fragmentation of RNA. 
2.3 Bioinformatic analysis 
2.3.1 Methylation array 
2.3.1.1 Pre-processing of raw 450K/EPIC microarray data 
BeadArray IDAT files were obtained and preprocessed using the (R/Bioconductor) 
package minfi (Aryee et al., 2014). Data from both array platforms was combined at 
the RedGreenChannelSet level and any probes not shared between the two platforms 
were discarded prior to normalisation. 
2.3.1.2 Quality control of 450K/EPIC microarray data 
Quality control of the DNA methylation microarray data was carried out using internal 
minfi functionality for QC. Detection P-value as well as array-specific control probe 
intensities were assessed for any evidence of failed or poor-quality arrays. Where 
detection P-values for probes on an array > 0.05 in 5% of probes or more, the sample 
was removed from the dataset prior to normalisation. 
2.3.1.3 Normalisation of 450K/EPIC microarray data 
Normalisation of data was carried out using the normal-exponential out-of-band (noob) 
method using single sample normalisation as this approach allows a flexible sample 
processing pipeline and removes the need to preprocess an entire dataset in one batch 
while still controlling for technical variability (Triche et al., 2013). Datasets intended for 
use with copy-number estimation were retained at this point and were nor subject to 
additional steps outside of the specific copy-number estimation pipeline. 
Following normalisation, the dataset was mapped to the human genome using the 
Illumina array manifest for genome assembly hg19/GRCh37 and beta-value ratios 
were obtained for each probe retained in the dataset. 
2.3.1.4 Non-specific filtering of CpG probes 
Probes were removed based on several filtering criteria. Probes that mapped up to 2 
nucleotides away from a known SNP and where a minor allele frequency (MAF) was 
greater than 0.05 were removed. Sex chromosomes were removed and any probes 
mapping to non-methylated loci (typically used as control probes). Finally, probes 
shown to cross-hybridise to multiple loci on the genome were removed based on 
recommendations from two publications specifically analysing the hybridizing 
behaviour of the 450K/EPIC arrays (Chen et al., 2013; Pidsley et al., 2016).  
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2.3.1.5 Estimating Copy-Number Aberrations using methylation array data 
450K/EPIC methylation array data was used to estimate DNA copy-number using the 
package conumee (R/Bioconductor). 119 samples in the “Control” group from the 
Molecular Neuropathology 2.0 (MNP2.0) dataset (Capper et al., 2018) were used as 
control reference arrays. The analysis was run using default parameters. Gain or loss 
of individual chromosomal arms was estimated using the method discussed in 
Schwalbe et al. (2017b) with the cut-off for a “Loss” event of -0.22 and a “Gain” event 
of 0.12.  
2.3.2 Expression array 
2.3.2.1 Pre-processing of Affymetrix expression microarray data 
Affymetrix expression array data was processed using the affy package 
(R/Bioconductor). Raw CEL files were read into AffyBatch objects and normalised 
using Robust Multi-Array Average expression measure (RMA) method (Irizarry et al., 
2003) 
2.3.2.2 Non-specific filtering of Affymetrix probes 
For the purpose of clustering and dimensionality reduction, non-specific filtering of 
probes was carried out using the genefilter package (R/Bioconductor). Probes were 
temporarily transformed from log2-scale and retained if they satisfied two criteria: a 
coefficient of variation > 1 and at least 5% of samples having an intensity of 200 or 
greater. 
2.3.2.3 Differential expression analysis (DE) 
Supervised analyses of differential expression were carried out using the limma 
package (R/Bioconductor). The model formula and testing contrasts were constructed 
using internal functionality and using phenotypic data factors such as sub-group, age, 
CNS location and other factors relevant for testing. An empirical Bayes method was 
used to obtain either the moderated t-statistics or F-statistic and the p-value provided 
was adjusted for multiple testing using the “Benjamini & Hochberg” method. 
2.3.3 RNA-Sequencing 
Total RNA (RIN > 7) was prepared for RNA-sequencing using Illumina Tru-seq RNA-
seq Library Preparation Kit. Library was run on an Illumina HiSeq2500, 4 x multiplex 
as a 100bp paired-end run at around 90M reads per sample. 
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2.3.3.1 Pre-processing of raw sequencing data 
Fastq files from RNA-seq experiments were subject to quality control check using 
FastQC. Reads were aligned to HG19 (USCS) genome using RNA-STAR. Read 
counts were generated by HT-seq-count mapping to the GENCODEv17 library. 
2.3.4 Clustering analysis 
2.3.4.1 Hierarchical clustering 
Hierarchical clustering was performed using the ConsensusClusterPlus package 
(R/Bioconductor). A distance matrix was generated as 1- Pearson correlation 
coefficient and clustered using the k-means algorithm for 1000 repetitions and an item 
resampling rate 0f 80%. 
2.3.4.2 Non-negative matrix factorisation (NMF) 
Non-negative matrix factorisation was carried using the NMF package 
(R/Bioconductor). The default package parameters were ued for all analyses at 256 
iterations. Resampling NMF was carried out using the method outline in Schwalbe et 
al. (2017b) for 1000 repetitions and an item resampling rate of 80%. An initial training 
NMF result was calculated for the range of metagenes (k) being tested. For the range 
of k, test data was initially subject to resampling without replacement at the specific 
resampling rate and subsequently clustered again by NMF for 256 iterations and a 
pseudo-inverse metagene projection was carried out as described in (Tamayo et al., 
2007) onto the whole training NMF result. The resulting projection was clustered by K-
means for the number of clusters in the range of k. The resulting frequency of 
assignment to the same cluster group was recorded and an average of the NMF H 
values for each metagene calculated. Clustering robustness was estimated using the 
initial metrics provided by the NMF package as well as the Corrected Rand Index 
(CRAND), Cohen’s Kappa coefficient, Average Silhouette calculated from k-means 
clustering for each combination of k metagenes and k clusters and the proportion of 
samples in each combination of k metagenes and k clusters that are assigned to the 
same metagene with a frequency 95% or greater.  
Comparison of NMF with hierarchical clustering was carried out on subsets of data. 
Although not included as part of this thesis, hierarchical clustering and NMF were 
carried out with different numbers of methylation array probes based on different 
thresholds of standard deviation. Additionally, different hierarchical clustering and NMF 
computation algorithms offered by the respective R packages were used. Metrics of 
subgrouping were inspected alongside the resulting number and content of subgroups. 
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Although some variability in a subset of the data does exist, with around 10% of 
samples being assigned different subgrouping calls, the overall subgrouping for the 
majority of the datasets despite different approaches to thresholding, the clustering 
method and algorithm. Due to the additional features of NMF such as the basis and 
coefficient matrices defining metagenes within the data and its overall robustness 
through the analyses, NMF was chosen as the main method of subgrouping for this 
thesis.  
A more formal comparison of subgrouping approaches was published as part of the 
international ATRT consensus project parts of this thesis analysis contributed to. The 
ATRT consensus study text has been accepted for publication and is currently 
available as a pre-publication document (doi: 10.1093/neuonc/noz235). 
2.3.4.3 T-distributed Stochastic Neighbour Embedding (t-SNE) and Uniform Manifold 
Approximation and Projection (UMAP) 
T-SNE was carried out using the package Rtsne (R/Bioconductor) on a distance matrix 
generated as 1- Pearson correlation coefficient without PCA. Exact t-SNE was carried 
out with the theta parameter of 0. Perplexity was set to default where the package 
function allowed, and where the function stated the perplexity was too high, the value 
was reduced to satisfy the internal threshold and based on subjective judgement of the 
final visualisation. Each t-SNE analysis was iterated 5000 times. 
UMAP was carried out using the package uwot (R/Github) using default parameters 
and the number of neighbours based on subjective judgement of the final visualisation. 
2.3.5 Gene pathway analysis 
2.3.5.1 Gene-set enrichment analysis (GSEA) 
GSEA was carried out using version 2.2.4 of the program on pre-ranked datasets with 
geneset msigdb version 6.2, 1000 permutations and maximum and minimum geneset 
thresholds set to 500 and 15, respectively. 
2.3.6 Survival analysis 
Overall survival (OS) and progression-free survival (PFS) were calculated from date of 
diagnosis to date of death, record of progressive disease or censored. Survival curves 
were generated using the package survminer (R/Bioconductor). Cox proportional 
hazard regression modelling was carried out using the package survival for both 
univariate and multivariate analyses. ROC curves used to test survival models were 
generated using the package survivalROC (R/Bioconductor) 
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2.3.7 Estimation of immune infiltration using DNA methylation 
2.3.7.1 Generation of signature matrix 
The custom limma-based function as described by Chakravarthy et al. (2018) was 
used to fit linear models performing a pairwise comparison between each of the cell 
types. A maximum of 200 top features per pairwise comparison were selected 
restricting to probes showing a median beta-value difference of 0.2 and FDR of 0.01. 
Beta-values were scaled to between 0-100 and probe means per cell type calculated 
to form a signature matrix compatible with CIBERSORT.  
2.3.7.2 Running CIBERSORT 
Input methylation matrices were created by processing raw .idat files as per above. 
Data were sourced from published GEO datasets GSE70460, GSE109381, 
GSE77353, GSE63669, GSE60274; Array Express dataset E-MTAB-5528 and the 
MRT cohort generated as part of this thesis. CIBERSORT was run in relative mode 
using the provided R script (https://cibersort.stanford.edu) using 1000 permutations 
without quantile normalization.  
2.3.7.3 Validation and benchmarking of signature matrix 
The signature matrix was inspected to verify that each cell type was accounted for by 
specific hypo/hyper-methylated CpGs and not unduly compromised by batch effects. 
Likewise, t-SNE (package rtsne) was used to visualize the cell-type specificity of the 
signature matrix. The mean and sd of signature matrix CpGs were inspected in each 
of the 80 CNS-tumor methylation types represented in dataset GSE109381 to identify 
possible outlier or confounding effects between immune-cell type specific CpGs and 
tumor cell types. 
Deconvolution performance was benchmarked against 18 gold standards i.e. 6 x 
methylation profiles of peripheral blood mononuclear cell (PBMC) mixtures with known 
flow-cytometry and 12 x mixtures of reference pure populations DNA in known 
proportions (GSE112618). Performance was also benchmarked against simulated 
mixtures generated to contain know quantities of a given cell type. This was achieved 
by taking the mean beta-value of each pure cell reference and applying a random 
uniform distribution such that each simulated mixture contained a fixed amount of a 
given cell type (100 simulations for each) and a fixed 75% cancer cell signature derived 
from relevant cancer cell reference lines. Correlation with methylCIBERSORT 
estimates was tested by the Spearman Rank method. 
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A Breast cancer dataset (GSE20713, GSE72308) containing 87 samples with parallel 
Affymetrix HGU133p2 expression profiles and 450K Methylation profiles was used to 
compare relative cell type estimates from both methylCIBERSORT and the classic 
expression CIBERSORT run using standard signature matrix LM22 
(cibersort.stanford.edu) in relative mode using 1000 permutations with quantile 
normalization. meTIL score (an independent measure of T Lymphocyte infiltration 
based upon methylation status of 5 CPGs) was calculated following the method as 
described by Jeschke et al. (2017)  
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As previously discussed, ATRT and ECRT share many common biological and clinical 
characteristics, appear to have similar aetiology and exhibit the same sole molecular 
feature of bi-allelic SMARCB1 loss. Historically, the similarities and differences 
between the two broad tumour types have been discussed by citing comparable 
studies or similar outcomes in various small datasets.  
The first, and currently only study to directly compare expression in ATRT and ECRT 
examined 10 RTK and 13 ATRT tumours by gene expression and miRNA profiling 
array (Grupenmacher et al., 2013). The authors reported 122 genes significantly 
differentially expressed between the two tumour types, but failed to identify miRNA 
differences. Genes downregulated in ATRT included TBX2, HOXA5/9, IGFBP5 while 
genes upregulated in the group included FABP7, SOX2, NEUROG2, and BMP7. 
In the last 5 years, a number of studies have sought to analyse the molecular features 
of either ATRT, or ECRT and these can give insights into the overlapping biology of 
MRT as well as highlight the key features which separate these tumours. Han et al. 
(2016) carried out clustering of gene expression microarray data from human primary 
tumours alongside a series of tumours derived from mouse-modelling of MRT during 
embryogenesis, and public datasets of stem cell populations. By perturbing Smarcb1 
using a temporal gene knockout system in mice, they showed high incidence of intra-
cranial tumours resembling ATRT and they examined the gene expression and 
pathway relationships between the different tumour types alongside these murine-
derived tumours. For MRT, they identified 3 intra-cranial sub-groups termed (hIC1-3) 
and a single extra-cranial sub-group (hEC). By comparing each sub-group with 
populations of stem cells, they showed that hEC as well as hIC1/2 correlated 
expression with embryonal stem cells (ESC), neuroepithelium, and to a lesser extend 
neural progenitor cells. Additionally, hEC and hIC1/3 but not hIC2 showed significant 
correlation with neural crest cells and mesenchymal stem cells.  
hIC1,2 and 3 showed high expression of neural gene ACTL6A suggesting a neural 
progenitor lineage, while hEC showed high expression of homeobox genes such as 
TBX2 and HOXC, although moderate expression was noted in hIC2 and hIC3 for the 
two genes, respectively. Interestingly, the paper highlighted differential expression 
between sub-groups of the gene HMOX1 encoded on chromosome band 22q12, which 
is relatively close to the position of SMARCB1 (22q11). An emerging feature of MRT 
is the different types of chromosome 22 aberrations between sub-groups, with the 
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MYC sub-group showing the lowest frequency of whole and partial chromosome 22 
loss (Johann et al., 2016; Torchia et al., 2016). This could, in part, explain the higher 
expression levels of HMOX1 in the hEC and hIC1 sub-groups in the publication as 
these also share higher expression of MYC and lower expression of ASCL1, HES5 
and GLI1, although this has not been investigated further. 
Subsequently, two analyses on ATRT and ECRT respectively were published later in 
2016 looking at sub-groups and biological heterogeneity in the tumour types. Chun et 
al. (2016) published an analysis of ECRT transcriptomic data. RNA-Seq data for 40 
primary tumours, (comprising 34 RTK and 6 extra-renal ECRT) showed the presence 
of two expression sub-groups. Sub-group 1 (n  = 22) contained all the extra-renal 
ECRT cases and was showed high expression of immune genes such as 
immunoglobulins and genes associated with BMP pathway signalling such as BMP4. 
Sub-group 2 showed increased WNT signalling such as WNT5A. Importantly, 
comparing their sub-group definition to the 122 differentially expressed genes 
highlighted by Illumina HT-12 array in ATRT and RTK (Grupenmacher et al., 2013) the 
authors suggested that sub-group 1 could resemble ATRT (11/29 genes up in ATRT) 
while sub-group 2 RTK (21/92 genes up in RTK). In addition to the transcriptomic 
analysis, the authors carried out ChIP sequencing (ChIP-seq) on 10 MRT primary 
tumours, 3 MRT cell lines and 3 human embryonal stem-cell (hESC) lines, identifying 
significant H3K27 acetylation density at HOXA,B,C gene clusters, consistent with the 
previous findings of Han et al. of HOX gene association with hEC.  
The second published analysis, focusing on ATRT examined 150 methylation array 
and 49 gene expression array profiles. They identified 3 ATRT sub-groups for which 
they defined a broad definition of SHH, TYR and MYC using ChIP association with 
gene enhancer regions. The three groups showed differences in localisation, type of 
SMARCB1 mutation and gene expression with SHH being the most neuronal group 
showing high expression of GLI2, SOX11 and MYC being the most mesenchymal 
group expressing MYC and HOXC most highly among the 3 groups. 
Taken together these findings show that differences between MRT may not be simply 
explained by where they originate. They suggest that in both their transcription profile 
and epigenetic regulation MRT occurring in the CNS may resemble their extra-cranial 
counterpart, or vice versa and rather than simply focusing on the tumour location, it is 
important to understand the nature of any disease subgroups that exist. The degree of 
overlap between ATRT and ECRT therefore still remains difficult to pin down and 
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requires further elucidation to fully assess the biological overlap between tumours 
occurring between tissues of vastly different function.  
3.2 Aims 
The aims of this chapter are to highlight the common features shared by all MRT 
regardless of localisation by comparing them to other tumour types of embryonal origin 
as well as examine the specific differences between ATRT and ECRT using expression 
and methylation profiling. 
The degree of overlap will be examined to understand whether a recommendation for 
future subgrouping and therapeutic targeting strategies should be aimed at MRT as a 
whole.  
3.3 Results 
3.3.1 ATRT and ECRT share methylation and expression features across 
anatomically distinct sites 
In order to compare gene expression between different embryonal tumours, relevant 
Affymetrix HG U133Plus2.0 gene expression datasets were obtained from publications 
and online public repositories. Although other datasets were available, this platform 
was selected due to the availability of multiple tumour types and the ability to process 
and normalise the combined raw dataset. In order to generate the final dataset, 
samples which were found to have duplicated GEO accessions or not to cluster by t-
SNE with their published subgroup assignment were removed. A final table of the 
samples used is provided in the Appendix 8.2 along with a designation for inclusion 
and a reason for their removal. 
A total of 824 HGU133Plus2.0 profiles were analysed from 7 tumour types: ATRT (n = 
111, GSE35493, GSE64019 GSE67851, GSE70678, GSE73038 GEO/NIH), ECRT (n 
= 20, GSE64019 GEO/NIH), Ewing Sarcoma (EWS; n = 103, GSE34620 GEO/NIH), 
medulloblastoma (MB; n = 214, GSE10327, GSE12992, GSE37418, GSE73038 
GEO/NIH), neuroblastoma (NB; n = 137, GSE1623, GSE16476 GEO/NIH), 
rhabdomyosarcoma (RMS; n = 101, E-TABM-1202 ArrayExpress/EMBL-EBI) and 




Figure 5. 2D t-SNE embedding plot of 824 embryonal tumour U133Plus2.0 expression array profiles  using the log2-
fold expression intensities of 4934 most variable probes. MB: medulloblastoma, NB: neuroblastoma, EWS: Ewing 
sarcoma, RMS: rhabdomyosarcoma, WT: Wilms tumour. 
T-SNE embedding of the 4934 most variable probes (Figure 5) shows each tumour 
type reliably generates unique clusters. ATRT and ECRT cluster together without 
visible separation between extra-cranial samples, although the segregated structure 
suggests ECRT behaving as a sub-type. Importantly, the presence of classical MB 
sub-groups (WNT, SHH, Grp 3/4) shown by the separation of the MB population into 
at least 3 distinct clusters suggest that intra- and extra-cranial localisations of MRT 
have a more related transcriptional programme than sub-groups of MB derived from 




Figure 6. Venn diagram of the resulting significantly differentially expressed probes in the U133Plus2.0 gene 
expression array between multiple tumour types and MRT.  
Supervised differential expression analysis was done using the package limma 
(R/Bioconductor) by combining ATRT and ECRT profiles into a single MRT cohort and 
carrying out an empirical Bayes method to obtain a moderated F-statistic and p-value 
for comparisons between MRT and other tumour types. Of the total 39620 probes 
included in the analysis from the HGU133Plus2.0 array, 3310 probes were significantly 
differentially expressed in at least 3/5 comparisons and 372 were identified MRT-
specific as defined by being significant in each differential expression comparison (p < 
0.05, absolute mean log2FC > 1) (Figure 6). More specifically, 60% (244/372) were 
found to also to exhibit the same expression pattern in each comparison – always 
upregulated in MRT or always downregulated relative to other tumours (p < 0.05, 
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Figure 7. Heatmap of relative gene expression between MRT and other embryonal tumour types.  The top 100 
differentially expressed probes are shown. Red denotes high expression and blue denotes low expression. The 
data is scaled by row. 
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The top differentially expressed genes between MRT and other tumours include 
FGFBP3, HHIP, TFPI2, SLC2A3, FGF13, SOX11 and FAT3. Enrichment of genes 
associated with nervous system development, osteoblast differentiation, and WNT 
signalling was noted using DAVID highlighting the many lineage markers these 
tumours express however the highly specific and stringent nature of the analysis likely 
underestimates differences due to many cancer pathways being shared across 
multiple tumour types.  
3.3.2 Analysis of differences between ATRT and ECRT highlights location-
specific features 
In order to examine the differences in gene expression between ATRT and ECRT, a 
supervised differential gene expression analysis was carried out on 131 MRT 
U133Plus2.0 profiles (ATRT n = 111, ECRT = 20). 553 probes were found to be 
significantly differentially expressed between the two MRT types (p < 0.05, absolute 
log2FC > 2). Probes significantly enriched in ATRT included SOX2, FABP7, OTX2, 
ASCL1 and GFAP, while ECRT expression showed high expression of HOXA/B/C, 
IGF2 and MYC. 
Functional annotation using DAVID for the ATRT enriched probes (n = 490) was 
predominated by pathways/genesets related to neuronal function and neural 
development. ECRT enriched probes (n = 63) identified a smaller set of 
pathways/genesets largely associated with embryonal development and skeletal 
system development. Importantly, among profiles in the ATRT dataset, a small group 
(n = 12) exhibited expression much more in line with ECRT including high expression 




Figure 8. Heatmap of relative gene expression between ATRT and ECRT.  The top 100 differentially expressed 




Figure 9. Heatmap of relative gene expression between ATRT and ECRT RNA-Seq.  The top 100 differentially 





Differential expression analysis of an MRT RNA-Seq cohort (ATRT n = 10, ECRT n = 
13) was carried out to further interrogate the differences. 2050 genes were found to be 
differentially expressed between ATRT and ECRT. Genes enriched in ATRT largely 
supported previous findings including overexpression of FABP7, SOX2, and GFAP, 
and functional annotation with DAVID of the 1691 genes associated with and 
overexpressed in ATRT showed a predominance of neural development and function 
genesets. 359 genes associated with ECRT included HOX cluster genes, and 
functional annotation showed enrichment of inflammatory response, skeletal and 
muscle development. A heatmap of the differential expression findings are shown in 
Figure 9. 
3.3.3 Combined MRT sub-grouping strategies recapitulate previous ATRT-only 
models 
Previous sub-grouping strategies have largely relied on a single MRT type and only 
one publication has co-clustered ATRT and ECRT tumour profiles (Han et al., 2016). 
Differential expression between MRT and other embryonal tumours as well as between 
types of MRT partially supports previous findings that ECRT sub-types may resemble 
their CNS counterparts and vice-versa. In order to investigate the relationship between 
existing sub-grouping strategies for ATRT and ECRT tumours, unsupervised clustering 
was carried out using NMF. 
Using the published 3 sub-group annotation of ATRT from Johann et al. (2016) and 
ECRT data obtained from public databases, the resulting sub-grouping schemes were 
compared in order to ascertain whether inclusion of ECRT caused previously defined 
sample subgroup to drastically change and whether the addition of ECRT would simply 
create a separate sub-group such as hEC in Han et al. (2016). 
Figure 10 shows the NMF clustering quality metrics derived from two consensus NMF 
unsupervised clustering results. Figure 10A shows the results obtained from clustering 
49 ATRT profiles from from Johann et al. (2016), Figure 10B shows the results from 
the combined 131 MRT dataset. Both the cophenetic coefficient and dispersion index 
in A indicate a 3-group result as the most optimal, while in B both measures steadily 
decline as the number of sub-groups is increased. However, when comparing the 
resampled group calls between shared samples between the two clustering models 
(Table 3) only 4% (2/49) of samples were reclassified. In other words, although the 
measures of cluster robustness by the NMF package do not favour any result above 2 
groups in the MRT NMF dataset, the resulting resampled group allocations are almost 
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identical between the two datasets showing that addition of additional samples 
including ECRT into the dataset did not significantly alter the existing sub-grouping but 
allowed to also assign sub-groups to ECRT and ATRT together. 
 
Figure 10. NMF cluster quality metrics for  A) clustering of 49 samples from 49 ATRT only B) clustering of 131 MRT 




Figure 11. Sankey plot comparison between different NMF clustering cohorts  49 ATRT-only and combined MRT 
and the published classification from Johann et al. (2016) or the MRT localisation derived from the expression array 
dataset.  
In the combined MRT expression cohort, all additional 20 ECRT samples clustered to 
the MYC sub-group. Notably, there was more disagreement between the NMF 
methods used in this analysis and the published group assignments based on 
hierarchical clustering with 22% (11/49) samples being reassigned to a different sub-
group – most commonly moving between MRT and TYR. It can be assumed that the 
differences are largely caused by the use of different clustering strategies and 
highlights a need for a consensus approach to sub-grouping in MRT. 
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However, is possible to combine data from all MRT localisations and still obtain a 




49ATRT only NMF SHH TYR MYC 
SHH 13 1 2 
TYR 0 14 4 
MYC 2 2 11 




131 MRT NMF SHH TYR MYC 
SHH 14 1 1 
TYR 0 14 4 
MYC 3 2 10 
Agreement = 78%, disagreement 22% 
 
 
131 MRT NMF 
49ATRT NMF SHH TYR MYC 
SHH 15 0 2 
TYR 0 17 0 
MYC 0 0 15 
Agreement = 96%, disagreement 4% 
Table 3. Comparison of agreement and disagreement between 3 clustering approaches:  Published calls from 
Johann et al. (2016), 49ATRT–only NMF and combined MRT NMF. 
3.4 Discussion  
Currently, there is no definitive sub-grouping strategies that combine both ATRT and 
ECRT. Previous publications have shown that sub-groups of MRT can resemble their 
distally localised counterparts in expression profiles and DNA methylation, but despite 
a number of large genomic studies, MRT sub-types are still analysed and studied 
separately. The findings in this chapter highlight the relatedness of ATRT and ECRT 
by showing that differences between the localisations appear to closer resemble 
disease sub-groups than distinct tumour types. In addition, the expression programme 
of MRT appears to be more closely related than sub-groups of other CNS tumours 
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largely derived from a single location in the brain. This chapter presented an MRT-
specific expression signature that was derived by comparing MRT against other 
embryonal tumours in a stringent differential expression analysis. Combined MRT 
subgrouping schemes were compared with those derived in only a single tumour type 
and it was shown that despite a reduction in the resulting clustering metrics, resampled 
subgroup calls from consensus NMF did not differ on the addition of ECRT and the 
clustering was able to accommodate tumour types from different parts of the body 
without clustering artifacts 
Differences between types of MRT appear to be largely related to the typical tissues 
they are found in. ATRT overexpress genes associated with neuronal function and 
neural development while ECRT display a less cohesive expression programme 
consistent with the differing localisations. Notably, it was not possible to expand the 
ECRT proportion of the cohort and it can be considered a limitation of the analysis as 
the differential expression between embryonal tumour types and also between ATRT 
and ECRT will be skewed towards the larger ATRT component. Nevertheless, it was 
still shown that ECRT contributed unique expression markers including a strong 
expression of HOX cluster genes and MYC.  
The findings highlighted in this chapter suggest that future sub-grouping approaches 
should include both ATRT and ECRT and that moving forward, there should be a 
concerted effort to further delineate the relationship between these two tumour sub-
types by expanding the size and quality of the available profiling cohorts. In addition, 
the results point to a common biology shared by all MRT which could play a role in 
future therapeutic strategies. However, there is considerable heterogeneity between 
MRT cases and the relatively successful combined clustering approach suggests that 
rather than focusing on sub-types as defined by tumour location, MRT heterogeneity 
could perhaps be better defined as the result of disease subgroups, which have already 




4 Generating a molecular signature of MRT sub-groups 




Restricting analysis to only examine differences between localisations of MRT does 
not account for the full extent of the heterogeneity seen in the disease. Chapter 3 
already discussed how sub-sets of ECRT can resemble the CNS disease and vice-
versa, however differences in markers expressed by the tumours as reported in 
literature, variability in response to therapies and ultimately patient survival also point 
towards potential disease sub-groups. As well as explaining the currently observed 
tumour heterogeneity, sub-grouping can further reveal novel aspects of the tumour 
biology by highlighting differential gene, pathway, and epigenetic features. It can allow 
for disease prognostication and even identify new therapeutic targets and better inform 
our current approach to treating MRT.  
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A number of sub-grouping schemes for MRT have been proposed. They differ by the 
type of MRT used in analysis, analysis carried out, sub-group number, and the sub-
group definitions. A summary of the currently available sub-grouping strategies is 
outlined in (Table 4). Before beginning of this study in 2015, a sub-grouping scheme 
was proposed for ATRT only by (Torchia et al., 2015). Sub-grouping was carried out 
on Illumina HT-12 v4.0 expression array analysing 43 primary tumours. The authors 
reported two groups as identified by unsupervised hierarchical clustering and NMF, 
noting that one of the groups showed additional heterogeneity but acknowledged small 
cohort size as a limitation of confidently classifying more than two clusters. Sub-
grouping was validated with IHC assay for expression of ASCL1, a member of the 
NOTCH pathway identified to be differentially expressed between proposed sub-
groups. Low expression of this marker had a significantly higher associated risk and 
worse survival and was the first study to extract prognostic information from ATRT sub-
grouping. 
Subsequently, in early 2016, a sub-grouping study comprising both ATRT (n = 30) and 
ECRT (n = 20) was carried out by (Han et al., 2016) as part of a wider comparison 
between a mouse model of MRT and the human disease. Hierarchical clustering with 
resampling using the ConsensusClusterPlus R package identified 4 MRT sub-groups 
separate to medulloblastoma and neuroblastoma comparators. The three described 
intra-cranial groups (hIC1-3) and one extra-cranial group (hEC) were further explored 
for differential gene expression as well as correlation with expression profiles for 
various stem cell and progenitor populations. hIC2 was shown to correlate strongly 
with neuro-epithelium and other early neuronal lineages. Lower correlation was 
observed in the other sub-groups, with hIC3 showing weak correlation in all 
comparisons likely attributed to the fact the group only contained 5 samples. hEC 
correlated strongly with embryonal stem cell populations. Differential gene expression 
analysis highlighted similar features in the sub-groups with hIC2 showing high 
expression of genes associated with early neural development SOX2, POU3F1/2 and 
ASCL1, hIC1 showing lower levels of expression of these genes but high BMP pathway 
gene expression, and hIC3 showing expression of glial genes such as GFAP. The main 
feature of hEC was the lack of expression of neural progenitor genes, high MYC and 
HOXA/C gene expression as well expression of various cytokines such as TGFBR2, 
TGFBR3. Although this study did not include any prognostic or survival annotation, it 
generated a sub-grouping scheme comparing all types of MRT and provided an 
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overview of expression differences that hint at multiple possible cells of origin of the 
tumours. 
Two separate publications published in the same journal issue examined ATRT and 
ECRT tumours, respectively. (Johann et al., 2016) carried out clustering on 150 ATRT 
450K methylation and 49 ATRT HGU133Plus2.0 expression array profiles using 
ConsensusClusterPlus. The analysis identified 3 sub-groups as the most favourable 
clustering result with a high degree of concordance between the two platforms (88%, 
23/26) for samples with both data types available. They termed the sub-groups “ATRT-
SHH”, “ATRT-TYR” and “ATRT-MYC”, with the SHH group showing high SHH 
signalling with overexpression of MYCN and GLI2, TYR sub-group containing the 
majority of patients <1 year old and showing high expression of the TYR and MITF 
genes and MYC overexpressing the gene MYC. Importantly, unlike the SHH sub-group 
of MB, ATRT-SHH harboured no aberrations in any SHH-pathway genes. The authors 
also noted that the ATRT-SHH sub-group could be further clustered into sub-types by 
methylation, suggesting additional heterogeneity in this cluster. Whole-genome DNA 
(WGS) and RNA-Seq for 18 samples was carried out but did not identify any additional 
mutations aside from in SMARCB1 varied across sub-group. The authors described 
differences in activating mutations across the proposed sub-groups with ATRT-TYR 
showing broad chromosome 22q deletions which were not prevalent in the other sub-
groups. In addition to this, all sub-groups were shown to harbour high levels of whole-
genome and promoter-specific DNA methylation compared to other embryonal 
tumours, with ATRT-TYR showing the highest of the three groups. 
(Chun et al., 2016) carried out RNA-Seq, WGS and microRNA sequencing of ECRT 
including both RTK and extra-renal tumours. From NMF clustering of 40 RNA-Seq 
profiles, they identified 2 stable sub-groups. Group 1 comprised tumours from all ECRT 
locations, contained older patients (50% >1 year old) and had overexpressed genes 
associated with immune function, and BMP-signalling. Group 2 contained only RTK 
cases, was enriched for younger patients (72% <1year old) and overexpressed WNT-
signalling genes. The study also compared microRNA profiles from ECRT with other 
tumour and normal cell types identified two groups – one clustering with synovial 
sarcoma and one that clustered with normal cerebellum and neural crest cell tumours. 
Taken together, these results suggest that at least a sub-set of ECRT share regulatory 
and transcriptomic features with ATRT once again showing that sub-groups in MRT 
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potentially cut across tumour localisations rather than being strictly dictated by 
anatomical site. 
In late 2016, Following on from the 2015 study which identified 2 ATRT sub-groups 
with differing survival, (Torchia et al., 2016) published an expanded ATRT sub-group 
scheme identifying 3 ATRT sub-groups through a combined analysis of DNA 
methylation and gene expression array. The authors noticed similar age distribution, 
SMARCB1 alterations and gene expression features to (Johann et al., 2016) with 
Group 1 resembling ATRT-SHH, Group 2A ATRT-TYR and Group 2B ATRT-MYC. The 
authors went on to demonstrate that Group 2 tumours were sensitive to dasatinib and 
nilotinib as well as validating other downstream targets. 
In a relatively short space of less than 2 years, 5 different sub-grouping approaches 
have been suggested for MRT. The schemes share some parallels but there is no 
consensus on the number of sub-groups, their molecular features and if these groups 
present different prognostic and therapeutic opportunities. This situation is further 
complicated by examples of subsequent literature utilising varying sub-grouping 
strategies, as well as a DNA methylation-based molecular sub-group classifier for CNS 
tumours having been developed (Capper et al., 2018) that uses only one sub-grouping 
approach.  
There appears to be a clear need for a consensus sub-grouping approach in MRT not 
only to generate a more complete understanding of the different features of sub-groups 
presented by the array of profiling and analyses carried out, but also to provide a single, 
unified platform that informs future clinical and biological research in this tumour type. 
In order to address this issue partially, an international collaboration is currently 
underway to generate a consensus ATRT-only sub-grouping approach to which the 
analysis presented here contributed in part and the manuscript currently in peer-review 
is attached. However, no current such consensus analysis currently exists for MRT as 
a whole. Therefore in this chapter, an expanded consensus analysis encompassing all 
types of MRT is presented. 
4.2 Aims 
The aims of this chapter were to, firstly, carry out a meta-analysis of publicly available 
and newly-profiled MRT datasets in order to contrast and compare the current sub-
grouping schemes in MRT. The optimum number of sub-groups was assessed, as well 
as analysing the gene expression and DNA methylation array molecular signature and 
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clinicopathological features of each group in order to provide a recommendation 
consensus MRT sub-grouping strategy. 
Secondly, the inclusion of ECRT and additional newly-profiled ATRT profiles were be 
used to investigate whether additional sub-groups may be identified in MRT, and 
further defined by clinicopathological features. 
4.3 Differential methylation and expression analysis of MRT sub-groups 
reveals group-specific changes 
4.3.1 Meta-analysis of gene expression array  
HGU133Plus2.0 gene expression array data comprising 131 primary tumours (ATRT 
n = 111, extra-renal ECRT n = 16, and RTK n = 4, see Methods 2.1.3) was initially 
subject to consensus NMF clustering described in Methods 2.3.4.2 in order to generate 
a single comparable sub-group assignment across datasets. Clustering identified 3 
stable clusters based on clustering metrics shown in Error! Reference source not f
ound.A-E with 95% (125/131) of samples being assigned a consensus NMF call. 5% 
(6/131) of samples were assigned as NC due to failing to reliably cluster to a single 
metagene. Nomenclature for the consensus NMF clusters was chosen as SHH, TYR, 
MYC and non-classifiable (NC) due to this scheme being the chosen nomenclature 
proposed in the current ATRT consensus meta-analysis. 
Comparing the (Han et al., 2016) sub-grouping to the consensus NMF result for 
samples obtained from the study shows a considerable degree of overlap between the 
two schemes. hIC2 completely overlaps with the consensus NMF group SHH, hIC1 
has 84.6% (11/13) overlap with group TYR with 2 samples being assigned to hIC2 and 
the hEC group completely overlaps with MYC. 2 samples from the hIC3 group were 
assigned to SHH, 1 sample to MYC and the other 2 samples in this group failed to gain 
a group assignment (Error! Reference source not found.F). It is not clear whether g
roup hIC3 is a group of outlier samples, a result spurious clustering or is indeed a 
genuine sub-group that is simply too small to reliably cluster the data. However the 
strong concordance between the (Han et al., 2016) sub-groups and the group 
assignments from the consensus NMF analysis suggests a direct parallel between the 
two schemes, especially given they were both generated with a method based on NMF 
clustering.  
Comparing the (Johann et al., 2016) sub-groups to the group assignments generated 
by consensus NMF also highlights shows a high degree over overlap. 87.5% (14/16) 
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of ATRT-SHH overlap with the consensus NMF SHH group, 77.8% (14/18) of ATRT-
TYR overlaps with consensus NMF TYR and 66.7% (10/15) ATRT-MYC overlaps with 
consensus NMF MYC (Figure 12F). As discussed in Chapter 3, the lower level of 
concordance likely originates from the difference in clustering method since the 
authors derived their group assignments using ConsensusClusterPlus. Importantly, 
only 1 sample from this dataset failed to reliably gain a group assignment with the 
consensus NMF approach. This highlights a reason for carrying out consensus meta-
analysis to generate a robust dataset with reliable calls to facilitate classification of 
future MRT profiles.  
 
Figure 12.Consensus NMF cluster metrics from clustering HGU133Plus2.0 gene expression array data  
comparisons are made across every NMF rank and every combination of metagenes A) Corrected Rand index 
calculated from k-means clustering of projected NMF metagenes, red denotes higher similarity between clustering 
iterations B) Average silhouette from k-means clustering of projected NMF metagenes red denotes higher silhouette 
score C) Cohen’s kappa calculated from k-means clustering of projected NMF metagenes, red denotes higher level 
of agreement across iterations D) Percentage of samples in dataset which were assigned a group call with greater 
than 95% frequency following resampling, red denotes more samples receiving robust call E) Training NMF cluster 
metrics red denotes cophenetic correlation, purple denotes dispersion index and blue denotes the silhouette score 
F) Agreement between previously published sub-grouping schemes for comparable samples, percentages indicate 
the number of samples where the previously published sub-group corresponds to the Consensus NMF result, non-
classified samples were excluded 
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Examining the clinicopathological differences between the consensus NMF sub-
groups highlights sub-group specific features (Figure 13). The TYR group shows the 
lowest age (mean = 17.5 months, maximum = 51.6 months) with SHH showing an 
intermediate age distribution (mean = 29 months, maximum = 120 months) and MYC 
showing older patients (mean = 35.2, maximum = 114). Only 60% of the cohort had 
any patient age data available, 29/131 had continuous data available and 50/131 had 
discrete data as 3 age categories. In order to carry out statistical analysis between 
sub-groups, all available data was converted to compatible categorical data with 
groups <2 years old, 2-5 years old and >= 5 years old. Chi-square testing did not show 
a significant difference between sub-groups when analysed in this way.  
The MYC sub-group contains all extra-cranial tumours and a sub-set of ATRT (n = 11). 
Chi-square testing CNS location across sub-groups showed a significant enrichment 
of infratentorial tumours in the TYR sub-group (n = 17/19, p = 0.025). Supratentorial 
tumours were distributed approximately equally across SHH and MYC (SHH n = 6/12, 
MYC n = 5/11 ATRT). Published mutational data was limited but chi-squared testing 
showed significant enrichment of focal SMARCB1 deletion (defined as loss of exons 




Figure 13. Sub-group clinicopathological features as defined by consensus NMF for HGU133Plus2.0 MRT data A) 
Violin plot of age distribution across sub-groups B) Age distribution by sub-group; C) CNS location by sub-group 
INF = infratentorial, SUP = supratentorial. B,C Data is shown as a proportion of the total, missing values are 
removed. D) Chi-square test residuals for significant comparisons. 
Differential expression analysis of gene expression array data was carried out in order 
to examine differences between MRT sub-groups. Gene expression was compared 
using the package limma (R/Bioconductor) for each group in relation to the other two. 
The moderated t-statistic was obtained and used to generate a ranked gene list for the 
basis of GSEA analysis. A summary of significant GSEA results in shown in Figure 14. 
As previously published, the SHH sub-group expresses high levels of neural lineage 
genes such ASCL1, HRS1 DTX1and NOTCH1 of the NOTCH pathway; and GLI2, 
PTCH1, BOC of the SHH pathway, as well as MYCN. GSEA highlighted an enrichment 
of neuronal differentiation genesets (GO SPINAL CORD DEVELOPMENT, NES 2.08, 
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q = 0.002; GO HIPPOCAMPUS DEVELOPMENT, NES = 2.07, q = 0.002; GO CELL 
MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION, NES = 2.00, q = 
0.004) and SHH signalling (HALLMARK HEDGEHOG SIGNALING, NES 1.88, q < 
0.001). Interestingly, SHH demonstrated a significant enrichment of genesets 
associated with active DNA replication and cell division (GO DNA STRAND 
ELONGATION INVOLVED IN DNA REPLICATION, NES = 2.34, q < 0.001; 
HALLMARK E2F TARGETS, NES = 2.76, q < 0.001). It is unclear as to the biological 
significance of this enrichment and further investigation would be required to define the 
relationship with any clinical associations. 
The TYR sub-group shows high expression of the TYR gene as highlighted in other 
publications. In addition, there was noted overexpression in BMP pathway genes such 
as BMP4, developmental transcription factors such as OTX2 and melanocyte –
promoting MITF. GSEA highlighted enrichment of epithelium-associated genesets 
(HALLMARK EPITHELIAL MESENCHYMAL TRANSITION, NES = 2.02, q < 0.001; 
GO AXONEME ASSEMBLY, NES = 2.35, q < 0.001) suggesting an association of the 
TYR group with neuroepithelium, a feature previously noted in the hIC1 from (Han et 
al., 2016). 
The MYC sub-group shows high expression of the MYC as well as a number of HOX-
cluster genes including HOXC10. Geneset enrichment highlighted a large number of 
immune activation associated genesets (GO ACTIVATION OF IMMUNE RESPONSE, 
NES = 2.70, q < 0.001; GO INFLAMMATORY RESPONSE, NES = 2.63, q < 0.001) as 
well as highlighting a mesenchymal component in this sub-group (HALLMARK 
EPITHELIAL MESENCHYMAL TRANSITION, NES = 2.52, q < 0.001). The recurring 
immune association highlights an interesting feature that is not present in the other 
MRT sub-groups. It is not clear what biological role is played by the immune system in 





Figure 14. Radar plot showing the genesets identified to be significantly enriched across MRT sub-groups in 
HGU133Plus2.0. The Normalised Enrichment Score (NES) is plotted. Genesets are coloured by their associated 
significantly enriched sub-group. Red = TYR, blue = SHH, green = MYC, black = significant in both TYR and MYC 
differential expression analyses with different genes enriched. 
4.3.2 Meta-analysis of methylation array data 
Clustering of DNA methylation array data comprising 263 primary tumours (ATRT n = 
213, ECRT n = 21, RTK n = 19, MRT n = 10, see Methods 2.1.3) was subject to 
consensus NMF clustering. This identified 3 stable clusters (Figure 15) with 258/263 
samples being assigned a consensus NMF call. 5 samples were not assigned a sub-




Figure 15. Consensus NMF cluster metrics from clustering DNA methylation array data  comparisons are made 
across every NMF rank and every combination of metagenes A) Corrected Rand index calculated from k-means 
clustering of projected NMF metagenes, red denotes higher similarity between clustering iterations B) Average 
silhouette from k-means clustering of projected NMF metagenes red denotes higher silhouette score C) Cohen’s 
kappa calculated from k-means clustering of projected NMF metagenes, red denotes higher level of agreement 
across iterations D) Percentage of samples in dataset which were assigned a group call with greater than 95% 
frequency following resampling, red denotes more samples receiving robust call E) Training NMF cluster metrics 
red denotes cophenetic correlation, purple denotes dispersion index and blue denotes the silhouette score 
Comparison of the combined MRT consensus NMF sub-group assignment with the 
published sub-group calls from Johann et al. (2016) showed high concordance. 86% 
of ATRT-SHH (51/59) samples clustered to the SHH group, 98% of ATRT-TYR (45/46) 
clustered to the TYR consensus group and 97% of ATRT-MYC (31/32) to the MYC 
sub-group.  
The TYR group, again, shows the lowest age (mean = 20.8 months, maximum = 132.4 
months) with SHH showing an intermediate age distribution (mean = 26.6 months, 
maximum = 127.6 months) and MYC containing older cases (mean = 45.8, maximum 
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= 181.4). Chi-square testing did not show a significant difference between age 
categories.  
Unlike the gene expression array results, not all ECRT cases were segregated to the 
MYC sub-group TYR also contains ECRT and RTK (4/39 and 6/39, respectively). 
Supratentorial tumours are significantly enriched in SHH (38/66, p = 0.0023), while 
infratentorial tumours are significantly enriched in TYR (46/66, p < 0.001). Although not 
statistically significant, the MYC sub-group features the only example of a spinal cord 
tumour, while TYR features 3 cases where tumours span across the tentorial boundary 
(termed “transtentorial”). These cases were derived from the UK MRT cohort based on 
more detailed CNS localisation information, and while it is possible that other 
transtentorial cases exist in the dataset, location information for published data is 
limited and it was not possible to explore this further at this time.  
Analysis of available mutation data showed significant enrichment of partial loss of 
chromosome 22 (as defined by loss of a region spanning multiple genes, p = 0.025) 
and SMARCB1 point mutations in the TYR subgroup (p = 0.012). Although 8/15 
reported cases of SMARCB1 deletion was in the MYC sub-group this was not found to 
be significant in contrast to the gene expression consensus NMF cohort. 
4.3.3 MRT methylation analysis reveals additional heterogeneity 
Having shown that combined MRT clustering can recapitulate multiple previously sub-
grouping strategies including the existing 3 sub-group definitions previously proposed 
in ATRT, analysis was carried out to investigate whether the expanded cohort could 
yield any additional information and further explain the heterogeneity seen in the 
disease. To this end, a consensus NMF results beyond k=3 were considered for their 
clustering robustness, and the rank of k=5 was chosen as after this result, there was a 
significant drop-off in all NMF cluster quality metrics (Figure 15). 
The k = 5 NMF solution was able to assign 256/263 samples a sub-group call with over 
95% consistency. SHH-Infratentorial (SHH.Inf) and SHH-Supratentorial (SHH.Sup) 
sub-groups clusters mapped very closely to the consensus NMF k=3 SHH cluster (n = 
33/33, n = 46/50, respectively). The names for these two sub-groups originating from 
the k = 3 SHH cluster is due to the significant differential enrichment of the two broad 
CNS localisations and is discussed in more detail later in this chapter. The k = 5 TYR 
sub-group mapped almost completely to its k = 3 TYR (66/68) counterpart but 
comprises ATRT only, unlike the k=3. A novel cluster, termed MRT-Hypomethylated 
81 
 
(HYPO, nomenclature discussed below) mapped partially to k = 3 TYR and MYC (n = 
23/42, n = 18/42, respectively), and cluster k = 5 MYC mapped fully to MYC (63/63). K 
= 5 HYPO and MYC were the only clusters to contain ECRT and RTK cases as well 
as ATRT. In addition, group assignments were obtained from the MNP2.0 for a 
proportion of the total cohort, kindly provided by Dr Pascal Johann (DKFZ, Heidelberg) 
as part of the ATRT consensus analysis.  ‘ATRT, SHH’ mapped to clusters 
SHH.Inf/SHH.Sup, with only 8/72 being reclassified (HYPO n = 4/72, MYC = 1/72, NC 
= 3/72), ‘ATRT, TYR’ mapped wholly to its k = 5 counterpart and ‘ATRT, MYC’ to MYC 
with one sample not receiving a consensus NMF call (Figure 16).  
 
Figure 16. Sankey diagram of consensus NMF sub-group assignments  from k=3 (top) and k=5 (middle) solutions, 
with additional comparison to the MNP2.0 classifier (bottom); NC = no consensus 
Analysis of differences between the two groups SHH.Inf and SHH.Sup showed they 
significantly vary by the CNS localisation and patient age. SHH.Inf is significantly 
enriched for infratentorial tumours (23/28, p < 0.001) and contained the youngest 
patients (mean = 11.1 months, maximum = 44.6) while SHH.Sup was significantly 
enriched for supratentorial tumours (35/38, p < 0.001) and older patients (mean 39.3 




Figure 17. Sub-group characteristics as defined by consensus NMF sub-group assignment from clustering 
methylation array data;  A) CNS location by sub-group INF = infratentorial, SUP = supratentorial, SPINE = spinal 
cord tumours, TRANS = transtentorial; B) Tumour type by sub-group MRT = cases where clinical data on MRT 
locale is not available; C) Age distribution by sub-group; A,B,C) Data is shown as a proportion of the total, missing 
values are removed; D) Violin plot of age distribution across sub-groups; E) Chr 22 copy-number estimation as 
generated by conumee F) Chi-square test residuals for significant comparisons. 
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Next, the HYPO sub-group was analysed in order to understand the features that 
differentiate this novel this cluster from the k = 3 solution. This group showed a unique 
profile of CpG methylation when comparing the top 8675 most differentially methylated 
probes used for NMF clustering (Figure 18). The average beta-values in this group of 
patients were lower than any other cluster, suggesting a general hypomethylation 
across all tested CpGs. This effect persisted even when comparing different probe 
types based on their understood relationship to CpG islands 
(Shelf/Shore/Island/OpenSea). This consistent hypomethylation across all CpGs led to 
this group being termed as the Hypomethylated “HYPO” group.  
 
Figure 18. Distribution of average beta-value across sub-groups defined from the k = 5 consensus NMF solution. 
CpGs are annotated based on the Illumina 450K/EPIC manifest for relation to CpG island. 
This group contains younger patients (mean = 23.3 months, maximum = 132.4) 
compared to the MYC k = 5 group (mean 45 months, maximum 181.44). Notably, this 
group contains the only case of reported SMARCA4 mutation which was assigned a 
sub-group call by consensus NMF at k = 5. This cluster comprises all 3 types of MRT. 
Estimation of chromosomal arm copy number using conumee (R/Bioconductor), 
identified a significant enrichment of chromosome 22q arm copy-number neutral 




This chapter contained multiple meta-analyses comparing existing sub-grouping 
strategies for MRT, examining both gene expression and methylation array data. The 
combined ATRT and ECRT cohort recapitulated previous analyses focusing on only 
one tumour type and allowed parallels to be drawn between different sub-grouping 
methods, highlighting the effectiveness of consensus NMF in generating robust sub-
group assignments by utilising resampling approaches.  
Based on the findings discussed in this chapter, MRT can be defined as a 
heterogeneous disease displaying at least 3 molecular sub-groups with differences in 
patient age, SMARCB1 mutation, and localisation, based on gene expression and 
methylation profiling. Although different methods may be used in order to cluster MRT, 
the resulting sub-groups are largely recapitulated regardless of algorithm used and 
reinforce the existence of these sub-groups as more than just the result of clustering 
high-dimensional biological data. In addition, the use of consensus NMF allows 
assessment of cluster robustness by testing the frequency a sample is assigned a 
particular sub-group call and allowing low-confidence samples to be identified 
As well as a meta-analysis of the current proposed sub-grouping strategies, a 
proposed 5 group sub-grouping based on methylation array is presented and can 
provide a more comprehensive definition of MRT heterogeneity by capturing specific 
differences in tumour localisation, patient age and the nature of SMARCB1-inactivating 
mutations.  
The analysis presented here also suggests avenues for further expansion of the sub-
grouping, in particular the need for an expanded gene expression cohort to match the 
power of the available methylation data. Features of individual sub-groups such as the 
immune reactivity of the MYC sub-group, the involvement of DNA and cell replication 
pathways in SHH and the differences between infratentorial and supratentorial 
localisation of these tumours should be investigated further. The newly defined HYPO 
sub-group as identified by k = 5 consensus NMF remains to be fully characterised, 
although a number of features of this group have been presented. Lack of 
clinicopathological annotation is a significant limiting factor to further defining sub-
group characteristics in MRT. Expanding sub-grouping strategies to a larger number 
of sub-groups requires more statistical power to identify sub-group specific changes, 
which is currently not available for a number of features including SMARCB1 mutation 
and other gene alterations as well as detailed tumour localisation. 
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Having defined a consensus sub-grouping strategy for MRT, it is necessary to assess 
whether it is possible sub-grouping can improve our understanding of MRT survival 
and be useful in patient prognostication. Only limited survival analysis has been carried 
out in rhabdoid tumours, and never on a combined MRT cohort. As such it is a 
significant gap in the current understanding of the disease.  
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5 Survival analysis of MRT using sub-group specific and 




The aim of this chapter is to carry out a survival analysis using clinical factors and 
derived subgrouping information of a cohort of 113 MRT samples collected from UK 
Children's Cancer and Leukaemia Group (CCLG) cancer centres. The analysis will 
explore common survival features as well as examine any clinical relevance of 
subgrouping MRT using consensus NMF subgroups derived in Chapter 4. 
5.2 Summary of MRT cohort 
Data was collected alongside primary tumour material and was received either fully 
anonymised or was anonymised by either Dr Stephen Crosier, Prof Simon Bailey or Dr 
Claire Keeling (Newcastle upon Tyne Hospitals Trust). Additional anonymised clinical 
annotation was provided by Dr Particia O’Hare and Dr Jessica C Pickles (Great 
Ormond Street Hospital for Children Trust) as part of the INSTINCT high risk paediatric 
brain tumour collaboration programme. 
The raw clinical data was reduced to relevant fields where information was relevant to 
this study and amenable to statistical analysis. For tumour type, various classification 
schemes were collapsed to the following: ATRT for any tumour occurring within the 
CNS including the brainstem and spinal cord; ECRT for tumours occurring outside of 
the central nervous system but not within the kidney; RTK for tumours occurring 
specifically within the kidney. Where the tumour type classification was not available, 
it was inferred from pathological information or broadly inferred from other clinical data 
such as therapeutic approach. Samples were received with clear evidence of 
SMARCB1 loss, as well as compatible histology but site of tumour was not available 
and not possible to infer based on current data (n = 7). Those samples were still profiled 
by DNA methylation array and are currently being investigated further with the data 
providers. For the purpose of this study there were classified as simply MRT, but not 
included in survival analysis. 
CNS location for ATRT was derived from the localisation information of the tumour. 
The boundary of the tentorium cerebelli was used as a distinguishing factor, and 
tumours were classified as either infratentorial when occurring in structures below this 
boundary (cerebellum, pons, medulla, and brainstem, infratentorial ventricles) or 
supratentorial (lobes, central brain structures, supratentorial ventricles) when occurring 
beyond this boundary. Spinal ATRT was defined as any tumours classified as arising 
in the spinal cord of the CNS. Transtentorial tumours are defined as those that cannot 
be confidently said to have emerged either from the infratentorial or the supratentorial 
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space. Both spinal and transtentorial tumours were excluded from survival analysis 
due to low numbers (n = 1, 2 respectively).  
Consensus NMF subgroups derived from previous work outlined in Chapter 4 were 
included as additional annotation. Where confident subgroup assignment could not be 
given following resampling, subgroup has not been assigned and samples removed 
from analysis. Sex was classified as male or female based on reported information. 
Age was defined as either the age of the patient on the date of sample tumour material 
being obtained by surgical intervention, or if surgery was not attempted, data was taken 
from the data of the pathological report detailing a diagnosis of MRT. Metastasis status 
was recoded from a number of compatible fields and collapsed to the common Yes/No 
factor. Where tumour stage was given, a stage of M0 or M0/1 was classified as No 
evidence, the latter was further defined from available clinical information, M1+ was 
classified as evidence of metastasis.  
Overall survival was calculated from age at surgery/diagnosis to recorded age of death 
or last patient review. Progression-free survival was calculated from age of 
surgery/diagnosis until the first record of an event – classified as progressive or 
recurring disease, second malignancy or metastasis. 
Table 5. A summary table of the MRT cohort assembled as part of this thesis. Summary statistics and numbers of 
samples that are annotated for various clinical features are provided. 
Variable Category Number Percent (%) 
Primary Cases Total 113 100 
    
Group ATRT 63 56 
 
RTK 19 17 
 
ECRT 24 21 
 
MRT 7 6 
    
CNS Location Infratentorial 28 44 
 
Supratentorial 24 38 
 
Transtentorial 2 3 
 
Spinal 1 2 
 
N/A 8 13 
    
Subgroup k = 3 SHH 27 24 
 
TYR 36 32 
 
MYC 47 42 
 
N/A 3 3 
    
Subgroup k = 5 SHH.Inf 10 9 
 
SHH.Sup 15 13 
 




HYPO 28 25 
 
MYC 37 33 
 
N/A 6 5 
    
Sex F 46 41 
 
M 60 53 
 
N/A 7 6 
    
Age Summary (months) Mean 30.02 N/A 
 
Median 14.25 N/A 
 
Min 0.00 N/A 
 
Max 181.44 N/A 
    
Age Category (years) Under 1 41 36 
 
1 to 3 36 32 
 
Over 3 27 24 
 
N/A 9 8 
    
Metastasis Yes 35 31 
 
No 49 43 
 
N/A 29 26 
    
PFS Known 76 67 
 
Unknown 37 33 
    
OS Known 78 69 
 
Unknown 35 31 
 
MRT primary tumour samples used in survival analysis were collected from UK CCLG 
cancer centres, or obtained from Brain UK. Loss of SMARCB1 was confirmed by IHC 
during diagnosis and prior to being submitted to the respective biobanks, where 
SMARCB1 status was not available it was confirmed prior to inclusion in this study. A 
full summary of the cohort is provided in Methods 2.1.1. 
Of the total cohort of 113 primary cases, 56% (n = 63) were ATRT, 17% (n = 19) were 
RTK, 21% (n = 24) were ECRT, and 7 samples held a diagnosis of MRT but location 
information was not available for these tumours. As such, while these 7 cases were 
included in sub-group discovery, they were not included in the survival analysis. The 
most common tumour site in ATRT was Posterior Fossa (41%, n = 26/63), and for 
ECRT Liver and Thorax were joint most common (17%, n = 4/24 in both). Of the total 
113 cases, OS was available for 69% (n = 78) and PFS for 67% (n = 76). Overall mean 
OS was 32.9 months (median = 13.5) and mean PFS was 28.9 months (median = 9.6 
months). 5-year OS was 21%, PFS was 14% and longest OS/PFS was 205.6 months 
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(17.1 years). Information on whether evidence for metastases was present was 
available for 74% of the cohort (n = 84), information on either recurrence or progression 
70% (n = 79), extent of resection was known for 51% (n = 58) after excluding cases 
with only biopsies recorded as the only surgical intervention, and 73% (n = 83) of cases 
had information on whether radiotherapy was received 
Age data was available for 92% of cases (n = 104). Average age at diagnosis was 30 
months (2.5 years) while the median was 14.25 months (1.2 years), the oldest patient 
at diagnosis was 181.44 months (15.1 years). Separated by MRT tumour type, ATRT 
median age was 15 months (1.25 years) and maximum was 181.44 (15.1 years), ECRT 
median age was 13 months (1.1 years) and maximum 104.1 months (8.7 years), RTK 
had a median age of 15.35 months (1.3 years) and a maximum of 74.6 months (6.2 
years). Of the total cohort, 36% were under the age of 12 months when diagnosed (n 
= 41). Sex information was available for 94% of the cohort and the F:M ratio was 0.77. 
Sub-group assignment using consensus NMF was obtained for 110/113 cases for k = 
3, and 107/113 cases for k = 5, based on procedures outlined in Chapter 4. Estimation 
of chromosome 22q loss from DNA methylation array profiling was available for 84% 
(n = 95) after excluding cases with a noise score >= 1.8 as define by the conumee R 
analysis. 
5.3 Survival analysis MRT using clinicopathological association 
Survival analysis was carried out by constructing survival curves and comparing 
groups using logrank testing and likelihood ratio testing. All comparisons were carried 
out on the whole cohort, and then split into either ATRT or ECRT where it was 
reasonable to do so.  
OS and PFS did not significantly differ by MRT localisation. For ATRT, infratentorial or 
supratentorial location was also found not to be significantly associated with survival 
differences. Comparisons of survival between consensus NMF k = 3 and k = 5 sub-
groups showed no significant difference. There was also no difference associated with 




Figure 19. Kaplan-Meier curves showing survival differences for extent of resection in MRT  A) Overall survival B) 
Progression Free Survival GTR = gross total resection STR = subtotal resection; p-value is provided from log-rank 
analysis, number of patients in each category is shown below the graphs. 
Likelihood ratio and logrank testing was carried out to test for significance in clinical 
data, p values for both are provided unless the value is the same, or a different test 
used. Significant differences in OS and PFS were identified comparing extent of 
resection in the full cohort (OS p < 0.001, n = 54; PFS p = 0.004/p = 0.002 n = 53) also 
in ATRT (OS p = 0.002, n = 39; PFS p = 0.03, n = 38)(Figure 19). Receipt of 
radiotherapy was significant in all comparisons and in both OS and PFS (MRT OS p < 
0.001, n = 73; PFS p < 0.001, n = 71). Evidence of metastases is also significant for 
all comparisons in both OS and PFS (MRT OS p < 0.001, n = 74; PFS p = 0.003/0.002, 




Figure 20. Kaplan-Meier curves showing survival differences for age categories in ATRT between patients under 3 
years of age and over 3 years of age  A) Overall survival B) Progression Free Survival <3 = younger than 3 years 
>=3  = 3 years or older at diagnosis; p-value is provided from log-rank analysis, number of patients in each category 
is shown below the graphs. 
Next it was examined age was associated with survival. Two sets of age categories 
were employed. First, patients were divided into either younger than 1 or 1 year old 
and older, second, they were divided into under 3 or 3 years and older. These 
categories were chosen to coincide with the typical approach to defer radiotherapy 
before age 3 in ATRT, and the higher risk previously described in patients under 1 year 
old. In the under 3 / older than 3 category OS was not significantly different in the whole 
MRT cohort, or ATRT and ECRT examined separately (Figure 20). Additionally, PFS 
was not found to be significantly different in ECRT when comparing across the two age 
categories. ATRT PFS was significantly lower for patients under the age of 3 (p = 
0.01/p = 0.02, n = 43) with 83% patients in that group succumbing to disease after the 
first year. While PFS analysis in the whole cohort was also significant, it is likely due 
to it also comprising the ATRT patients. Conversely, in the under 1 / older than 1 OS 
in ATRT was not found to significantly vary, while PFS for patients under 1 was 
significantly poorer (p = 0.04/p = 0.03, n = 43). In MRT, and ECRT, both OS and PFS 
varied significantly (ECRT OS p = 0.008/p = 0.003, n = 28; PFS p = 0.008/p = 0.003, 




Figure 21. Kaplan-Meier curves showing survival differences for age categories in ATRT between patients under 1 
years of age and over 3 years of age  A) Overall survival B) Progression Free Survival <1 = younger than 1 years 
>=1  = 1 years or older at diagnosis; p-value is provided from log-rank analysis, number of patients in each category 
is shown below the graphs. 
In a univariate Cox proportional hazard regression analysis, significant factors 
identified for MRT were radiotherapy, evidence of metastasis, extent of tumour 
resection, and patients being either older or younger than 3 at diagnosis. In ATRT 
evidence of progression or recurrence did not pass significance, while in ECRT 
subtotal resection status was only recorded in 1 case, and no evidence of progression 
was only found in 4 annotated cases making both of these variables not suitable for 
the analysis. A summary of the associated Hazard Ratios and p-values is available in 
Table 6.  
Table 6. Summary of Cox proportional hazard regression univariate analyses 
 




p value  
Combined MRT     
Radiotherapy (N) 0.21 (0.11-0.4) -4.7 22 2.10E-06  
Metastasis (N) 3.1 (1.7-5.5) 3.8 15 0.00012  
Reccurence/Progression (N) 4.9 (2.1-12) 3.6 13 0.00032  
Extent of Resection(GTR) 3.4 (1.7-7) 3.3 11 0.00081  
Chr 22q (Loss) 0.97 (0.53-1.8) -0.097 0.01 0.92  
Sex M 0.68 (0.4-1.2) -1.4 2 0.16  
Age (Under 3) 0.57 (0.3-1.1) -1.8 3.1 0.078  
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Age (Under 1) 0.46 (0.26-0.8) -2.7 7.4 0.0066  
Subgroup SHH 1 (0.55-1.8) 0.031 0 0.98  
Subgroup TYR 0.77 (0.42-1.4) -0.85 0.72 0.39  
Subgroup MYC 1.3 (0.72-2.2) 0.8 0.64 0.42  
ATRT Only 
    
Radiotherapy (N) 0.21 (0.086-0.53) -3.4 11 0.00079  
Metastasis (N) 3.4 (1.5-7.6) 2.9 8.5 0.0036  
Reccurence/Progression (N) 2.3 (0.91-5.7) 1.8 3.1 0.077  
Extent of Resection (GTR) 3.9 (1.5-9.7) 2.9 8.2 0.0041  
Chr 22q (Loss) 0.55 (0.24-1.3) -1.4 1.9 0.17  
Sex M 0.6 (0.28-1.3) -1.3 1.8 0.18  
Age (Under 3) 0.56 (0.24-1.3) -1.4 1.8 0.17  
Age (Under 1) 0.62 (0.29-1.3) -1.2 1.5 0.22  
Subgroup (SHH) 1.1 (0.52-2.3) 0.23 0.05 0.82  
Subgroup (TYR) 0.83 (0.38-1.8) -0.47 0.22 0.64  
Subgroup (MYC) 1.2 (0.44-3.2) 0.33 0.11 0.74  
ECRT Only 
    
Radiotherapy (N) 0.2 (0.074-0.56) -3.1 9.4 0.0021  
Metastasis (N) 2.9 (1-8.1) 2 4 0.046  
Reccurence/Progression (N)         
Extent of Resection(GTR)         
Chr 22q (Loss) 1.6 (0.52-4.8) 0.8 0.64 0.42  
Sex M 0.87 (0.35-2.1) -0.3 0.09 0.76  
Age (Under 3) 0.63 (0.23-1.7) -0.89 0.8 0.37  
Age (Under 1) 0.27 (0.11-0.69) -2.8 7.6 0.0057  
Subgroup (SHH)         
Subgroup (TYR) 0.67 (0.22-2) -0.71 0.51 0.48  
Subgroup (MYC) 1.5 (0.49-4.5) 0.71 0.51 0.48  
 
Variables found to be significant in univariate analysis were analysed as covariates in 
a multivariate Cox proportional analysis. In a multivariate Cox proportional hazard 
analysis of MRT OS, radiotherapy and age category over/under 3 years was found to 
be independently significant (receipt of radiotherapy HR 0.09 (0.018 – 0.41 95% CI), p 
= 0.002, Age >=3 HR 5.4 (1.069 – 27.22 95% CI) p = 0.041 respectively) and for PFS 
only radiotherapy was significant (HR 0.14 (0.04 – 0.52 95% CI) p = 0.003) (Figure 22). 
OS was analysed in the ATRT cohort using a multivariate Cox proportional hazard 
analysis showing, receipt of radiotherapy (HR 0.054 (0.008 – 0.36 95% CI), p = 0.003), 
extent of resection (HR 3.68 (1.04 − 13.05 95% CI), p = 0.044) and age over/under 3 
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years (HR 8.17 (1.2 – 55.4 95% CI), p = 0.032) were significant. Cox proportional 
hazard testing in ATRT PFS, and both ECRT OS and PFS, found only radiotherapy 
remained a significant variable in the multivariate analysis.  
 
Figure 22. Forest plot from multivariate cox proportional hazard analysis for MRT overall survival 
Despite the lack of significance of any subgroup-specific survival analysis at univariate 
level, further analysis was carried out to see whether combinations of variables 
involving sub-group could be used to stratify patients. In 2018, Michael Fruhwald, 
presented a poster abstract analysing a European ATRT cohort and identified a sub-
group specific risk stratification comprising patient age and membership of the TYR 
sub-group (Fruehwald et al., 2018). 
Receiver operating characteristic (ROC) curves were generated for combinations of 
variables from Cox proportional analysis models. These types of visualisations are a 
useful way of displaying the sensitivity (true positive rate) and 1-specificity (false 
positive rate) of a diagnostic marker. Here, time-dependent ROC curves are used in 
order to compare the effectiveness of different combinations of variables at predicting 
2-year survival from MRT OS and PFS. Variables tested were either consensus NMF 
k = 3 subgroup and age under/over 3 years, or age under/over 1 year. Area under the 
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curve (AUC) was compared to select the most effective combination of variables that 
predicts survival.  
 
Figure 23. ROC curves for Cox proportional hazard ratio 2-year survival predictions for multiple combinations of 
age and subgroup categories  A) overall survival B) progression free survival; U/O 1yo = Under/Over 1 year old; 
U/O 3yo = Under/Over 3 year old; TP = true positive, FP = false positive 
For both OS and PFS, the combination of TYR subgroup and the category of 
under/over 1 year generated the highest AUC (OS 0.677, PFS 0.725). (Figure 23) 
although there was only a small difference overall between the predictive power of the 
combinations used. Survival curves of the resulting stratification were then generated. 
A category of moderate risk (MR) was assigned to any patient with a subgroup of TYR 
and under the age of 1 at diagnosis, and a high risk (HR) category was assigned for 
any patients in another subgroup, or above the age of 1. This scheme differs somewhat 
to the scheme originally presented in the abstract where TYR subgroup and age <1 
year was classified as low risk, either TYR or age ,1 year as intermediate risk and high 
risk was assigned to cases > 1 year not in TYR subgroup. Due to the limitations of the 
cohort size the classification was reduces to two categories by combining the 
intermediate and high risk categories. MRT and ATRT cohorts both showed significant 
survival differences between MR and HR groups (MRT OS p = 0.02, log rank; PFS p 
= 0.005, log rank; ATRT OS p = 0.046, log rank; PFS p = 0.0052, log rank). ECRT only 
did not show significant difference between risk, however as there were only 4 patients 
that were identified as having moderate risk, it is not clear whether this could be a 




This chapter presented the survival analysis for the UK MRT cohort and highlighted a 
number of significant clinical factors which impact survival. In addition, to presenting a 
survival overview of the cohort generated as part of this thesis, the analysis highlighted 
clinical factors that were significant in both ATRT and ECRT tumours and showed a 
combined risk associated across tumour types. Location specific survival features were 
also identified and likely correspond to both the nature of the tumours and the general 
approach and practicalities of therapy that are available and utilised in treating ATRT 
and ECRT.  
The main variable identified to be highly significant across all groups was radiotherapy 
received. In the cohort, of the 13 ATRT patients where clinical data was available, only 
1 patient did not receive radiotherapy, while in the ECRT cohort over half 16/30 patients 
did not receive radiotherapy. While the reason for this high number of patients in ECRT 
not receiving radiotherapy is not clear, it highlights the need for all patients with ECRT 
to undergo radiotherapy if possible given the survival for non-receivers was extremely 
poor (2-year survival 17%) much in the same way as other survival analyses have 
done for MRT. The results also highlighted the importance of complete surgical 
resection in this cohort. While there are many reasons why complete resection is not 
always possible, the impact on survival in both ATRT and ECRT is clear and is 
consistent with findings from other studies. 
An interesting finding of the analysis was the antagonistic relationship between age 
and PFS. When comparing patients under and over the age of 3, PFS in ATRT was 
significantly different between the two categories suggesting patients under the age of 
3 were much more likely to have progressive disease, but did not significantly vary in 
ECRT. Patients under the age of 1 were significantly less likely to survive in with ECRT 
as well as showed more progressive disease, while survival in ATRT was not affected. 
This could perhaps reflect the type of therapy the patients received, although 
unfortunately there is a lack of chemotherapy information for this cohort, which is a 
significant limitation. Additional efforts are currently ongoing in order to collect this data, 
but it is currently available for only a small fraction of the cohort. 
This analysis also partially validated a stratification approach combining both subgroup 
and patient age in order to improve stratification over the predictive ability that the two 
presented as separate single predictors. The initial concept from the stratification was 
presented at the 18th International Symposium on Pediatric Neuro-Oncology (ISPNO 
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2018) June 30 – July 3. It is currently expected that the expanded version of that 
analysis will be submitted to peer review and publication shortly. Despite this, the use 
of the subgrouping information in MRT in order to generate a novel prognostic scheme 
is an encouraging first step in the efforts to characterise differences between MRT 
subgroups and define clinically-relevant molecular differences between tumours. While 
currently limited by low numbers of tumours in this study, the combination and meta-
analysis of multiple survival cohorts in future could identify additional novel prognostic 
features of subgroups. It should therefore be a primary focus in future studies given 
how historically it has been difficult to obtain large, multicentre survival analyses. This 
also underlines the importance of generating a consensus subgrouping scheme which 
enables the comparison of cohorts generated in different studies to undergo a common 
classification strategy and therefore allow any subgroup associations to be applied to 
a much wider cohort.  
Finally, as well as working towards expanding current cohort size, efforts should also 
be made to continue to explore MRT biology and further develop current understanding 
of differences between MRT localisations and subgroups. As previously discussed in 
Chapter 3 and Chapter 4 the MYC subgroup in MRT shows overexpression of a large 
set of genes associated in immune development, and function. Any immune interaction 
of this group, and others is a potential target of future research and may be able to 








There is evidence to suggest that the immune system may have some involvement in 
the biology of MRT, although the extent and specific association remains to be fully 
elucidated. Overexpression of genes associated with the immune system was reported 
when analysing sub-groups of ECRT (Chun et al., 2016). In this thesis, sub-group 
specific expression differences in MRT highlighted the enrichment of immune-specific 
genes in the MYC sub-group (Chapter 4). Although immune involvement in MRT has 
not previously been examined, the role and nature of the tumour immune micro-
environment (TIME) has been interrogated for a number of other CNS tumours with a 
view to investigate suitability for immune-therapy.  
Immune-therapies are an attractive alternative anti-cancer strategy alongside the 
conventional approaches of surgery, chemotherapy and radiotherapy that may be 
particularly well suited to targeting diffuse infiltrative growing tumours. The field of 
cancer immunotherapy has grown expansively in recent years to include the 
therapeutic use of cancer vaccinations, chimeric antigen receptor (CAR) T-cell therapy 
and agents which block immune-checkpoint receptors and/or ligand interactions such 
as CTLA-4 and PD-1. Each can provoke a significant anti-tumour response in patients 
within varied tumour types (Prins et al., 2011; Quail and Joyce, 2013; Hinrichs and 
Rosenberg, 2014; Topalian et al., 2015; Butowski et al., 2016; Voena and Chiarle, 
2016; Quail and Joyce, 2017). However, for each patient who derives clinical benefit 
from a particular immunotherapeutic agent there are many whom do not (Bockmayr et 
al., 2019). The composition of the TIME is a critical determinant of tumour-immune 
interactions and can direct response to treatment (Hirata and Sahai, 2017). Therefore, 
to take full advantage of the potential of immunotherapy - or combinations with targeted 
agents - treatment approaches need to be tailored to the specific TIME. 
Detailed studies of the TIME are being conducted to predict response to 
immunotherapy and uncover mechanisms of treatment resistance. While anti-PD-1 
antibodies nivolumab and pembrolizumab and an anti-CTLA-4 antibody Ipilimumab are 
FDA approved for, and can produce durable responses in, patients with metastatic 
melanoma (Robert et al., 2015a; Robert et al., 2015b; Weber et al., 2015), non-small 
cell lung cancer (Rizvi et al., 2015) and renal cell carcinoma (Tomita et al., 2019), the 
majority of patients do not respond. Comparative studies between responders and 
non-responders indicate that multiple factors, including pre-existing T-cell infiltration, 
checkpoint molecule expression within the tumour and mutational burden with 
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consequent production of neo-antigens correlate with response to immune-therapy. 
For instance, colorectal cancer of the molecular subtype CMS1 are characterised by 
DNA mismatch-repair defects, microsatellite instability and hypermutation with 
accompanying infiltration of CD8+ T cells (Mlecnik et al., 2016) and expression of 
immune-checkpoint proteins CTLA-4, PD-1, PD-L1 and IDO-1 (Gatalica et al., 2014; 
Angelova et al., 2015; Becht et al., 2016). CMS1 patients show significant responses 
to anti-PD-1 therapies (Boland and Ma, 2017). 
Tumours are frequently described as being immunologically “hot” or “cold” with a 
presumed implication for the effectiveness of particular tumour immune therapies. 
“Hot” tumour TIMEs are broadly characterised by high expression of the PD-1 ligand 
(PD-L1) and by infiltration of cytotoxic lymphocytes (CTLs) expressing PD-1. “Cold” 
tumours being relatively sparsely infiltrated with CTLs, at least within the tumour core 
(Binnewies et al., 2018). Childhood brain tumours are thought to be relatively 
immunologically “cold” due to paucity of mutations (i.e. generally lacking neoantigens 
(Grobner et al., 2018)). To date, quite limited information on TIME in childhood brain 
tumours has been published and in piecemeal fashion. In adult brain tumours, several 
immune cell types have identified roles in, and associations with, tumour development. 
For instance, TAMs (Tumour Associated Macrophages) are believed to make up a 
large proportion of immune cells in gliomas (Graeber et al., 2002), and to be generally 
pro-tumourigenic and associated with a higher tumour grade (Komohara et al., 2008; 
Hambardzumyan et al., 2016). Furthermore, the number of neutrophils appears to 
have prognostic value (Fossati et al., 1999; Bertaut et al., 2016) and immuno-
suppressive Regulator T-cells (Treg) are significantly increased in patients with Glioma 
as a proportion of the peripheral CD4+ cell pool; they also account for a substantial 
proportion of the TIME (Fecci et al., 2006; Hussain et al., 2006). Simple extrapolation 
from adult brain tumours is unlikely to be informative given the underlying differences 
in tumour biology. 
A number of methods exist to characterize and quantify TIME directly e.g. IHC, 
Fluorescence-assisted cytometry (FACS), Cy-TOF, single cell RNA-sequencing. 
These may be costly, laborious and/or difficult to multiplex. Indirect techniques have 
been developed to estimate TIME in silico by deconvoluting complex mixtures of cell 
types from profiles of bulk populations using pure populations of cell types as a 
reference (Gentles et al., 2015; Newman et al., 2015; Teschendorff and Zheng, 2017). 
CIBERSORT is a notable algorithm which uses support vector regression modelling to 
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deconvolute cell types and has been applied to several cancer datasets (Newman et 
al., 2015). CNS tumours have been extensively DNA methylation profiled using arrays, 
most prominently by Capper et al. (2018) who published a cohort of 3,764 CNS-
tumours (including 1403 patients < 18 years old) representing 80 tumour DNA 
methylation types and sub-types closely related to WHO histopathological entities. The 
Paediatric Brain Tumour Group, Newcastle University and others have published 
further large series of some of the major paediatric CNS types i.e. MB (Cavalli et al., 
2017; Northcott et al., 2017; Schwalbe et al., 2017a; Sharma et al., 2019a), ATRT 
(Johann et al., 2016; Torchia et al., 2016) and paediatric High Grade Gliomas (pHGG) 
(Mackay et al., 2017; Mackay et al., 2018) with extensive clinical annotation and 
parallel multiomic data (RNA-seq, copy-number profiles, Exome/Whole-genome 
Sequencing). This chapter discusses the implementation of methylCIBERSORT - a 
recent adaptation of the CIBERSORT algorithm which uses genome-wide DNA 
methylation data (Chakravarthy et al., 2018) - to characterize the TIME of >6000 CNS 
tumours, assessing variation and the relationship with clinico-pathology or outcome.  
6.2 Aims 
This chapter aimed to develop a DNA methylation based approach to estimation 
tumour infiltration on CNS tumours in order to carry out a primary investigation of the 
extent of immune infiltration in CNS malignancies. First a signature matrix needed to 
be generated which could accurately estimate immune infiltration on CNS tumours. 
Secondly clinicopathological factors would be compared with resulting estimations of 
immune infiltration to identify significant associations. 
6.3 Results 
6.3.1 Validation and benchmarking of signature matrix 
A signature matrix was constructed from reference DNA methylation profiles of pure 
flow-sorted populations of cells. This signature matrix represents a set of differentially 
methylated CpGs selected and weighted to reflect specificity for a given cell type and 
is used as the basis of cell deconvolution by methylCIBERSORT. The final signature 
matrix consisted of 2215 differentially methylated CpGs distinguishing between 12 
broad cell types: regulatory T-cells (Treg), CD4+ T-cells (CD4T), CD8+ T-cells (CD8T), 
B-cells (B-cell), Natural Killer (NK) cells, eosinophils, neutrophils, monocytes, 
endothelial cells, glial cells, neurons and cancer. The matrix was verified such that (i) 
specific differentially methylated CpGs were captured for each cell type (ii) the absence 
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of batch effects following processing (iii) the CpGs selected were not confounded by 




Figure 24.A) Heatmap of the resulting 2215 CpG probe beta-value signature matrix as generated by the methylCIBERSORT package.  Hierarchical clustering was carried out on columns 
and rows as denoted by dendrograms. B) t-SNE embedding of resulting signature matrix beta-values C) Relative proportion comparisons between DNA-mixture and Flow Validated test 
data and the resulting methylation-based CIBERSORT estimate D) Scatter-plot showing the comparison between initial proportions of modelled mixture data and resulting methylation-
based CIBERSORT estimate E) Pan-CNS cohort showing only 2215 CpG probes selected in the signature matrix F) Scatter-plot showing comparison between methylation-based 
CIBERSORT fraction of B-cells and the expression-based estimates from parallel data G) Scatter-plot showing comparison between methylation-based CIBERSORT fraction of CD8T 
and the expression-based estimates from parallel data
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The new signature matrix was benchmarked using publicly available methylation 
profiles of PBMCs with known cell composition as determined by flow-cytometry or 
constituted from mixtures of reference DNAs of known proportions. A significant level 
of correlation was found between the methylCIBERSORT estimates and the flow 
cytometry measurements and known DNA mixtures (Rho = 0.84 p<0.001, n=36 and 
Rho = 0.91 p<0.001, n=72 respectively, Figure 24C). 100 synthetic mixtures for each 
cell type generated in silico were tested using methylation profiles of random pure cell 
populations mixed 1:4 with a mixture of cancer cell line profiles (Figure 24D). Again, 
there was a highly significant correlation between estimated and actual cell 
composition (Rho = 0.98 p<0.001, n=1100). A dataset comprising Breast Cancer 
samples for which parallel 450K Methylation and Affymetrix U133Plus2.0 expression 
profiles were available was analysed using both methylCIBERSORT and standard 
expression CIBERSORT (LM22 signature matrix). Where reference cell populations 
were comparable (i.e. had been flow sorted using the same antibodies) directly, or by 
aggregation and where tumour infiltration was present, there was a significant 
correlation (e.g. B-cells, T-cells) between methyl and expression CIBERSORT (Figure 
24E,F). 
6.3.2 Tumour Immune Microenvironment in Malignant Rhabdoid Tumours is 
associated with subtype and prognosis in a Tumour location dependent 
manner. 
MethylCIBERSORT analysis was ran on a set of 229 MRT, made up of 192 ATRT 
samples and 37 ECRT. MRT are on average infiltrated predominantly by Tregs (19% 
of non-cancer cells), monocytes (18%), B-cells (15%) and CD8T (13%) (Figure 25A). 
Taking the three previously published molecular subgroups of ATRT (ATRT-TYR, 
ATRT-SHH, ATRT-MYC [23]) and ECRT the distribution of each estimated immune 
cell type is significantly different with respect to ATRT subgroup (all p<0.05) (Figure 
25A). Post-hoc testing shows the most significant are NK, Treg, B-cells (each greater 
in ATRT-TYR) and CD8T (significantly greater in ATRT-MYC and ATRT-SHH) (Figure 
25A-B). Surprisingly, no immune cell types were found to be significantly different 




Figure 25.A) Comparison of estimated proportions and type of non-cancer cells in MRT by sub-group and by location  B)t-SNE plot representing the methylation profiles of 229 MRT. 
The colours of dots in the central panel map to published molecular subgroups. Text represents centroids of individual subtypes. Background shading represents the 2D spatial density 
estimation of the amount of Tumour Infiltrating Lymphocytes (TILs); red shading equals relatively greater than average infiltration and blue less than average. Exploded side panels 
represent enlarged areas of interest wherein both dot colour and background shading represent the relative amount of the particular immune cell infiltration denoted. Red denotes 
relatively greater than average infiltration and blue less than average. C) Kaplan-Meier plot showing significantly different overall survival (OS) in ATRT with > or < median numbers of 
B-cells. D) Kaplan-Meier plot showing significantly different overall survival (OS) in ECRT with > or < median numbers of CD8+T cells.
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Consensus clustering of MRT immune cell infiltration estimates identifies four robust 
immune subgroups which cut across the tumour subgroups and named here MRT IC1-
4. MRTIC1 and MRTIC3 constitute minor clusters, only 2% (4/229) and 6% (14/229) of 
all MRT, and have relatively high proportion of neutrophils and monocytes respectively. 
Both clusters contain a disproportionate number of ECRT and ATRT-TYR (Chi-
Square=48.218, p<0.001) (Figure 26A). MRTIC4 constitutes 32% (74/229) of all MRT 
and is characterised by a relatively high proportion of CD8T and relatively low 
infiltration of other immune cell types. MRTIC2 constitutes 60% (137/229) of all MRT 
and is characterised by a relative lack of CD8T and relatively moderate infiltration of 
other immune cell types; 83% (59/71) of ATRT-TYR are of this type. 
Examining association with outcome in ATRT, a greater than median level of B-cells 
was associated with a significantly improved PFS (Log-rank, p=0.01, n=21) (Figure 
25C). In ECRT a greater than median level of CD8T was associated with a significantly 
poorer overall survival (Log-Rank p=0.0023, n=30) (Figure 25D). It should be noted 
that molecular subgroup alone was non-significant with respect to overall survival in 
both ATRT and ECRT. 
No significant differences in immune infiltration are seen with respect to age category 
(<2 vs >2 years), presence of metastases at diagnosis and type of SMARCB1 
mutation. The only significant clinico-pathological association is a lower proportion of 
monocytes and a higher proportion of NK cells in infratentorial compared to 
supratentorial ATRT (W=1469.5 & W=2726.5 respectively, both p<0.001) (Figure 
26C,D). 
CYT score, PDL1 expression, calculated in samples for which parallel RNA-seq data 
was available, was significantly correlated with methylCIBERSORT estimates of TILs 
in MRT (all p<0.01, n = 23) (Figure 26Figure 26E,F).Taken as a whole this underlines 





Figure 26. A) Heatmap showing row-scaled relative levels of immune cell infiltration in 229 Malignant Rhabdoid Tumors (MRT)  ordered by immune cluster MRTIC1-4. B) Barplot showing 
estimated proportion of cell infiltration by molecular subgroup. C) Boxplot showing estimated monocyte infiltration and D) NK infiltration in ATRT by CNS location 
(infratentorial/supratentorial) E) scatterplot showing PDL1 expression and F. CYT score correlation with proportion of TILs as estimated by methylCIBERSORT. G) Boxplot showing CYT 




6.3.3 methylCIBERSORT analysis of a pan-CNS Tumour methylation cohort 
shows significant differences in Tumour immune microenvironment 
related to Tumour type and grade 
MethylCIBERSORT was applied to a set of 3,764 pan-CNS tumour methylation profiles 
(plus an additional 141 control/hematopoietic samples) published by Capper et al. 
(2018). This reference set is the training resource of the Molecular Neuro-Pathology 
2.0 (MNP2.0) classifier and represents 80 methylation tumour types/sub-types closely 
related to WHO histopathological entities and divided into 13 broad histological 
categories. A relative proportion of the 12 cell types were estimated and indicators of 
deconvolution performance examined. As further validation, the relative proportion of 
cancer cells estimated by methylCIBERSORT was significantly correlated with the 
estimate of tumour purity provided by Capper et al. (2018) (based on machine learning 
estimates trained on a set of known glioma positives) (Rho = 0.71, p<0.01, n = 3784, 
Figure 27B). The sum of the estimated proportions of all Tumour Infiltrating 
Lymphocytes (TILs) (i.e. Treg, CD4T, CD8T and NK), correlates significantly with the 
meTIL score (an independent measure of T Lymphocyte infiltration based upon 
methylation status of 5 CPGs) defined by Jeschke et al. (2017) (Rho = 0.29, p<0.001, 
n = 3764, Figure 27B). As expected, control samples having a known inflammatory or 
reactive tumour microenvironment were associated with a large increase in the 
estimated median proportion of neutrophils (86% vs 0%, W=0, p<0.001) and 
monocytes (50% vs 17%, W=17 p<0.001) respectively compared to the average of 




Figure 27. Barplots of the estimated median infiltration of specific cell types as a proportion of all non-cancer cell types (range scaled from 0-1) in 3,763 CNS tumour samples from the 
panCNS tumor cohort.  Data shown by tumor type/subtype highlighting the range and variation of immune cell infiltration in different CNS tumor types. B) Scatterplot showing the 
estimated methylCIBERSORT cancer fraction correlates significantly with published estimates of tumor purity; Scatterplot showing the estimated methylCIBERSORT estimate of total T-
lymphocyte infiltration correlates significantly with an independent meTIL score C) Boxplot showing a negative association between proportion of estimated cell types and WHO-grade. 
D) Barchart showing differences in frequency of patients of different WHO grade by immune cluster. E) Boxplot showing methylCIBERSORT estimates of monocyte and neutrophil 




Calculating the median estimated relative proportions of non-cancer cell types showed 
that on average across all CNS tumour types the largest fractions of non-cancer cells 
proportionally were Tregs (20% of all non-cancer cells) and monocytes (20%) followed 
by B-cells (16%), CD8T (14%), eosinophils (12%), NK cells (12%), CD4T (9%), and 
neutrophils (8%). Relatively modest proportions of neuronal (3%), endothelial cells 
(2%), and glia (1%) were estimated.  
Individual tumour types/subtypes varied significantly in the relative proportions of 
infiltrating cell types; each cell type was significantly non-randomly distributed with 
respect to tumour type/subtype (as calculated by Kruskal-Wallis one way analysis of 
variance (KW), each p<0.001) (Figure 27A). Post-hoc testing (Dunn test) reveals the 
relative number of TILs, and indeed the total amount of infiltrating cells, was 
significantly less in high grade tumour types such as embryonal tumours (i.e. MB, 
ATRT, ETMR) than in Low Grade Gliomas (LGG) (p<0.001). Examining the median 
relative proportions of the 11 non-cancer cell types across CNS tumours those with the 
greatest variance are monocytes, Treg and CD8T. Notably, LGG subtypes have a 
proportionally greater number of monocytes making up an estimated 35% of all 
infiltrating cells compared to 13% in embryonal tumours. CD8T, for example, is 
proportionally greater in MBGrp3 and MBSHHCHLD, making up an estimated 48% and 40% 
of all infiltrating cells respectively compared to 6% in LGG. Tregs are relatively greater 
proportionally in the Sellar tumours (specifically pituitary adenomas) constituting an 
estimated 36% of all infiltrating cells compared to 14% in glioblastoma and 17% in 
embryonal tumours (Figure 27A).  
Consensus clustering of immune cell estimates identifies an optimal 3 immune clusters 
refered to as panCNSIC1-3. Members of panCNSIC1 have a relatively high proportion of 
Tregs and a relative lack of CD8T cells. panCNSIC2 have a relatively high proportion of 
CD8T and low proportions of CD4T/Tregs and NK cells. panCNSIC3 has a relatively 
high proportion of monocytes and relative lack of CD8T (Figure 28). Membership of an 
immune cluster was related to but by no means exclusively dictated by tumour type. 
Whilst immune cluster is significantly non-random with respect to tumour 
subgroup/subtype (Chi-square=3303, p<0.001, most tumour subgroups cut across 




Figure 28. t-SNE plot showing clustering of the panCNS cohort by immune cell estimates. Large panel shows three immune clusters (IC1-3), smaller panels show the location and 
distribution of tumours of particular subgroup, grade, stage and age, immune cell estimates are represented as a red-white colour scale. P-values represent statistical test for non-
random association of a given characteristic with immune-cluster
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The significance of association with available clinico-pathological characteristics (WHO 
grade, disease stage i.e. metastases/relapse/diagnosis, age category i.e. <3 years / 3-
16 years / >16 years, tumour location, gender) was assessed and the proportion of 
immune cell types was significantly associated with each of the clinico-pathological 
characteristics with the exception of gender. The strongest association was with WHO 
grade for which the average infiltration of certain immune cell types (eosinophils, 
CD4T, B-cell, Treg, NK, monocytes and TILs) decreases proportionally with increasing 
WHO Grade (I-IV) (Figure 27C, Figure 27E). Immune cluster membership is 
significantly associated with WHO grade (Chi-square = 1249.3, p<0.01). 87% 
(509/587) of all WHO Grade I tumours belong to panCNSIC3 and panCNSIC2 consists 
of 86% (492/571) Grade IV tumours (Figure 27D). Such associations are unsurprising 
given the strong interdependence of clinico-pathological factors with tumour subtype. 
However, a regression analysis using only tumour types for which grade, age category 
and tumour location was variable showed a number of clinico-pathological associations 
significant independently of tumour subgroup. B-cells, CD4T, eosinophils and Tregs, 
were each significantly negatively associated with tumour stage (each p<0.01) 
independently of subgroup. Monocytes were also significantly positively associated 
with spinal location independent of subgroup. In summary, this analysis reveals the 
existence of at least three distinct TIME classes across CNS tumours strongly related 
to but not exclusively dictated by tumour subgroup and grade. 
6.3.4 Tumour Immune Microenvironment in Medulloblastoma is related to molecular 
subtype but provides independent prognostic information 
Having estimated TIME in a panCNS cohort, more specific analyses were applied to 
the single tumour entity medulloblastoma; applying methylCIBERSORT to a set of 
2325 MB methylation profiles, published by The Paediatric Brain Tumour Group and 
others, for which more detailed clinico-pathological and parallel multiomics data was 
available. Each of these studies elaborated upon the 4 classic subgroups of MB 
(MBWNT, MBSHH, MBGrp3 & MBGrp4) to describe further derivative subtypes 
including high-risk or low-risk subtypes of MBGrp3/Grp4. The most abundantly 
estimated infiltrated non-cancer cell types on average across all MB subgroups were 
CD8T (27% of all non-cancer cells), B-cells (16%) and eosinophils (15%). The 
proportion of each cell type was significantly different with respect to the 4 classic 
subgroups (all p<0.001) and post-hoc testing shows significantly greater CD8T in 
MBGrp3 vs MBGrp4 (7.3-fold, p<0.001), greater NK in MBGrp4 vs other subgroups 
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(9.7-fold, all comparisons p<0.001) and greater B-cells in MBSHH vs other subgroups 
(3-fold, all comparisons p<0.001) (Figure 29A,B).  
A meta-analysis was recently published describing a further refinement of the 
MBGrp3/Grp4 subgroups into eight subtypes I-VIII. These subtypes are also 
associated with differences in estimated levels of each cell type with the exception of 
monocytes (each p<0.002). Post-hoc analysis shows the most significant differences 
to be CD8T (greater in subtype II), Tregs (less in subtype II), NK (greater in subtypes 
VIII), B-cells (less in subtype III) (all comparisons p<0.01) (Figure 4A,B). Significant 
differences were apparent between MBSHH subtypes. Both the infant SHH subtype 
and the SHH gamma subtype show significantly greater proportions of B-cells than 




Figure 29. A) Barplots of the estimated median infiltration of specific cell types as a proportion of all non-cancer cell types (range scaled from 0-1) in 2,325 Medulloblastoma by subgroup 
(classic 4 medulloblastoma consensus subgroups) by SHH subtype and by 10 group consensus.  B) t-SNE plot representing the methylation profiles of 2,325 Medulloblastoma. The 
colours of dots in the central panel map to the classic 4 molecular subgroups; red = SHH, blue = WNT, yellow = Grp3, green = Grp4. Text represents centroids of individual subtypes as 
reported variously. Background shading represents the 2D spatial density estimation of the amount of Tumour Infiltrating Lymphocytes (TILs); red shading equals relatively greater than 
average infiltration and blue less than average. Exploded side panels represent enlarged areas of interest wherein both dot colour and background shading represent the relative amount 
of the particular immune cell infiltration denoted. Red denotes relatively greater than average infiltration and blue less than average. C) Kaplan-Meier plot showing significant difference 
in overall survival in MBGrp4 by immune cluster. D) Kaplan-Meier plot showing significantly different progression free survival (PFS) within the MBGrp3 subtypes by low (< median) or 
high (> median) levels of Treg infiltration
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Consensus clustering of MB immune cell estimates identifies an optimal 4 immune 
clusters referred to here as MBIC1-4 which cut across each of the MB 
subgroups/subtypes (Figure 30A). MBIC1 constitutes 7% (167/2325) of all MB and is 
characterised by relatively high proportions of B-cells and CD8T and a 
disproportionately high number of MBSHH patients; 83% of MBIC1 are also MBSHH 
(Chi-Square = 425.59, p <0.001). MBIC2 constitutes 7% (162/2325) of all MB and is 
characterised by relatively high proportions of Treg, eosinophils, NK and low 
proportions of CD8T. MBIC3 constitutes 42% (981/2325) of all MB has relatively low 
proportions of CD8T, relatively moderate levels of all other infiltrating immune types 
and a disproportionately high proportion of MBGrp3/Grp4 (78% of MBIC3). MBIC4 
constitutes 44% (1015/2325) of all MB and is characterised by a relatively high 
proportion of CD8T cells and relatively low-moderate levels of other infiltrating immune 
cell types (Figure 30A,B).  
For a subset of MB samples, both methylation and RNA-seq data were available. It 
was therefore possible to calculate the expression based metric “Cytolytic score” (CYT 
= the mean expression of GZMA and PRF1) as described by Rooney et al [37] and 
this was significantly correlated with methylCIBERSORT estimates of TILs (Rho = 
0.18, p=0.015, n=185) and differed significantly by immune cluster (F=4.1, p=0.008, n 
= 185) being greatest in MBIC1 and poorest in MBIC3 (Figure 30B). Expression of 
immune checkpoint gene PDL1 was also significantly different with respect to immune 
clusters (both p<0.01); MBIC1 in particular showed high expression of PDL1. 
Further associations between infiltrating cell estimations and clinico-pathological 
variables (within the four classic subgroups) were examined including: MYC/MYCN 
amplification, TP53 mutation and metastatic stage. MYC amplification in MBGrp3 was 
associated with a significantly higher proportion of TILs, CD8T and B-cells (KW=8.7, 
16.7, 18.9 respectively, each p<0.01, n = 408), and a lower infiltration of Tregs 




Figure 30.A) t-SNE plot showing clustering of the MB cohort by immune cell estimates.  Large panel shows four immune clusters (MBIC1-4), smaller panels show the location and 
distribution of tumour of particular subgroup, immune cell estimates are represented as a red-white colour scale. P-values represent statistical test for non-random association of a given 
characteristic with immune-cluster. B) Boxplot showing expression of PDL1, PD1 and CYT score by MB immune cluster. C) Boxplot showing proportion of non-cancer cells by presence 
of MYC amplification in MBGrp3. D) Kaplan-Meier plot showing significantly different progression free survival (PFS) in infant MBSHH  by low (< median) or high (> median) levels of 
Treg infiltration. E) Kaplan-Meier plot showing significantly different progression free survival (PFS) in MBGrp4 by low (< median) or high (> median) levels of monocyte infiltration.
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Estimated immune cell infiltration was examined for association with survival in each 
subtype (excluding MBWNT). Membership of MBIC2 was associated with poorer 
overall survival (OS) in MBGrp4 (Log-Rank p=0.0079, n = 399) (Figure 29C). Cox-
regression shows several individual cell types are significantly associated with 
outcome. For Infant MBSHH a greater than median proportion of Tregs was 
significantly associated with a poor progression free survival (PFS: z=-2.187 p=0.029 
n=59) (Figure 30D). In some instances, immune cell estimates provide prognostic 
information independent of previously established survival associated methylation 
subtypes. For instance, a greater than median proportion of monocytes in MBGrp4 is 
associated with a poor prognosis (OS: z=-2.742, p=0.006, n=399, PFS: z=-2.06 
p=0.039 n=133). Multivariate analysis shows that this association is significantly 
prognostic independent of the MBGrp4 High-risk/Low-risk subgrouping (OS: z=-2.742, 
p=0.006, n=399, PFS: z=-2.06 p=0.039 n=133) (Figure 30E). Likewise, the proportion 
of Tregs distinguishes two groups within the previously described MBGrp3 Low Risk 
subtype with significantly different survival (Log-Rank p<0.001, 5yrEFS 88% vs 52%) 
(Figure 29D). This demonstrates that immune infiltration estimates are able to add 
additional prognostic information not readily available from previous methylation-based 
analysis. 
6.3.5 Differences in proportion of immune cell infiltration in HGG are associated with 
subtype, Histone/MAPK mutation, clinicopathological characteristics and prognosis 
A cohort of 401 primarily paediatric High-Grade Glioma (pHGG) samples were 
analysed. pHGG were on average infiltrated predominantly by monocytes (26% of non-
cancer cells), Tregs (15%) and eosinophils (13%) (Figure 31A). CD8T infiltration in 
pHGG was generally less than MB and MRT. Several cell types varied significantly 
with respect to tumour subgroup i.e. WT-A, WT-B, WT-C, IDH, GBM G34 & GBM K27. 
These include monocytes, CD8T, TILs and eosinophils (each p<0.001), Figure 31A,B). 
Post-hoc testing shows significantly greater monocytes in WT-A vs other subgroups, 
(2.9-fold, all comparisons p<0.001), significantly greater CD8T in GBM with G34 
mutations, (1.7-fold, all comparisons p<0.05) and significantly less eosinophils in GBM 
with G34 mutations (2.3-fold less, all comparisons p<0.001). Furthermore, the number 
of TILs and indeed the overall level of immune cell infiltration is significantly higher in 
the WT-A subgroup (1.6-fold greater, and 1.9-fold greater respectively, all comparisons 
p<0.01) and significantly lower in GBM-G34 than other pHGGs (1.8-fold and 2.0-fold 
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respectively, all comparisons p<0.01). The WT-A subgroup generally contains pHGG 




Figure 31. A) Barplots of the estimated median infiltration of specific cell types as a proportion of all non-cancer cell types (range scaled from 0-1) in 401 pHGG.  B) t-SNE plot representing 
the methylation profiles of 401 pHGG. The colours of dots in the central panel map to subgroup. Background shading represents the 2D spatial density estimation of the amount of 
Tumour Infiltrating Lymphocytes (TILs); red shading equals relatively greater than average infiltration and blue less than average. Exploded side panels represent enlarged areas of 
interest wherein both dot colour and background shading represent the relative amount of the particular immune cell infiltration denoted. Red denotes relatively greater than average 
infiltration and blue less than average. C,D,E) Kaplan-Meier plot showing significant difference in overall survival in WT-A, WT-C and G34 subgroups by low (< median) or high (> median) 
levels of B-cell and NK infiltration. F) Boxplot showing the proportion of monocytes and CD4T cells in pHGG by presence/absence of a MAPK mutation. G) Boxplot showing TIL proportion 
as estimated by methylCIBERSORT for a subset of pHGG samples for which histopathology-based estimates of lymphocyte infiltration were available. H) Estimates of TILs were 
significantly greater in patients classified as Categories 1 (present) or 2 (abundant) than Category 0 (absent).
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Consensus clustering of pHGG immune cell estimates identifies an optimal 3 immune 
clusters referred to here as pHGGIC1-3 which cut across each of the pHGG subtypes 
(Figure 6SA). pHGGIC3 overlaps primarily with panCNSIC1/panCNSIC2 and 
pHGGIC2 overlaps with panCNSIC3 (Figure 3SC). pHGGIC1 constitutes 31% 
(126/401) of all pHGG and is characterised by high proportions of Tregs, eosinophils, 
NK and CD4T. pHGGIC2 constitutes 17% (71/401) of all pHGG and is characterised 
by high proportions of monocytes and a disproportionately high frequency of WT-A 
subtypes; 77% (55/73) of all pHGGIC2 are also WT-A. pHGGIC3 constitutes 51% 
(204/401) of all pHGG and tumours show intermittently moderate levels of CD8T and 
relatively low levels of other infiltrating immune cell types. 87% (43/49) of all GBM G34 
belong to this cluster (Figure 32A,B).  
Examining the association of cell infiltration with survival within each of the pHGG 
subgroups using cox-regression reveals the following significant associations Lower 
than median concentrations of B-cell and CD8T in WT-A patients are associated with 
a poor OS (z=3.735, p<0.001, n=80 & z=1.991, p=0.047, n=80 respectively). Higher 
than median concentrations of CD4T and NK in GBM G34 patients is associated with 
a poor OS (z=-2.193, p=0.028, n=42 & z=-2.417, p=0.016, n=42 respectively) (Figure 




Figure 32.A) t-SNE plot showing clustering of the pHGG cohort by immune cell estimate large panel shows four immune clusters (pHGGIC1-3),  smaller panels show the location and 
distribution of tumours of particular subgroup, immune cell estimates are represented as a red-white colour scale. P-values represent statistical test for non-random association of a 
given characteristic with immune-cluster. B) Heatmap showing row-scaled relative levels of immune cell infiltration in 401 pHGG ordered by immune cluster pHGGIC1-3. C) Kaplan-
Meier plot showing significant difference in overall survival in WT-A patients by low (< median) or high (> median) levels of CD8+T infiltration. D) Kaplan-Meier plot showing significant 
difference in overall survival in G34 patients by low (< median) or high (> median) levels of CD4T infiltration.
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Clinico-pathological/biological features examined for association with estimated cell 
types include WHO stage, gender, age <1 or age < 3, presence of BRAF and/or other 
MAPK mutation. Several immune types were significantly associated with these 
clinicopathological criteria. As previously noted (Mackay et al., 2018) the presence of 
MAPK mutations was associated with higher immune cell infiltration; specifically of 
monocytes and CD4T cells (W=3614 & W=3453 respectively, both p<0.001). For a 
subset of samples histopathology-based estimates of lymphocyte infiltration were 
available which categorised patients as per Rutledge et al. (2013). Estimates of TILs 
were significantly greater in patients classified as Categories 1 (present) or 2 
(abundant) than Category 0 (absent) (F=7.839, p<0.01, n = 61). Again, taken as a 
whole, the significant relationships between molecular subgroup, prognosis, mutation 
and immune infiltration in pHGG are clear. 
6.4 Discussion  
Using a methylation-based deconvolution analysis the TIME of >6000 individual 
(primarily paediatric) CNS tumours was estimated. Diversity in TIME composition 
across these CNS tumours was demonstrated as well as significant associations 
variously with tumour type, subtype, stage, grade, location, mutation and survival. The 
notion of the CNS, and by association CNS tumours, as immune privileged and 
inaccessible to immune cells is increasingly outdated (Quail and Joyce, 2013), 
nevertheless the analysis lends weight to the idea of a diverse TIME across a wide 
range of CNS tumours. 
The implications of the results are as follows. First, that the nature of immune cell 
content is associated with - but not exclusively dictated by - a particular tumour type or 
subtype. Second, that at least three broad CNS TIME subgroups strongly associated 
with tumour type and grade can be identified by clustering immune cell types and that 
within individual tumour types (MB, ATRT, pHGG) further immune subgroups may be 
described. Immune subgroups cut across the conventional CNS molecular tumour 
subgroups such that a patient may simultaneously belong to a given molecular 
subgroup and also independently a particular immune subgroup. Furthermore, these 
immune subgroups have different immunophenotypic characteristics (different CYT 
scores, expression of PDL1, etc) and are associated with WHO Grade. Third, that key 
molecular features recognised as molecular drivers, such as MYC amplification in MB 
or H3.3G34 mutations in HGG, are associated with distinct TIMEs and particular 
infiltrating cell types raising the possibility that these mutations are directly influencing 
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the tumour microenvironment; perhaps as adjunct to their intrinsic oncogenic 
mechanism. Fourth, that by extracting molecular information about TIME it is possible 
to access significant prognostic information independent of conventional molecular 
subgroups raising the possibility of their future incorporation into existing prognostic 
biomarker schemes. It should be noted that prognostic associations with immune cell 
infiltration appear to be context dependent; increased CD8T infiltration, for instance, 
does not universally denote a poor outcome. 
The results are broadly in accordance with the small number of recent investigations 
into immune infiltration in paediatric CNS tumours. Mackay et al. (2018) identified a 
relative lack of TILs in histone mutant pHGG compared to hypermutator and PXA-like 
(WT-A) subgroups and this is borne out by the analysis here. Bockmayr et al. (2019) 
expression analysis of a mixed cohort of adult and paediatric gliomas identifies 4 
immune clusters (including monocyte and T-cell dominated clusters) not wholly 
inconsistent with the results here. They show some associations with overall survival, 
however these are mainly within the older (>40 years) and IDH mutated subgroup. 
Bockmayr et al. (2018) also analysed expression (by microarray) of immune markers 
in 763 medulloblastomas and concluded, similarly, that MBSHH tumours had larger 
numbers of T-cells overall than other subgroups. In contrast to findings here, they did 
not identify associations with MB survival as was the case for Vermeulen et al. (2018) 
study of 26 MB patients. 
methylCIBERSORT is a method of convenience especially given the prevalent use of 
methylation profiling within paediatric CNS tumours. Limitations of tumour biopsies and 
representative sampling notwithstanding, the analysis provides much breadth but 
clearly not the depth that may be achieved by single cell RNA-seq analysis. The 
analysis is further limited by its reliance on pure cell populations with no guarantee that 
the methylation signatures of these processed cells are identical to those within the 
tumour stroma. It should also be noted that there is likely “dark-matter” i.e. immune 
infiltration for which the reference population are absent or incomplete. Nevertheless, 
there have been several efforts to validate and benchmark the estimates using 
simulations and parallel expression/protein-based methods and provide justification for 
the broad accuracy of this approach in CNS tumours.  
Finally, the results and the immune clusters developed here indicate important 
differences in TIME across paediatric brain tumour types. Immune clusters are clearly 
related to the expression of conventional immune targets such as PDL1 in MB and 
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ATRT and in a broad sense indicate which immune subgroups are “hot” or “cold”. The 
immune clusters identified break down, broadly speaking, into the Monocyte 
dominated (i.e. panCNSIC3, and pHGGIC1/2) the balanced or CD4+T type (i.e. 
panCNSIC1, MBIC2/3 and MRTIC2) and the CD8+T type (i.e. panCNSIC2, MBIC1/4 
and pHGGIC3). With such information one may in future begin to match individuals or 
groups of individuals TIMEs to immunotherapy responses or lack thereof. Even in the 
most simplistic terms it seems to follow that an a priori paucity of infiltrating Cytotoxic 
T Lymphocytes and the lack of a supportive TIME may be unconducive to immune 
checkpoint blockade as a therapeutic strategy, but instead may be amenable to 
approaches which alter the TIME or genetically redirect T-cell immunity. 
In conclusion, this analysis gives first indications of the potential future therapeutic and 
prognostic possibilities of immuno-methylomic profiling as an adjunct to 
methylation/expression-based sub-classification. A future in-depth high-resolution 
approach incorporating spatial information is now required and in silico deconvolution 
approaches may ultimately be used to triage and to inform selection of immunotherapy 




7 Summary and Discussion  
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7.1 Malignant Rhabdoid Tumours 
MRT are a rare and aggressive paediatric malignancy with unmet clinical need owing 
to the lack of effective therapies, and poor response to current therapy approaches. 
MRT can occur throughout the body and present different challenges when diagnosed 
in the CNS as ATRT and in other parts of the body as ECRT, limiting therapeutic 
options. 
The main and typically only molecular feature of these tumours, SMARCB1 has been 
shown to play a key role in tumorigenesis in MRT and is present in a majority of cases 
(Versteege et al., 1998; Biegel et al., 1999). SMARCB1 knock-out experiments in 
mouse models show rapid development of tumours including sarcomas and tumours 
resembling MRT transcriptional profiling (Klochendler-Yeivin et al., 2000; Guidi et al., 
2001; Han et al., 2016) . In addition, SMARCB1 loss has been linked to deregulation 
in a number of key developmental pathways such as WNT and SHH signalling, as well 
as effectors of chromatin remodelling such as EZH2.(Jagani et al., 2010; Wilson et al., 
2010; Mora-Blanco et al., 2014). 
Despite its stable genome, MRT shows considerable heterogeneity in tumour 
appearance (Fanburg-Smith et al., 1998), response to therapy and ultimately 
survival(Modena et al., 2013; Abu Arja et al., 2018). In an effort to characterise this 
heterogeneity, a number of subgrouping studies have been carried out since 2015 
seeking to identify the number and biological character of putative subgroups. A 
number of subgrouping schemes have been proposed, most focusing on subgrouping 
only one type of MRT. The numbers of subgroups differ between publications and while 
features identified hint at common biology such as the difference between a neural 
lineage in SHH/Group1 to mesenchymal differentiation in MYC/Group2B as well as the 
common overexpression of HOX cluster genes in both ATRT and ECRT (Chun et al., 
2016; Han et al., 2016; Johann et al., 2016; Torchia et al., 2016), currently consensus 
definition encompassing all MRT types exists. 
This study was developed in order to interrogate current subgrouping strategies, 
develop a consensus and make recommendations on the direction of future MRT 
clinical and molecular studies. In order to do this, the relationship between MRT 
occurring at different locations in the body were compared to identify whether a 
common MRT-specific molecular signature can be identified. Subsequently, a meta-
analysis of current MRT subgroups was carried out to identify optimum subgroups in a 
combined cohort of MRT and to explore additional subgroups as potential novel targets 
128 
 
for further research. Additional cases from CCLG cancer centres were collected as 
well as detailed clinical data and survival information. Subgroup specific survival 
analyses were carried out as well as more traditional comparisons between previously 
identified factors. Finally, prompted by association of MRT subgroups with immune 
signalling, an analysis to estimate immune cell content in a multiple CNS tumours, 
including MRT was carried out. 
Parallel to this study, an international collaboration between Germany, Canada, France 
and the United Kingdom was launched in 2017 in order to generate a consensus ATRT 
subgrouping scheme. Data from the study is not presented in the main thesis body and 
instead a more comprehensive subgrouping analysis was carried out to examine 
subgroups in MRT as a whole. The ATRT consensus study text has been accepted for 
publication and is currently available as a pre-publication document (doi: 
10.1093/neuonc/noz235).  
7.2 Investigating the biological relationship between ATRT and ECRT 
To date, this thesis is one of the only large-scale studies examining ATRT and ECRT 
in a combined cohort. Despite a general agreement across the field that ATRT and 
ECRT share many biological features, clinical and profiling studies have typically 
restricted their focus on one type of tumour only. There are many good reasons for 
this, clinically approaches to treating ATRT and ECRT vary with radiotherapy being 
more common in young patients with ECRT while being typically deferred in patients 
under 3 years old in ATRT. Secondly, any chemotherapeutic agents identified for 
ATRT therapy would require access to the CNS via the blood-brain barrier.  
Despite this, the analysis demonstrated a high degree of genetic and epigenetic 
overlap between ATRT and ECRT especially when compared against other embryonal 
tumours and tumours which originate from a single tissue or location which display 
more variability. An MRT-specific signature was identified highlighting common gene 
expression across ATRT and ECRT. As well as this, it was shown that subgrouping 
strategies which were developed in ATRT only can be recapitulated in a combined 
MRT cohort.  
Based on the findings in this thesis, ATRT and ECRT are highly compatible with 
combined analyses with both transcriptomic and epigenetic approaches. Shared gene 
expression and high degree of overlap between ATRT and ECRT when compared to 
other embryonal tumours points to common biology that could be exploited 
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therapeutically. One conclusion of this study is that future analysis of MRT should 
encompass all tumour types and that any potential therapeutic strategies used in ATRT 
be considered in ECRT and vice-versa. 
7.3 Generating a molecular signature of MRT subgroups 
Subgrouping studies have proposed a number of different subgrouping schemes and 
their defining characteristics such as differential expression of neural and 
mesenchymal lineage genes, differences in SMARCB1 mutation type, differences in 
age and location for CNS tumours. (Chun et al., 2016; Han et al., 2016; Johann et al., 
2016; Torchia et al., 2016). In addition to this, a DNA methylation based classifier 
MNP2.0 has been developed which includes ATRT (Capper et al., 2018).  
In order to evaluate currently utilised subgrouping schemes in ATRT and ECRT and 
compare and contrast optimum subgroup number and content, a meta-analysis using 
a consensus NMF approach was carried out. This method utilised resampling to 
robustly call subgroups and identify poorly clustering samples. Using published data 
as well as a newly profiled cohort defined in this thesis, 450K/EPIC methylation 
analysis was carried out on a combined MRT cohort, and a gene expression array 
analysis on combined MRT HGU133Plus2.0 arrays.  
The resulting subgrouping shows a high degree of concordance between previous 
studies and identified similar gene expression and methylation features between 
previous subgrouping strategies and the consensus subgrouping approach utilised 
here. This thesis presents a 3 group consensus subgrouping strategy which aligns a 
number of previous schemes and provides a robust method for analysis of additional 
profiles.  
In addition, this thesis expanded on current subgrouping by exploring greater numbers 
of subgroups. The resulting subgrouping scheme identified novel clinicopathological 
differences between subgroups, such as localisation and age differences between 
SHH.Infratentorial and SHH.Supratentorial, or identified a novel subgroup with a 
unique methylation landscape and characterised by lack of broad chromosome 22q 
changes. These novel subgroups were previously only described as heterogeneity in 
the existing subgroup scheme (Johann et al., 2016). 
The clinical relevance of subgrouping MRT has been previously examined in a single 
study which found significant survival differences using subgroups the authors defined 
(Torchia et al., 2015). Whether the consensus subgrouping scheme proposed here will 
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further expand current stratification in MRT remains to be seen. The generation of a 
large, well annotated clinical dataset will be required to rigorously test different clinical 
outcomes based on subgroup membership 
7.4 Survival analysis in MRT 
A cohort of 113 MRT cases was generated as part of this thesis and collected from 
CCLG centres and the Brain UK registry. Clinical data was obtained for cases where 
possible and survival information was collected to test the association of different 
clinicopathological features with MRT survival. 
The most significant factors that affected survival in this cohort were radiotherapy, 
evidence of metastasis, surgical resection extent, and age of patients at diagnosis. 
Other factors such as consensus NMF subgroup, chromosomal arm loss in 22q, sex 
were not significantly associated with survival differences. 
However, despite not initially being a significant predictor of survival in a univariate 
approach, consensus NMF k = 3 subgroup contributed to a significant survival 
stratification scheme when combined with a newly proposed (Fruehwald et al., 2018) 
age stratification of < 1 year old and assignment to the TYR subgroup. Significant 
survival differences were shown in the MRT and ATRT cohorts with both the 5-year 
OS and PFS being >50% in patients allocated to the moderate risk group.  
In addition to this, the survival analysis recapitulated results showed previously in 
ATRT only for factors such as radiotherapy and surgical resection (Torchia et al., 2015) 
extent validating them in this cohort. 
7.5 Estimating immune infiltration in CNS tumours 
Expression of genesets associated with immune function and development was noted 
in this study in the MYC subgroup of MRT. Previous publications have also identified 
immune system genes as being significantly differentially expressed across MRT 
subgroups (Chun et al., 2016) 
Immune infiltration has been identified as an important hallmark of cancer as a whole 
(Hanahan and Weinberg, 2011) and more recently identified to be therapeutically 
targetable with a number of novel therapeutic agents (Rizvi et al., 2015; Robert et al., 
2015b; Herbst et al., 2016; Shen and Zhao, 2018; Tomita et al., 2019).However, these 
studies have shown that response to therapy appears to be heavily influenced by the 
nature of the tumour immune infiltration and that understanding of the nature of the 
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TIME in a particular tumour can shed light on whether it would be a suitable target for 
immune therapeutics.  
Carrying out a large-scale IHC immune cell analysis on the cohort developed as part 
of this thesis was not possible. However, a number of in-silico approaches for 
estimating TIME from genomic data have been developed (Newman et al., 2015; 
Chakravarthy et al., 2018). Based on the CIBERSORT method, adapted for DNA 
methylation array it was possible to carry out an initial estimation of tumour immune 
infiltration on large cohort of pan-CNS tumours including ATRT and to compare and 
contrast the types of immune differences seen across different types of CNS tumours 
originally published as part of the MNP2.0, as well as data provided by collaborators.. 
The method required the generation of a methylation signature matrix specific to 
immune cells of interest which was generated from publicly available immune cell 
methylation array profiling data for 11 immune and normal cell populations (CD8T, 
CD4T, Treg, Bcell, natural killer, monocytes, neutrophils, eosinophils, neuronal and 
glial tissue and endothelial tissue). Benchmarking and validation were carried out to 
measure the accuracy of the estimation which showed significant, high correlation to 
known flow-cytometry validated profiles and the estimation.  
Analysis of MRT immune infiltration estimation identified a number of immune clusters 
based on the level of estimated infiltration. Novel associations with survival for specific 
cell types such Bcells in ATRT and CD8T in ECRT. Comparative analysis in other CNS 
tumour types identified a large number of different significant associations with immune 
cluster, such as tumour grade, patient age, and subgroups if tumours. The developed 
analysis pipeline provides a convenient and powerful method estimation of immune 
cell infiltration in CNS tumours. 
7.6 Limitations 
During the development of this thesis a number of limitations were identified as part of 
the study and may present potential caveats on results provided here.  
Clinical data collected as part of this thesis cohort was not well annotated for 
therapeutic intent. Evidence of therapy was taken as a positive indicator of an attempt 
to treat the MRT but lack of therapeutic information was not excluded as this would 
heavily reduce the effective cohort size. In addition, chemotherapy information was 
highly variable and it was not always possible to ascertain whether HDCT was utilised. 
Germline SMARCB1 mutation testing in the cohort was available for a small number 
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of patients but was generally missing for the majority of cases. As this is a largely 
retrospective cohort, it is not possible to capture this data at this time. 
In DNA methylation array profiling of samples, array quality was analysed and a 
decision was made for what cut-off threshold for a number of array quality metrics to 
use. As a large proportion of the dataset was FFPE, array quality scores were typically 
below recommended thresholds for fresh and high quality tissue arrays. Extra 
measures were taken in order to avoid any technical error effects from poor quality 
profiling and any samples which showed spurious clustering or an exceedingly noisy 
and poor quality array profile were excluded from the study. 
SMARCB1 mutation information is only available as part of the published cohorts 
utilised in this thesis. Statistical analyses of enrichment of specific SMARCB1 mutation 
types were therefore based on a smaller proportion of the overall cohort used in 
Chapter 3 & 4. In order to overcome this limitation, chromosome copy-number 
estimation in methylation array was used as a surrogate measure for chromosomal 
arm loss in chromosome 22q, however this method is not full proof and can be subject 
to noise in the array due to the overall array quality. 
CIBERSORT analysis was carried out using a signature matrix of pure cell populations 
derived from publicly available data. The pure cell populations isolated as part of the 
datasets were not isolated with the same method and employed a number of different 
markers for cell-sorting and positive population enrichment. As there was no control 
over the methodology of the sorting and purification process, there is no guarantee that 
the populations included in the signature matrix are completely pure and represent a 
wholly pure population of the immune cells of interest. Due to this inherent uncertainty, 
despite high correlations with validation datasets, the results of the immune infiltration 
estimation were treated as an estimation only and that any subsequent findings would 
require validation before they can be treated as biologically real. 
7.7 Future work 
7.7.1 Expanding survival analysis cohort 
A number of independently published survival cohorts are available for MRT however 
the data for these has largely not been made publically available. A collaboration 
between a number of large clinical data studies combined with the current subgroup 
consensus analysis would allow for a much more powerful survival analysis of 
clinicopathological factors. Work is currently ongoing to complete clinical annotation 
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for the MRT cohort developed as part of this study. Where available clinical annotation 
should be sought to be as complete as possible.  
7.7.2 Further identification of subgroup-specific features 
This study has highlighted an MRT subgrouping scheme that incorporates a number 
of previously proposed subgroupings and combines both ATRT and ECRT. Currently 
available datasets can be utilised in novel ways in order to further define the differences 
between subgroups. Differentially methylated DNA regions can be inferred from 
constituted CpG probe regions of known association and significant correlation. In 
addition to this, methylation array data can be correlated with currently available 
transcriptomic analysis to show direct correlation between gene expression DNA 
methylation in significantly differentially methylated genes. 
7.7.3 Novel ‘omics profiling 
A number of new and established platforms are now optimised for use in low quality 
material such as FFPE. It would be possible to profile FFPE material using low-depth 
RNA-sequencing or bisulphite sequencing as an alternative to the more dated DNA 
methylation array and gene expression array. Generating a large cohort of detailed 
transcriptomic data for MRT is a highly important future goal. 
7.8 Final summary 
This study has applied a wide array of bioinformatic methods in order to interrogate 
heterogeneity in MRT biology. Differences between ATRT and ECRT were analysed 
in order to justify a future direction of combined MRT, subgroup-based research. Data 
presented in this thesis highlights a large degree of biological overlap between MRT 
tumours as a whole and provides evidence for a combined approach of targeting all 
MRT for future study and clinical analysis.  
Subgroup consensus analysis identified robust, well annotated and characterised 
subgroups in MRT providing a methodology for future consensus efforts as well as 
further characterising novel aspects of subgrouping by identifying novel subgroup 
features such as tumour location, age and DNA methylation levels. In addition, novel 
approaches using already generated data, allow for new biological features to be 
explored such as the immune landscape of MRT. This thesis makes provides a number 
of significant foundations for future directed study in MRT. 
Work carried out as part of this thesis has also informed an international ATRT 
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T SHH SHH.Inf 
ATRT, 
SHH 0.962 M 4.3 
Cerebral hemispheres; Posterior of 
Thalamus; 3rd Ventricle Y Y FALSE 
NMB 1040 
ATR
T SHH SHH.Inf 
ATRT, 
SHH 0.972 M 17 Posterior fossa Y Y FALSE 
NMB 1081 
ATR
T SHH SHH.Inf N/A N/A M 44.6 Pineal gland Y Y FALSE 
NMB 1083 
ATR
T SHH SHH.Inf N/A N/A M 12.3 Pineal gland Y Y FALSE 
NMB 461 
ATR
T SHH SHH.Inf N/A N/A F 8 Posterior fossa Y Y FALSE 
NMB 1074 
ATR
T SHH SHH.Inf N/A N/A M 0.2 Posterior fossa Y Y FALSE 
NMB 1082 
ATR




T SHH SHH.Inf 
ATRT, 




T SHH SHH.Sup N/A N/A 
N/




T SHH SHH.Sup 
ATRT, 




T SHH SHH.Sup 
ATRT, 
SHH 0.997 M 0 ATRT NOS N N N/A 
NMB 1076 
ATR




T SHH SHH.Sup 
ATRT, 




T SHH SHH.Sup 
ATRT, 
SHH 0.057 M 72 Cerebral hemispheres N N N/A 
NMB 1069 
ATR
T SHH SHH.Sup N/A N/A M 7.2 Cerebral hemispheres Y Y FALSE 
NMB 1208 
ATR
T SHH SHH.Sup N/A N/A F 127.6 Frontal lobe Y Y FALSE 
NMB 843 
ATR
T SHH SHH.Sup N/A N/A F 74 Frontal lobe Y Y FALSE 
NMB 846 
ATR
T SHH SHH.Sup N/A N/A F 79.2 Frontal lobe Y Y FALSE 
NMB 854 
ATR
T SHH SHH.Sup 
ATRT, 
SHH 1 F 18.6 Frontal lobe; Parietal lobe Y Y N/A 
NMB 775 
ATR
T SHH SHH.Sup N/A N/A F 36.9 Frontal lobe Y Y FALSE 
NMB 888 
ATR
T SHH SHH.Sup 
ATRT, 
SHH 0.999 M 58 Posterior fossa Y Y TRUE 
NMB 1080 
ATR




T SHH N/A 
ATRT, 
SHH 0.691 F 4.32 Cerebellum N N N/A 
NMB 1062 
ATR
T SHH N/A N/A N/A M 64.6 Posterior fossa Y Y TRUE 
NMB 842 
ATR
T SHH N/A 
ATRT, 
SHH 0.989 F 18.6 ATRT NOS Y Y FALSE 
NMB 1010 
ATR
T TYR TYR N/A N/A M 9.9 Cerebropontine angle; Spine Y Y N/A 
NMB 1039 
ATR
T TYR TYR 
ATRT, 






T TYR TYR 
ATRT, 
TYR 1 F 6.96 posterior fossa N N N/A 
NMB 16 
ATR




T TYR TYR N/A N/A M 7.8 Cerebellum N N N/A 
NMB 1070 
ATR
T TYR TYR N/A N/A M 0.8 Posterior fossa Y Y FALSE 
NMB 1072 
ATR
T TYR TYR N/A N/A M 3.2 Posterior fossa Y Y FALSE 
NMB 1075 
ATR
T TYR TYR N/A N/A F 15 Posterior fossa Y Y TRUE 
NMB 1211 
ATR
T TYR TYR N/A N/A M 0.1 Posterior fossa N N FALSE 
NMB 488 
ATR
T TYR TYR N/A N/A F 6 Posterior fossa Y Y N/A 
NMB 1215 
ATR
T TYR TYR N/A N/A F 10.5 Posterior fossa; Midline other Y Y TRUE 
NMB 957 
ATR
T TYR TYR N/A N/A M N/A Frontal lobe N N FALSE 
NMB 776 
ATR
T TYR TYR 
ATRT, 
TYR 1 M 80.5 Posterior fossa Y Y FALSE 
NMB 778 
ATR
T TYR TYR N/A N/A M 106.5 Posterior fossa Y Y FALSE 
NMB 853 
ATR
T TYR TYR 
ATRT, 
TYR 1 M 7.8 Posterior fossa N Y TRUE 
NMB 919 
ATR
T TYR HYPO N/A N/A M 3.2 Posterior fossa Y Y FALSE 
NMB 920 
ATR




T TYR HYPO 
ATRT, 
SHH 0.765 F 12 Posterior fossa N N N/A 
NMB 1073 
ATR
T TYR HYPO N/A N/A M 67.5 Pineal gland Y Y FALSE 
NMB 779 
ATR
T TYR HYPO N/A N/A M 132.4 ATRT NOS Y Y TRUE 
NMB 1212 
ATR
T TYR HYPO N/A N/A F 14 Posterior fossa Y Y FALSE 
NMB 836 
ATR
T TYR HYPO N/A N/A M 19.1 ATRT NOS Y Y FALSE 
NMB 878 
ATR
T TYR HYPO N/A N/A M 7.8 ATRT NOS Y Y FALSE 
NMB 1063 
ATR
T MYC HYPO N/A N/A F 22.6 
Cerebral hemispheres; Temporal lobe; 
Optic chiasm; Thalamus Y Y TRUE 
NMB 1217 
ATR
T MYC HYPO N/A N/A F 2.5 
Cerebral hemispheres; Pineal gland; 
Other Y Y TRUE 
NMB 1213 
ATR




T MYC MYC 
ATRT, 
MYC 0.893 F 24 Thalamus N N N/A 
NMB 885 
ATR




T MYC MYC 
ATRT, 
MYC 0.736 M 181.44 Cerebral hemispheres N N N/A 
NMB 1079 
ATR




T MYC MYC 
ATRT, 




T MYC MYC 
ATRT, 
MYC 0.987 M 171 Spinal cord N N N/A 
NMB 1214 
ATR
T MYC MYC N/A N/A F 16.5 Pineal gland Y Y TRUE 
NMB 1216 
ATR





T MYC MYC 
ATRT, 
MYC 1 F 3 ATRT NOS N N FALSE 
NMB 856 
ATR
T MYC MYC 
ATRT, 
MYC 0.992 F 135.3 Intramedullary Y Y FALSE 
NMB 876 
ATR
T N/A SHH.Sup N/A N/A M 22.4 Frontal lobe N N FALSE 
NMB 478 
ATR
T N/A SHH.Sup N/A N/A M 13.7 ATRT NOS N N FALSE 
NMB 887 RTK TYR HYPO N/A N/A M 44.4 Kidney Y Y FALSE 
NMB 997 RTK TYR HYPO N/A N/A M 1.6 Kidney Y Y TRUE 
NMB 875 RTK TYR HYPO N/A N/A F 8.3 Kidney N N TRUE 
NMB 1007 RTK TYR HYPO N/A N/A M 18.2 Kidney Y Y N/A 
NMB 860 RTK TYR HYPO N/A N/A F 6.7 Kidney Y Y TRUE 
NMB 886 RTK TYR HYPO N/A N/A F 9.2 Kidney N N TRUE 
NMB 1006 RTK MYC HYPO N/A N/A M 18.2 Kidney Y Y FALSE 
NMB 844 RTK MYC HYPO N/A N/A M 4.4 Kidney Y Y TRUE 
NMB 847 RTK MYC HYPO N/A N/A F 7.9 Kidney N Y TRUE 
NMB 879 RTK MYC HYPO N/A N/A M 13.8 Kidney N N N/A 
NMB 1009 RTK MYC MYC N/A N/A F 24 Kidney Y Y TRUE 
NMB 998 RTK MYC MYC N/A N/A F 12 Kidney Y Y TRUE 
NMB 1261 RTK MYC MYC N/A N/A 
N/
A N/A Kidney N N N/A 
NMB 852 RTK MYC MYC N/A N/A M 3.8 Kidney Y Y TRUE 
NMB 865 RTK MYC MYC N/A N/A M 44.9 Kidney Y Y FALSE 
NMB 877 RTK MYC MYC N/A N/A M 45.1 Kidney Y Y TRUE 
NMB 841 RTK MYC MYC N/A N/A F 16.9 Kidney N N N/A 
NMB 881 RTK MYC MYC N/A N/A M 29.1 Kidney N N FALSE 
NMB 848 RTK N/A HYPO N/A N/A M 74.6 Kidney N N N/A 
NMB 1008 
ECR
T TYR HYPO N/A N/A F 12 Lung Y Y TRUE 
NMB 1266 
ECR
T TYR HYPO N/A N/A F 30 Bladder Y Y FALSE 
NMB 1273 
ECR
T TYR HYPO N/A N/A 
N/
A 0 Paraspine N N N/A 
NMB 840 
ECR
T TYR HYPO N/A N/A M 5.4 Thorax Y Y TRUE 
NMB 1264 
ECR
T MYC HYPO N/A N/A M 6 Thorax Y Y TRUE 
NMB 1265 
ECR
T MYC HYPO N/A N/A 
N/
A N/A Craniovertebral junction; Cervical spine N N N/A 
NMB 1269 
ECR
T MYC HYPO N/A N/A F 9 Liver Y Y FALSE 
NMB 838 
ECR
T MYC HYPO N/A N/A F 5.4 Abdomen Y Y TRUE 
NMB 845 
ECR
T MYC HYPO N/A N/A M 14.5 Armpit Y Y FALSE 
NMB 839 
ECR
T MYC HYPO N/A N/A M 2.2 Abdomen Y Y TRUE 
NMB 849 
ECR
T MYC HYPO N/A N/A F 0.3 Spine N N FALSE 
NMB 862 
ECR
T MYC HYPO N/A N/A M 13.4 Liver Y Y TRUE 
NMB 864 
ECR
T MYC HYPO N/A N/A F 56.9 Buttock Y Y TRUE 
NMB 850 
ECR





T MYC MYC N/A N/A F 21 Thorax; Mediastinum Y Y FALSE 
NMB 1262 
ECR
T MYC MYC N/A N/A 
N/
A N/A Paratracheal N N N/A 
NMB 1267 
ECR
T MYC MYC N/A N/A F 51.6 Neck Y Y FALSE 
NMB 861 
ECR
T MYC MYC N/A N/A M 93.3 Bladder Y Y FALSE 
NMB 896 
ECR
T MYC MYC N/A N/A M 104.1 Thorax Y Y TRUE 
NMB 882 
ECR
T MYC MYC N/A N/A M 12.6 Abdomen Y Y TRUE 
NMB 880 
ECR
T MYC MYC N/A N/A M 15.6 Liver N N TRUE 
NMB 835 
ECR
T MYC MYC N/A N/A M 17.1 Pelvis N N N/A 
NMB 863 
ECR
T MYC MYC N/A N/A F 8.5 Pelvis Y Y FALSE 
NMB 883 
ECR
T MYC MYC N/A N/A M 11.7 Liver N N TRUE 
NMB 959 
MR
T SHH SHH.Inf 
ATRT, 
SHH 1 F N/A MRT NOS Y Y FALSE 
NMB 958 
MR
T SHH SHH.Inf N/A N/A F N/A MRT NOS Y Y FALSE 
NMB 1042 
MR
T TYR TYR N/A N/A 
N/
A 25.2 MRT NOS N N N/A 
NMB 914 
MR
T TYR TYR N/A N/A 
N/
A N/A MRT NOS N N N/A 
NMB 1041 
MR
T TYR HYPO N/A N/A F 0 MRT NOS Y Y N/A 
NMB 960 
MR
T MYC N/A 
ATRT, 
MYC 0.97 M N/A MRT NOS Y Y FALSE 
NMB 921 
MR
T MYC N/A N/A N/A M 7.3 MRT NOS Y Y TRUE 
 


































































































































































































































































































































































































































































































































































































































































































































































































































































































OD005  RMS GPL570 E-TABM-1202 RMS005 
FAL
SE NA 
OD006  RMS GPL570 E-TABM-1202 RMS006 
FAL
SE NA 
OD009  RMS GPL570 E-TABM-1202 RMS009 
FAL
SE NA 
OD010  RMS GPL570 E-TABM-1202 RMS010 
FAL
SE NA 
OD012  RMS GPL570 E-TABM-1202 RMS012 
FAL
SE NA 
OD015  RMS GPL570 E-TABM-1202 RMS015 
FAL
SE NA 
OD017  RMS GPL570 E-TABM-1202 RMS017 
FAL
SE NA 
OD026  RMS GPL570 E-TABM-1202 RMS026 
FAL
SE NA 
OD027  RMS GPL570 E-TABM-1202 RMS027 
FAL
SE NA 
OD029  RMS GPL570 E-TABM-1202 RMS029 
FAL
SE NA 
OD032  RMS GPL570 E-TABM-1202 RMS032 
FAL
SE NA 
OD033  RMS GPL570 E-TABM-1202 RMS033 
FAL
SE NA 
OD034  RMS GPL570 E-TABM-1202 RMS034 
FAL
SE NA 
OD035  RMS GPL570 E-TABM-1202 RMS035 
FAL
SE NA 
OD038  RMS GPL570 E-TABM-1202 RMS038 
FAL
SE NA 
OD039  RMS GPL570 E-TABM-1202 RMS039 
FAL
SE NA 
OD041  RMS GPL570 E-TABM-1202 RMS041 
FAL
SE NA 
OD042  RMS GPL570 E-TABM-1202 RMS042 
FAL
SE NA 
OD043  RMS GPL570 E-TABM-1202 RMS043 
FAL
SE NA 
OD046  RMS GPL570 E-TABM-1202 RMS046 
FAL
SE NA 
OD049  RMS GPL570 E-TABM-1202 RMS049 
FAL
SE NA 
OD050  RMS GPL570 E-TABM-1202 RMS050 
FAL
SE NA 
OD051  RMS GPL570 E-TABM-1202 RMS051 
FAL
SE NA 
OD052  RMS GPL570 E-TABM-1202 RMS052 
FAL
SE NA 
OD054  RMS GPL570 E-TABM-1202 RMS054 
FAL
SE NA 
OD055  RMS GPL570 E-TABM-1202 RMS055 
FAL
SE NA 
OD057  RMS GPL570 E-TABM-1202 RMS057 
FAL
SE NA 
OD058  RMS GPL570 E-TABM-1202 RMS058 
FAL
SE NA 
OD060  RMS GPL570 E-TABM-1202 RMS060 
FAL
SE NA 





OD067  RMS GPL570 E-TABM-1202 RMS067 
FAL
SE NA 
OD075  RMS GPL570 E-TABM-1202 RMS075 
FAL
SE NA 
OD076  RMS GPL570 E-TABM-1202 RMS076 
FAL
SE NA 
OD078  RMS GPL570 E-TABM-1202 RMS078 
FAL
SE NA 
OD080  RMS GPL570 E-TABM-1202 RMS080 
FAL
SE NA 
OD081  RMS GPL570 E-TABM-1202 RMS081 
FAL
SE NA 
OD082  RMS GPL570 E-TABM-1202 RMS082 
FAL
SE NA 
OD084  RMS GPL570 E-TABM-1202 RMS084 
FAL
SE NA 
OD085  RMS GPL570 E-TABM-1202 RMS085 
FAL
SE NA 
OD087  RMS GPL570 E-TABM-1202 RMS087 
FAL
SE NA 
OD090  RMS GPL570 E-TABM-1202 RMS090 
FAL
SE NA 
OD091  RMS GPL570 E-TABM-1202 RMS091 
FAL
SE NA 
OD092  RMS GPL570 E-TABM-1202 RMS092 
FAL
SE NA 
OD093  RMS GPL570 E-TABM-1202 RMS093 
FAL
SE NA 
OD094  RMS GPL570 E-TABM-1202 RMS094 
FAL
SE NA 
OD096  RMS GPL570 E-TABM-1202 RMS096 
FAL
SE NA 
OD100  RMS GPL570 E-TABM-1202 RMS100 
FAL
SE NA 
OD102  RMS GPL570 E-TABM-1202 RMS102 
FAL
SE NA 
OD104  RMS GPL570 E-TABM-1202 RMS104 
FAL
SE NA 
OD105  RMS GPL570 E-TABM-1202 RMS105 
FAL
SE NA 
OD106  RMS GPL570 E-TABM-1202 RMS106 
FAL
SE NA 
OD109  RMS GPL570 E-TABM-1202 RMS109 
FAL
SE NA 
OD110  RMS GPL570 E-TABM-1202 RMS110 
FAL
SE NA 
OD111  RMS GPL570 E-TABM-1202 RMS111 
FAL
SE NA 
OD112  RMS GPL570 E-TABM-1202 RMS112 
FAL
SE NA 
OD113  RMS GPL570 E-TABM-1202 RMS113 
FAL
SE NA 
OD114  RMS GPL570 E-TABM-1202 RMS114 
FAL
SE NA 
OD116  RMS GPL570 E-TABM-1202 RMS116 
FAL
SE NA 
OD117  RMS GPL570 E-TABM-1202 RMS117 
FAL
SE NA 
OD118  RMS GPL570 E-TABM-1202 RMS118 
FAL
SE NA 
OD120  RMS GPL570 E-TABM-1202 RMS120 
FAL
SE NA 





OD130  RMS GPL570 E-TABM-1202 RMS130 
FAL
SE NA 
OD131  RMS GPL570 E-TABM-1202 RMS131 
FAL
SE NA 
OD132  RMS GPL570 E-TABM-1202 RMS132 
FAL
SE NA 
OD133  RMS GPL570 E-TABM-1202 RMS133 
FAL
SE NA 
OD134  RMS GPL570 E-TABM-1202 RMS134 
FAL
SE NA 
OD136  RMS GPL570 E-TABM-1202 RMS136 
FAL
SE NA 
OD138  RMS GPL570 E-TABM-1202 RMS138 
FAL
SE NA 
OD139  RMS GPL570 E-TABM-1202 RMS139 
FAL
SE NA 
OD141  RMS GPL570 E-TABM-1202 RMS141 
FAL
SE NA 
OD142  RMS GPL570 E-TABM-1202 RMS142 
FAL
SE NA 
OD143  RMS GPL570 E-TABM-1202 RMS143 
FAL
SE NA 
OD144  RMS GPL570 E-TABM-1202 RMS144 
FAL
SE NA 
OD148  RMS GPL570 E-TABM-1202 RMS148 
FAL
SE NA 
OD149  RMS GPL570 E-TABM-1202 RMS149 
FAL
SE NA 
OD151  RMS GPL570 E-TABM-1202 RMS151 
FAL
SE NA 
OD152  RMS GPL570 E-TABM-1202 RMS152 
FAL
SE NA 
OD153  RMS GPL570 E-TABM-1202 RMS153 
FAL
SE NA 
OD155  RMS GPL570 E-TABM-1202 RMS155 
FAL
SE NA 
OD156  RMS GPL570 E-TABM-1202 RMS156 
FAL
SE NA 
OD157  RMS GPL570 E-TABM-1202 RMS157 
FAL
SE NA 
OD158  RMS GPL570 E-TABM-1202 RMS158 
FAL
SE NA 
OD159  RMS GPL570 E-TABM-1202 RMS159 
FAL
SE NA 
OD160  RMS GPL570 E-TABM-1202 RMS160 
FAL
SE NA 
OD307  RMS GPL570 E-TABM-1202 RMS307 
FAL
SE NA 
OD308  RMS GPL570 E-TABM-1202 RMS308 
FAL
SE NA 
OD311  RMS GPL570 E-TABM-1202 RMS311 
FAL
SE NA 
OD316  RMS GPL570 E-TABM-1202 RMS316 
FAL
SE NA 
OD317  RMS GPL570 E-TABM-1202 RMS317 
FAL
SE NA 
OD321  RMS GPL570 E-TABM-1202 RMS321 
FAL
SE NA 
OD323  RMS GPL570 E-TABM-1202 RMS323 
FAL
SE NA 
OD324  RMS GPL570 E-TABM-1202 RMS324 
FAL
SE NA 





OD329  RMS GPL570 E-TABM-1202 RMS329 
FAL
SE NA 
OD342  RMS GPL570 E-TABM-1202 RMS342 
FAL
SE NA 
OD353  RMS GPL570 E-TABM-1202 RMS353 
FAL
SE NA 
OD357  RMS GPL570 E-TABM-1202 RMS357 
FAL
SE NA 
OD358  RMS GPL570 E-TABM-1202 RMS358 
FAL
SE NA 
OD362  RMS GPL570 E-TABM-1202 RMS362 
FAL
SE NA 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2982 ATRT GPL570 GSE28026 








2983 ATRT GPL570 GSE28026 








2984 ATRT GPL570 GSE28026 








2985 ATRT GPL570 GSE28026 








2986 ATRT GPL570 GSE28026 








2987 ATRT GPL570 GSE28026 








2988 ATRT GPL570 GSE28026 








2989 ATRT GPL570 GSE28026 










2990 ATRT GPL570 GSE28026 








2991 ATRT GPL570 GSE28026 








2992 ATRT GPL570 GSE28026 








2993 ATRT GPL570 GSE28026 








2994 ATRT GPL570 GSE28026 








2995 ATRT GPL570 GSE28026 








2996 ATRT GPL570 GSE28026 








2997 ATRT GPL570 GSE28026 








2998 ATRT GPL570 GSE28026 








2999 ATRT GPL570 GSE28026 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.3 C) Cell populations used for the generation of the CIBERORT signature 
matrix  
Dataset Cell Type (number) Isolation method 
PMID: 27785870; GSE82234 (GEO/NCBI) Endothelial/HUVEC (6) 
Human umbilical vein endothelial cell donors; 
Supplemented Endopan 3 medium culture 
Provided by Ankur Chakravarthy 
PMID: 24057217; GSE50798 (GEO/NCBI) 
Glia (12) 
Dissected Medial Orbito-Frontal Cortex tissue; 




Dissected Medial Orbito-Frontal Cortex tissue; 
NeuN+ FACS (FACS Vantage with DiVa) 
Provided by Ankur Chakravarthy 
PMID: 23974203; GSE49667 (GEO/NCBI) 
CD4+ T Effector (6) 
Healthy donor blood buffy coat 
samples; CD45RA+ CD45RO− CD25− FACS 
CD4+ Treg (4) 
Healthy donor blood buffy coat 
samples; CD45RA+ CD45RO− CD25+ FACS 
FlowSorted.Blood.450k (Bioconductor) 
PMID: 22848472 
CD19+ B cells (6) 
Healthy donor PBMC; Ficoll-Paque Plus - PBMC 
(GE Healthcare, Sweden); CD19+ MACS 
(Miltenyi Biotech, Germany) 
CD8+ T cells (6) 
Healthy donor PBMC; Ficoll-Paque Plus - PBMC 
(GE Healthcare, Sweden); CD8+ MACS (Miltenyi 
Biotech, Germany) 
Eosinophil (6) 
Healthy donor PBMC; Ficoll-Paque Plus - 
Granulocyte (GE Healthcare, Sweden); 
Eosinophil Isolation kit II (Miltenyi Biotech, 
Germany) 
CD14+ Monocyte (6) 
Healthy donor PBMC; Ficoll-Paque Plus - PBMC 
(GE Healthcare, Sweden); CD14+ MACS 
(Miltenyi Biotech, Germany) 
Neutrophil (6) 
Healthy donor PBMC; Ficoll-Paque Plus - 
Granulocyte (GE Healthcare, Sweden); CD16+ 
MACS (Miltenyi Biotech, Germany) 
CD56+ NK cells (6) 
Healthy donor PBMC; Ficoll-Paque Plus - PBMC 
(GE Healthcare, Sweden); CD56+ MACS 
(Miltenyi Biotech, Germany) 
FlowSorted.CordBlood.450k (Bioconductor) 
PMID: 27019159 
CD19+ B cells (14) 
Healthy donor CBMC; Ficoll 1077; CD19+ MACS 
(Miltenyi Biotech, Germany) 
CD8+ T cells (12) 
Healthy donor CBMC; Ficoll 1077; CD8+ MACS 
(Miltenyi Biotech, Germany) 
CD14+ Monocyte (15) 
Healthy donor CBMC; Ficoll 1077; CD14+ MACS 
(Miltenyi Biotech, Germany) 
CD56+ NK cells (13) 
Healthy donor CBMC; Ficoll 1077; CD56+ MACS 




CD19+ B cells (11) 
Healthy donor CBMC; Lymphoprep (Stem Cell 
Technologies, Norway); CD19+ FACS (BD FACS 
Aria) 
CD14+ Monocyte (11) 
Healthy donor CBMC; Lymphoprep (Stem Cell 
Technologies, Norway); CD14+ FACS (BD FACS 
Aria) 
CD56+ NK cells (11) 
Healthy donor CBMC; Lymphoprep (Stem Cell 
Technologies, Norway); CD56+ FACS (BD FACS 
Aria) 
unpublished Cancer (25) 
MRT/MB Cell lines (D283, D341, D384, D425 x2, 
D458 x2, D556, DAOY, HDMB03, MED1, MED8A, 
ONS76, UW228, A204, BT12 x2, BT16, CHLA259, 
CHLA266 x2, G401 x2, WT1 x2) 
 
8.4 D) Cohorts of primary CNS tumours analysed by CIBERSORT 
Dataset Tumour Type (number) 
GSE70460 (GEO/NCBI) ATRT (150) 
GSE109381 (GEO/NCBI) Multiple CNS malignancies (3905) 
GSE60274 (GEO/NCBI) Glioblastoma (68) 
E-MTAB-5528 (n = 99), E-MTAB-5552 (ArrayExpress)/ 
PMID:29763623 (n = 71),  PMID:28966033 (n = 225). 
Additional unpublished (n = 6) 
Paediatric HGG/DIPG (401) 
Unpublished MRT Primary (88) 
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PMID:28726821, GSE93646, GSE85212 (GEO/NCBI) with 
232 sample exclusions to remove duplicates and poor QC  
Medulloblastoma (2325) 
GSE20713; GSE72308 (GEO/NCBI) Breast cancer (87 HGU133Plus2; 87 
HumanMethylation450K) 
 
8.5 E) Validation cell populations used in benchmarking CIBERSORT 
Dataset Cell Type (number) 
GSE112618 (GEO/NCBI) WBC mix (6) 
GSE110554 (GEO/NCBI) Artificial DNA mix: CD4+ T, CD8+ T, CD14+ monocyte, 
neutrophil, CD19+ B, CD56+ NK (12)  
GSE88824 (GEO/NCBI) CD19+ B cells (8) 
CD4+ T (8) 
CD8+ T cells (8) 
CD14+ Monocyte (8) 
neutrophil (8) 
CD56+ NK cells (8) 
 
